<PAGE>
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 25, 1997
SEC FILE NO. 333-30193
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
AMENDMENT NO. 1 TO FORM S-2
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
---------------
HANGER ORTHOPEDIC GROUP, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
---------------
DELAWARE 84-0904275
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
7700 OLD GEORGETOWN ROAD
BETHESDA, MD 20814
(301) 986-0701
---------------
IVAN R. SABEL
CHAIRMAN OF THE BOARD, PRESIDENT AND CHIEF EXECUTIVE OFFICER
HANGER ORTHOPEDIC GROUP, INC.
7700 OLD GEORGETOWN ROAD
BETHESDA, MD 20814
(301) 986-0701
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE)
PLEASE SEND COPIES OF COMMUNICATIONS TO:
ARTHUR H. BILL, ESQ. MICHAEL J. SILVER, ESQ.
FREEDMAN, LEVY, KROLL & SIMONDS HOGAN & HARTSON L.L.P.
1050 CONNECTICUT AVE., N.W. 111 SOUTH CALVERT STREET
WASHINGTON, D.C. 20036 BALTIMORE, MD 21202
---------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective.
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. [_]
If the Registrant elects to deliver its latest annual report to security
holders, or a complete and legible facsimile thereof, pursuant to Item
11(a)(1) of this form, check the following box. [_]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [_]
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [_]
---------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS
REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH
SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT
SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO
SECTION 8(A), MAY DETERMINE.
================================================================================
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CROSS REFERENCE SHEET
BETWEEN ITEMS OF FORM S-2 AND PROSPECTUS
<TABLE>
<CAPTION>
FORM S-2 ITEM LOCATION IN PROSPECTUS
------------- ----------------------
<C> <C> <S>
1. Forepart of the Registration Statement
and Outside Front Cover Page of
Prospectus........................... Outside Front Cover Page
2. Inside Front and Outside Back Cover
Pages of Prospectus.................. Available Information,
Incorporation of Certain
Documents by Reference
3. Summary Information, Risk Factors and
Ratio of Earnings to Fixed Charges... Prospectus Summary, The
Company, Risk Factors
4. Use of Proceeds....................... Use of Proceeds
5. Determination of Offering Price....... Underwriting
6. Dilution.............................. Not Applicable
7. Selling Security Holders.............. Not Applicable
8. Plan of Distribution.................. Underwriting
9. Description of Securities to be Description of Capital Stock
Registered...........................
10. Interests of Named Experts and Not Applicable
Counsel..............................
11(b). Information with Respect to the
Registrant........................... Prospectus Summary, The
Company, Price Range of Common
Stock, Dividend Policy,
Capitalization, Selected
Historical and Pro Forma
Consolidated Financial
Information, Management's
Discussion and Analysis of
Financial Condition and
Results of Operations,
Business, Financial Statements
12. Incorporation of Certain Information
by Reference......................... Documents Incorporated by
Reference
13. Disclosure of Commission Position on
Indemnification for Securities Act Not Applicable (See Part II--
Liabilities.......................... Item 17)
</TABLE>
<PAGE>
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
+INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A +
+REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE +
+SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY +
+OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT +
+BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR +
+THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE +
+SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE +
+UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF +
+ANY SUCH STATE. +
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
SUBJECT TO COMPLETION
JULY 25, 1997
4,500,000 Shares
[LOGO OF HANGER ORTHOPEDIC GROUP INC. APPEARS HERE]
Common Stock
--------
All of the shares of Common Stock offered hereby are being sold by Hanger
Orthopedic Group, Inc. ("Hanger" or the "Company"). The Company's Common Stock
is traded on the American Stock Exchange ("AMEX") under the symbol "HGR." On
June 25, 1997, the closing sale price of the Company's Common Stock was $9.06
per share.
--------
THE COMMON STOCK OFFERED HEREBY INVOLVES A HIGH DEGREE OF RISK.SEE "RISK
FACTORS" BEGINNING ON PAGE 7.
--------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
<TABLE>
<CAPTION>
================================================================================
PRICE UNDERWRITING PROCEEDS
TO DISCOUNTS AND TO
PUBLIC COMMISSIONS COMPANY(1)
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Per Share...................................... $ $ $
- --------------------------------------------------------------------------------
Total(2)....................................... $ $ $
================================================================================
</TABLE>
(1) Before deducting expenses of the Offering estimated at $700,000, payable by
the Company.
(2) The Company has granted to the Underwriters a 30-day option to purchase up
to 675,000 additional shares of Common Stock solely to cover over-
allotments, if any. To the extent the option is exercised, the Underwriters
will offer the additional shares at the Price to Public shown above. If the
option is exercised in full, the total Price to Public, Underwriting
Discounts and Commissions and Proceeds to Company will be $ , $ and
$ , respectively. See "Underwriting."
--------
The shares of Common Stock are offered by the several Underwriters, subject
to prior sale, when, as and if delivered to and accepted by them, and subject
to the right of the Underwriters to reject any order in whole or in part. It is
expected that delivery of the shares of Common Stock will be made at the
offices of Alex. Brown & Sons Incorporated, Baltimore, Maryland, on or about
, 1997.
Alex. Brown & Sons
INCORPORATED
Montgomery Securities
Legg Mason Wood Walker
Incorporated
THE DATE OF THIS PROSPECTUS IS , 1997.
<PAGE>
[INSERT U.S. MAP SHOWING PATIENT-CARE CENTERS, DISTRIBUTION CENTERS AND
MANUFACTURING FACILITIES.]
The Company's executive offices are located at 7700 Old Georgetown Road,
Bethesda, Maryland 20814. Its telephone number is (301) 986-0701.
THE UNDERWRITERS AND OTHER PERSONS MAY OVER-ALLOT OR EFFECT TRANSACTIONS THAT
STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OF THE COMPANY AT A
LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. FOR A
DESCRIPTION OF THESE ACTIVITIES, SEE "UNDERWRITING."
2
<PAGE>
PROSPECTUS SUMMARY
The following summary is qualified in its entirety by the more detailed
information and consolidated financial statements and notes thereto appearing
elsewhere in this Prospectus.
THE COMPANY
Hanger Orthopedic Group, Inc. is a professional practice management company
focused on the orthotic and prosthetic ("O&P") segment of the orthopedic
rehabilitation industry. The Company acquires and operates the practices of
orthotists and prosthetists, medical professionals that design, fabricate, fit
and supervise the use of external musculoskeletal support devices and
artificial limbs. The Company has acquired over 40 O&P businesses since 1986
and currently employs 201 certified O&P practitioners and operates 190 O&P
centers in 28 states and the District of Columbia. The Company also has
developed OPNET, Inc. ("OPNET"), a national preferred provider network of O&P
service professionals in 358 patient-care centers with 230 managed care
contracts. In addition to its practice management and patient-care services,
the Company manufactures custom-made and prefabricated O&P devices and is the
country's largest distributor of O&P components and finished O&P patient-care
products. The combination of practice management and patient-care services,
OPNET, distribution and manufacturing operations positions the Company as a
fully integrated O&P network.
The Company has been an active acquiror of O&P practices since 1986. The
Company experienced operating difficulties in 1994 and suspended its
acquisition program. In 1994 and 1995, the Company sold or closed nine
unprofitable patient-care centers and reorganized its management team. In late
1995, having reestablished a strong base of operations, the Company launched
OPNET and resumed its acquisition program with the November 1, 1996 acquisition
of J.E. Hanger, Inc. of Georgia ("JEH"), an O&P provider with 94 patient-care
centers in 15 states and the largest O&P distribution business in the United
States. The acquisition essentially doubled the Company's number of patient-
care centers and certified practitioners and significantly expanded its
distribution capabilities. Since January 1, 1997, the Company has also acquired
the assets of four additional O&P companies, representing an aggregate of nine
patient-care centers and 18 practitioners.
The Company estimates that the U.S. O&P patient-care services industry
represented approximately $2.0 billion in sales in 1995. Key trends expected to
increase the demand for O&P services include: (i) the growing elderly
population; (ii) more active lifestyles and emphasis on physical fitness; (iii)
cost savings through the use of outpatient O&P treatment to reduce
hospitalization; (iv) advancing technology in the design and manufacture of O&P
devices; and (v) the inherent need for replacement of O&P devices and
continuing care.
The O&P services market is highly fragmented and relatively underpenetrated
by professional practice management companies. Hanger is one of the two largest
companies in the O&P industry which, combined, accounted for less than 15% of
total estimated O&P industry revenue in 1995. There are an estimated 3,200
certified prosthetists and/or orthotists and approximately 2,670 O&P patient-
care centers in the United States. The Company believes that the O&P industry
will continue to consolidate as a result of a variety of factors, including:
(i) increased pressures from growth in managed care; (ii) demonstrated benefits
from economies of scale; and (iii) desire by independent orthotists and
prosthetists to obtain financial liquidity and concentrate on providing patient
care.
The Company's objective is to build a major national orthopedic
rehabilitation company focused on acquiring and operating O&P practices and
related businesses. The Company's strategy for achieving this objective is to:
(i) acquire and integrate O&P practices in targeted geographic areas across the
United States; (ii) develop new patient-care centers in existing markets; (iii)
expand and improve O&P practice management operations at existing and acquired
patient-care centers; (iv) increase the number of OPNET's O&P patient-care
service members and its contractual relationships with managed care
organizations; and (v) expand the Company's O&P manufacturing and distribution
operations.
3
<PAGE>
RECENT INTERIM RESULTS OF OPERATIONS
On July 21, 1997, the Company announced that net sales for the quarter ended
June 30, 1997 were $36.6 million, an increase of $22.6 million, or 161%, over
net sales of $14.0 million in the prior year's comparable period. Net income
for the second quarter of 1997 was $1.9 million, or $.17 per share, compared
with net income of $738,000, or $.09 per share, in the second quarter of 1996.
The Company's net sales for the six months ended June 30, 1997 amounted to
$67.5 million, an increase of $41.3 million, or 158%, over net sales of $26.2
million in the prior year's comparable period. Net income for the six months
ended June 30, 1997 was $2.5 million, or $.23 per share, compared with net
income of $888,000, or $.11 per share, in the six months ended June 30, 1996.
The increases in net sales and net income were attributable in large part to
the Company's acquisition of JEH on November 1, 1996. See "Management's
Discussion and Analysis of Financial Condition and Results of Operations--
Recent Acquisitions."
RISK FACTORS
The Common Stock offered hereby involves a high degree of risk. See "Risk
Factors."
THE OFFERING
<TABLE>
<S> <C>
Common Stock offered by the Company......... 4,500,000 shares
Common Stock to be outstanding after the
Offering................................... 13,965,811 shares(1)
Use of proceeds............................. Repayment of certain indebtedness
American Stock Exchange symbol.............. HGR
</TABLE>
- --------
(1) Excludes 3,722,931 shares of Common Stock issuable upon exercise of
outstanding stock options and warrants, at a weighted average exercise
price of $5.59 per share. See "Capitalization" and "Principal
Shareholders."
Unless the context otherwise requires, references to the Company include
Hanger Orthopedic Group, Inc. and its subsidiaries. Except as otherwise
specified, all information in this Prospectus assumes no exercise of the
Underwriters' over-allotment option. See "Underwriting."
4
<PAGE>
SUMMARY CONSOLIDATED FINANCIAL AND STATISTICAL DATA
(IN THOUSANDS, EXCEPT PER SHARE AND STATISTICAL DATA)
<TABLE>
<CAPTION>
QUARTERS
YEARS ENDED DECEMBER 31, ENDED MARCH 31,
---------------------------------------------------- ---------------------------
PRO FORMA PRO FORMA
AS ADJUSTED AS ADJUSTED
1992 1993 1994 1995 1996 1996(1) 1996 1997 1997(2)
------- ------- ------- ------- ------- ----------- ------- ------- -----------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS
DATA:
Net sales.............. $32,405 $43,877 $50,300 $52,468 $66,806 $131,557 $12,229 $30,950 $33,139
Acquisition and
integration costs,
restructuring costs
and loss from disposal
of assets............. -- -- 2,610 -- 2,479 2,479 -- -- --
Income from continuing
operations............ 2,113 4,428 4 5,843 4,695 10,801 701 2,636 3,101
Income (loss) from
continuing operations
before extraordinary
item and accounting
change................ 320 1,594 (2,280) 2,135 1,081 3,704 150 618 1,232
Income (loss) per
common share from
continuing operations
before extraordinary
item and accounting
change................ $ 0.03 $ 0.19 $ (0.28) $ 0.26 $ 0.12 $ 0.26 $ 0.02 $ 0.06 $ 0.08
Weighted average common
shares outstanding.... 7,565 8,344 8,290 8,291 8,663 14,544 8,324 9,978 14,542
</TABLE>
<TABLE>
<CAPTION>
MARCH 31, 1997
---------------------------------------
PRO FORMA
ACTUAL PRO FORMA(3) AS ADJUSTED(3)(4)
-------- ------------ -----------------
<S> <C> <C> <C>
BALANCE SHEET DATA:
Working capital........................ $ 28,825 $ 26,324 $ 27,153
Total assets........................... 138,158 144,248 144,206
Long-term debt......................... 68,815 72,944 37,242
Shareholders' equity................... 40,431 40,931 77,419
</TABLE>
<TABLE>
<CAPTION>
QUARTERS
ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
----------------------------- -------------
1992 1993 1994 1995 1996 1996 1997(5)
---- ---- ---- ---- ---- ---- -------
<S> <C> <C> <C> <C> <C> <C> <C>
STATISTICAL DATA:
Patient-care centers(6).......... 63 72 85 84 178 81 178
Certified practitioners(6)....... 82 104 125 119 199 90 197
Number of states (including
D.C.)(6)........................ 18 22 25 24 29 26 29
Same-center sales growth......... 7.3% 4.4% (3.7)% 5.2% 5.8% 8.8% 10.6%
EBITDA margin(7)................. 12.9% 16.1% 11.1% 16.1% 14.7% 10.6% 12.1%
Operating margin(8).............. 6.5% 10.1% 5.2% 11.1% 10.7% 5.7% 8.5%
Payor mix(9):
Private pay and other........... -- -- -- 43.4% 43.2% -- 43.0%
Medicare/Medicaid/VA............ -- -- -- 56.6% 56.8% -- 57.0%
Percentage of net sales from:
Practice management and patient-
care services................... 82.5% 76.8% 78.0% 78.5% 78.2% 78.5% 74.6%
Manufacturing................... 10.9% 18.3% 17.6% 16.3% 12.0% 15.7% 6.3%
Distribution.................... 6.6% 4.9% 4.4% 5.2% 9.8% 5.8% 19.1%
</TABLE>
See accompanying notes on following page.
5
<PAGE>
- --------
(1) Adjusted to give effect to: (i) acquisitions which occurred during 1996 and
the five months ended May 31, 1997; and (ii) the reduction in interest
expense resulting from the assumed use of the estimated net proceeds of
this Offering upon the sale by the Company of 4.5 million shares of Common
Stock offered hereby at an offering price of $9.06 per share, after
deducting the underwriting discounts and commissions and estimated offering
expenses payable by the Company, as if such transactions had occurred as of
the beginning of 1996. See "Use of Proceeds" and "Unaudited Pro Forma
Consolidated Condensed Financial Statements."
(2) Adjusted to give effect to: (i) acquisitions which occurred during the five
months ended May 31, 1997; and (ii) the reduction in interest expense
resulting from the assumed use of the estimated net proceeds of this
Offering upon the sale by the Company of 4.5 million shares of Common Stock
offered hereby at an offering price of $9.06 per share, after deducting the
underwriting discounts and commissions and estimated offering expenses
payable by the Company, as if such transactions had occurred as of the
beginning of 1997. See "Use of Proceeds" and "Unaudited Pro Forma
Consolidated Condensed Financial Statements."
(3) Adjusted to give effect to acquisitions which occurred during the five
months ended May 31, 1997. See "Unaudited Pro Forma Consolidated Condensed
Financial Statements."
(4) Adjusted to give effect to the sale by the Company of 4.5 million shares of
Common Stock in this Offering and the application of the estimated net
proceeds therefrom, assuming an offering price of $9.06 per share.
Shareholders' equity reflects debt discounts and deferred financing costs
of $2.0 million ($1.1 million net of tax benefit) expensed as a result of
the retirement of certain indebtedness from the assumed use of proceeds of
this Offering. See "Use of Proceeds."
(5) Excludes eight patient-care centers acquired subsequent to March 31, 1997,
and 17 certified practitioners employed by such patient-care centers.
(6) At end of period.
(7) "EBITDA" is defined as net income (loss) before interest expense, taxes,
depreciation and amortization, discontinued operations, non-recurring
charges, extraordinary item and accounting change. EBITDA is not a measure
of performance under GAAP. While EBITDA should not be considered in
isolation or as a substitute for net income, cash flows from operating
activities and other income or cash flow statement data prepared in
accordance GAAP, or as a measure of profitability or liquidity, management
understands that EBITDA is customarily used as a criteria in evaluating
healthcare companies. Moreover, substantially all of the Company's
financing agreements contain covenants in which EBITDA is used as a measure
of financial performance. See "Management's Discussion and Analysis of
Financial Condition and Results of Operations" for a discussion of other
measures of performance determined in accordance with GAAP.
(8) Operating margin is defined as net income (loss) before interest expense,
taxes, discontinued operations, non-recurring charges, extraordinary item
and accounting change.
(9) Payor mix data for the years ended December 31, 1995 and 1996 and for the
quarters ended March 31, 1996 and 1997 is based on a sampling of
approximately 40%, 75%, 30% and 75% of patient-care centers, respectively.
Payor mix data not available for the years ended 1992, 1993 and 1994.
6
<PAGE>
RISK FACTORS
In addition to other information in this Prospectus, the following factors
should be considered carefully in evaluating an investment in shares of the
Common Stock offered by this Prospectus. This discussion also identifies
important cautionary factors that could cause the Company's actual results to
differ materially from those described in forward-looking statements made by,
or on behalf of, the Company. In particular, the Company's forward-looking
statements, including those regarding the acquisition of additional patient-
care centers and related businesses, the adequacy of the Company's capital
resources and other statements regarding trends, could be affected by a number
of risks and uncertainties including those described below.
Risks Associated with Acquisition Strategy. The Company's business strategy
contemplates the continued acquisition and integration of O&P businesses. The
success of the Company's acquisitions will be determined by numerous factors,
including the Company's ability to identify O&P patient-care practices and
other O&P businesses suitable for acquisition, to acquire and finance such
businesses on acceptable terms and to integrate and operate such businesses
profitably after acquisition. No assurance can be given that future
acquisitions by the Company will be successfully consummated and integrated or
that such acquisitions will favorably affect the Company's business or
operations. See "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Liquidity and Capital Resources" and "Business--
Acquisitions."
Additional Financings. The Company's acquisition program requires
substantial capital resources. No assurance can be given that the Company's
available bank facility and other sources of capital will be sufficient to
provide for the Company's cash requirements for future acquisitions. The
Company may issue additional debt or equity securities in connection with the
acquisition of additional O&P patient-care centers. See "Management's
Discussion and Analysis of Financial Condition and Results of Operations--
Liquidity and Capital Resources" and "Business--Acquisitions."
Rapid Growth. The Company has pursued, and plans to continue to pursue, an
aggressive growth strategy. The rapid growth may place significant demands on
the Company's financial and management resources. There can be no assurance
that the Company will be able to manage this growth effectively. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and "Business."
Reimbursement Limitations. Approximately 56.8% and 57.0% of the Company's
net sales in 1996 and the first quarter of 1997, respectively, (based on a
sampling of approximately 75% of patient-care centers in both periods) were
derived from Medicare, Medicaid, the United States Department of Veterans
Affairs (the "VA") and certain state agencies, each of which sets maximum
reimbursement levels for O&P services and products. No assurance can be given
that reimbursement levels under such programs will not be lowered in the
future or that the percentage of the Company's net sales derived from sources
limiting reimbursement levels will not increase. Furthermore, the healthcare
industry is experiencing a trend towards cost containment as government and
other third-party payors seek to impose lower reimbursement rates and
negotiate reduced contract rates with service providers, which may adversely
affect the Company's operating results or financial condition. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations--Other" and "Business--Patient Reimbursement Sources."
Retention of Key Personnel. The success of the Company will depend in part
on its continued ability to retain Ivan R. Sabel, Chairman of the Board,
President and Chief Executive Officer of the Company, and qualified O&P
practitioners and other managerial and technical personnel. There can be no
assurance that the Company will be able to continue to retain all the
personnel necessary for continued growth. The loss of the services of key
personnel could have a material adverse effect on the Company. See
"Management."
7
<PAGE>
Variability of Quarterly Operating Results. The Company's operating results
have varied from quarter to quarter and may continue to vary. Quarterly
variations may result from, among other things, the non-recurring costs
associated with the acquisition of patient-care centers. The Company's
operating results for any particular quarter may not be indicative of results
for future periods.
Potential Liability and Insurance. The provision of O&P services and
products, as is the case with other healthcare services and products, involves
an inherent risk of liability that could have a material adverse effect on the
Company. No assurance can be given that insurance coverage will continue to be
available at commercially reasonable prices or that such insurance will cover
actual future liabilities.
Government Regulation. Most states do not require separate licensure for O&P
practitioners. However, several states currently require practitioners to be
certified by an organization such as the American Board for Certification in
Orthotics and Prosthetics (the "ABC"). While the Company endeavors to comply
with all state licensure requirements, no assurance can be given that the
Company will be in compliance at all times with these requirements. The
Company is subject to various federal and state laws pertaining to healthcare
fraud and abuse, including antikickback laws, false claims laws, and physician
self-referral laws. Antikickback laws make it illegal to solicit, offer,
receive, or pay any remuneration in exchange for, or to induce, the referral
of business. False claims laws prohibit anyone from knowingly and willfully
presenting claims for payment that contain false or fraudulent information.
Physician self-referral laws restrict the ability of a physician to refer
patients to entities with which the physician has a financial relationship, as
well as the ability of an entity to claim reimbursement for services furnished
pursuant to a prohibited referral. Violations of these laws are punishable by
criminal and/or civil sanctions, including, in some instances, imprisonment
and exclusion from participation in federal healthcare programs, including
Medicare, Medicaid, VA health programs and the Civilian Health and Medical
Program for the Uniformed Services ("CHAMPUS"). There can be no assurance that
one or more of the Company's practices will not be challenged by governmental
authorities under certain of these laws, that the Company would not be
required to alter its practices as a result, or that the occurrence of one or
more of these events would not result in a material adverse effect on the
Company's business and results of operations. The Company is subject to
federal and state antitrust laws which prohibit, among other things, the
establishment of ventures that result in certain anticompetitive conduct.
These laws have been applied to the establishment of certain networks of
otherwise competing healthcare providers. There can be no assurance that
governmental authorities would not bring an investigation or proceeding
challenging this or some other aspect of the Company's operations under these
laws, or that such an investigation or proceeding would not result in a
material adverse effect on the Company's business and results of operations.
See "Business--Government Regulation."
Competition. The business of providing O&P patient-care services is highly
competitive. In addition to many local O&P practices, there are several
regional and multi-regional competitors which operate numerous patient-care
centers. The competition among O&P patient-care centers is primarily for
referrals from physicians, therapists, employers, health maintenance
organizations ("HMOs"), preferred provider organizations ("PPOs"), hospitals,
rehabilitation centers, out-patient clinics and insurance companies on both a
local and regional basis. Hanger also competes with other providers of O&P
services such as hospitals, physicians and therapists. In connection with its
efforts to acquire additional O&P patient-care practices, the Company
encounters competition from several other companies. The Company also
encounters competition from other manufacturers of non-customized orthotic and
prosthetic components. Finally, although the Company is the country's largest
distributor of O&P products, a majority of which are manufactured by other
companies, Hanger encounters competition from numerous smaller companies
engaged in the distribution of O&P products. There can be no assurance that
levels of competition will not increase or that such competition will not have
a material adverse effect on the Company's O&P patient-care services,
manufacturing or distribution activities or O&P patient-care practice
acquisition program. See "Business--Competition."
8
<PAGE>
Shares Eligible for Future Sale. As of June 20, 1997, the Company had
9,465,811 shares of Common Stock outstanding, of which 8,366,811 shares are
freely tradeable without restriction under federal securities laws, except
shares held by affiliates of the Company. Of the currently outstanding shares,
1,099,000 constitute "restricted securities" as that term is defined under
Rule 144 under the Securities Act of 1933 and will be eligible for resale
commencing November 1, 1997, subject to compliance with volume limitations and
other restrictions under Rule 144. As of March 31, 1997, there were a total of
1,646,287 shares of Common Stock underlying outstanding options (of which
options for 531,921 shares are presently exercisable) and 2,076,644 shares
underlying outstanding warrants (of which warrants for 1,196,644 shares are
presently exercisable) to purchase shares from the Company. The shares
underlying substantially all of the outstanding options will be freely
tradeable upon issuance as a result of a currently effective registration
statement relating to certain of the Company's stock option plans and the
holders of substantially all of the outstanding warrants have rights to
require the Company to register the underlying shares. The Company, the
holders of an aggregate of 2,642,154 shares of Common Stock and the holders of
options and warrants to purchase 1,388,649 shares (including all shares
beneficially owned by the Company's directors and officers) have agreed that
they will not sell any shares of Common Stock held by them for a period of 90
days from the date of this Prospectus without the prior written consent of
Alex. Brown & Sons Incorporated. No prediction can be made as to the effect,
if any, that sales of shares of Common Stock, or the availability of such
shares for sale, will have on the market prices of the Company's Common Stock
prevailing from time to time. The possibility that substantial amounts of
shares may be sold in the public market may adversely affect prevailing market
prices for the Common Stock and could impair the Company's ability to raise
capital through the sale of its equity securities.
Absence of Dividends. The Company has never declared or paid, nor does it
intend to declare or pay, cash dividends on its Common Stock for the
foreseeable future, but intends instead to retain any future earnings to
finance expansion and operations. In addition, the Company's agreement with
its senior bank lender contains a minimum net worth covenant and prohibits the
payment of cash dividends. See "Dividend Policy" and "Management's Discussion
and Analysis of Financial Condition and Results of Operations--Liquidity and
Capital Resources."
9
<PAGE>
USE OF PROCEEDS
The net proceeds to the Company from the sale of the 4.5 million shares of
Common Stock offered hereby will be approximately $37.6 million ($43.4 million
if the Underwriters' over-allotment option is exercised in full), based upon a
public offering price of $9.06 per share.
The Company intends to use the net proceeds of the Offering to repay,
without penalty, existing indebtedness primarily incurred under the Company's
senior financing facilities (the "Facilities") with Banque Paribas (the
"Bank"), which were established on November 1, 1996. The Facilities were
established to provide up to $90.0 million principal amount of senior secured
financing that included: (i) $57.0 million of term loans (the "Term Loans")
for use in connection with Hanger's acquisition of JEH; (ii) an $8.0 million
revolving loan facility (the "Revolver"); and (iii) up to $25.0 million
principal amount of loans under an acquisition loan facility (the "Acquisition
Loans") for use in connection with future acquisitions. The proceeds of the
borrowings under the Term Loans and the Revolver, along with $8.0 million
raised on November 1, 1996 from the Bank and Chase Venture Capital Associates,
L.P. ("CVCA") upon the Company's issuance of Senior Subordinated Notes (the
"Senior Subordinated Notes") with detachable warrants, were primarily used to:
(i) provide $45.8 million cash consideration to JEH shareholders in connection
with the Company's acquisition of JEH; and (ii) refinance existing Hanger and
JEH indebtedness of approximately $20.7 million.
Of the $74.9 million principal amount of existing indebtedness of the
Company, the following amounts will be repaid out of the net proceeds of the
Offering: (i) the $8.0 million of Senior Subordinated Notes, maturing on
November 1, 2004 and bearing annual interest of 8.0%; (ii) $23.6 million
principal amount of Term Loans, maturing between December 31, 2001 and
December 31, 2003 and bearing annual interest between LIBOR plus 2.75% and
LIBOR plus 3.25%; (iii) $500,000 of borrowings under the Revolver, maturing on
November 1, 2001 and bearing annual interest of LIBOR plus 2.75%; and (iv)
$5.5 million principal amount of Acquisition Loans, maturing on November 1,
2001 and bearing annual interest of LIBOR plus 2.75%. Upon repayment of the
Senior Subordinated Notes, the Company will be required to write off the
unamortized debt discount, which was $1.9 million ($1.1 million net of tax
benefit) at March 31, 1997, recorded upon the issuance of such notes.
DIVIDEND POLICY
The Company has never declared or paid, nor does it intend to declare or pay
in the forseeable future, cash dividends on the Common Stock, but intends
instead to retain future earnings to finance expansion and operations. Certain
financial covenants in the Company's loan agreement with the Bank limit the
ability of the Company to pay dividends or make other distributions on the
Common Stock. See "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Liquidity and Capital Resources."
10
<PAGE>
PRICE RANGE OF COMMON STOCK
The Common Stock is listed and traded on the American Stock Exchange under
the symbol "HGR." The following table sets forth the high and low intra-day
sale prices for the Common Stock for the periods indicated as reported on the
AMEX:
<TABLE>
<CAPTION>
HIGH LOW
----- -----
<S> <C> <C>
YEAR ENDED DECEMBER 31, 1995
First Quarter.............................................. $3.13 $2.50
Second Quarter............................................. 3.50 2.19
Third Quarter.............................................. 3.88 2.75
Fourth Quarter............................................. 3.50 2.56
YEAR ENDED DECEMBER 31, 1996
First Quarter.............................................. $4.75 $2.63
Second Quarter............................................. 6.50 4.06
Third Quarter.............................................. 7.50 4.88
Fourth Quarter............................................. 7.38 5.81
YEAR ENDING DECEMBER 31, 1997
First Quarter.............................................. $7.00 $5.50
Second Quarter (through July , 1997)..................... 6.25
</TABLE>
On July , 1997, the last reported sale price of the Common Stock on the
AMEX was $ per share. At July 23, 1997, there were approximately 910
holders of record of Common Stock.
11
<PAGE>
CAPITALIZATION
The following table sets forth as of March 31, 1997: (i) the capitalization
of the Company; (ii) the capitalization of the Company on a pro forma basis to
reflect acquisitions completed after March 31, 1997; and (iii) the
capitalization of the Company on a pro forma as adjusted basis to reflect the
sale of the shares of Common Stock offered hereby (based on an assumed
offering price of $9.06 per share) and the application of the estimated net
proceeds therefrom, all as if they occurred on March 31, 1997:
<TABLE>
<CAPTION>
MARCH 31, 1997
-------------------------------------
PRO FORMA
ACTUAL PRO FORMA(1) AS ADJUSTED(2)
-------- ------------ --------------
(IN THOUSANDS)
<S> <C> <C> <C>
Outstanding debt:
Revolving Loan Commitment............... $ 500 $ 500 $ --
Acquisition Loan Commitment............. 5,500 8,065 --
A Term Loan............................. 29,000 29,000 18,280
B Term Loan............................. 28,000 28,000 17,650
8.0% Senior Subordinated Notes due
November 2004.......................... 6,067 6,067 --
Subordinated seller notes and other
miscellaneous obligations.............. 5,801 8,417 8,417
-------- -------- --------
Total outstanding debt.............. 74,868 80,049 44,347
-------- -------- --------
Mandatorily redeemable preferred stock:
Class C, par value $.01; 300 shares
authorized, issued and outstanding
liquidation preference of $500 per
share plus accrued dividends........... 284 284 284
Class F, par value $.01; 100,000 shares
authorized, no shares issued or
outstanding; liquidation preference
$1,000 per share plus accrued
dividends.............................. -- -- --
Shareholders' equity:
Common Stock--$.01 par value; 25,000,000
shares authorized; 9,493,766 shares
issued and 9,360,270 shares
outstanding; 9,557,766 shares issued
and 9,424,270 shares outstanding on a
pro forma basis; 14,057,766 shares
issued and 13,924,270 shares
outstanding on a pro forma as adjusted
basis(3)............................... 95 96 141
Additional paid-in capital............... 41,087 41,586 79,176
Accumulated deficit...................... (96) (96) (1,242)
Treasury stock, cost--(133,495 shares)... (655) (655) (655)
-------- -------- --------
Total shareholders' equity.......... 40,431 40,931 77,420
-------- -------- --------
Total capitalization............... $115,583 $121,264 $122,051
======== ======== ========
</TABLE>
- --------
(1) Gives effect to the consummation of the acquisitions after March 31, 1997.
See "Business--Acquisitions."
(2) Gives effect to the application of the net proceeds from the sale of 4.5
million shares of Common Stock offered hereby by the Company at an assumed
public offering price of $9.06 share. Shareholders' equity reflects debt
discounts and deferred finance costs of $2.0 million ($1.1 million net of
tax benefit) expensed as a result of the retirement of certain
indebtedness from the assumed use of proceeds of the Offering. See "Use of
Proceeds."
(3) Excludes: (i) 401,296 shares of Common Stock issuable upon exercise of
stock options outstanding under the Company's 1991 Stock Option Plan with
a weighted average exercise price of $5.62 per share at June 24, 1997;
(ii) 61,250 shares of Common Stock issuable upon the exercise of stock
options outstanding under the Company's 1993 Non-Employee Director Stock
Option Plan with a weighted average exercise price of $5.70 per share;
(iii) 69,375 shares of Common Stock issuable upon exercise of outstanding
non-qualified options at a weighted average exercise price of $8.46 per
share; and (iv) 1,196,644 shares of Common Stock issuable upon exercise of
outstanding warrants at a weighted average exercise price of $5.35 per
share. See "Principal Shareholders."
12
<PAGE>
SELECTED HISTORICAL AND PRO FORMA CONSOLIDATED FINANCIAL INFORMATION
The selected historical consolidated statement of operations data for the
years ended December 31, 1994, 1995 and 1996, and the selected consolidated
balance sheet data as of December 31, 1995 and 1996, presented below, are
derived from the audited Consolidated Financial Statements and Notes thereto
included elsewhere in this Prospectus. The selected historical consolidated
statement of operations data for the quarters ended March 31, 1996 and 1997,
and the selected historical consolidated balance sheet data as of March 31,
1997, are derived from unaudited financial statements included elsewhere in
this Prospectus, and include, in the opinion of management, all adjustments
(consisting only of normal recurring adjustments) necessary for a fair
presentation of the financial position and results of operations of the
Company for such periods. In view of the significance of JEH, which was
acquired by the Company effective November 1, 1996 in a transaction accounted
for as a purchase, the results of operations for the quarter ended March 31,
1997 are not comparable with the results for the quarter ended March 31, 1996.
Furthermore, the results of operations for the quarter ended March 31, 1997
are not necessarily indicative of the results to be expected for the entire
year ending December 31, 1997, or any future period.
The following selected pro forma consolidated financial information should
be read in conjunction with the Pro Forma Consolidated Condensed Financial
Statements for the year ended December 31, 1996 and quarter ended March 31,
1997, and the Notes thereto included elsewhere in this Prospectus. The pro
forma adjustments are described in the accompanying Notes to the Pro Forma
Consolidated Condensed Financial Statements.
13
<PAGE>
SELECTED HISTORICAL AND CONSOLIDATED FINANCIAL INFORMATION
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
QUARTERS
YEARS ENDED DECEMBER 31, ENDED MARCH 31,
-------------------------------------------------------- -----------------------------
PRO FORMA PRO FORMA
AS ADJUSTED AS ADJUSTED
1992 1993 1994 1995 1996 1996(4) 1996 1997 1997(5)
------- ------- ------- ------- ------- ----------- ------- ------- -----------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net sales.................... $32,405 $43,877 $50,300 $52,468 $66,806 $131,557 $12,229 $30,950 $33,139
Gross profit................. 17,277 24,207 27,091 27,896 34,573 64,264 6,344 14,720 16,111
Selling, general and
administrative.............. 13,064 17,124 21,340 19,362 24,550 46,137 4,997 10,925 11,783
Depreciation and
amortization................ 2,100 2,656 3,137 2,691 2,848 4,846 646 1,159 1,227
Acquisition and
integration costs(1)........ -- -- -- -- 2,479 2,479 -- -- --
Restructuring costs(1)....... -- -- 460 -- -- -- -- -- --
Loss from disposal of
assets(1)................... -- -- 2,150 -- -- -- -- -- --
Income from continuing
operations.................. 2,113 4,428 4 5,843 4,695 10,801 701 2,636 3,101
Interest expense............. (1,279) (1,167) (1,746) (2,056) (2,547) (4,075) (393) (1,527) (939)
Income (loss) from continuing
operations before taxes,
extraordinary item and
accounting change........... 807 3,221 (1,922) 3,680 1,971 6,740 263 1,065 2,123
Provision for income taxes... 487 1,627 358 1,544 890 3,036 113 447 892
Income (loss) from continuing
operations before
extraordinary item and
accounting change........... 320 1,594 (2,280) 2,135 1,081 3,704 150 618 1,232
Loss from
discontinued operations(2).. (35) (105) (407) -- -- -- -- -- --
Income (loss) before
extraordinary item and
accounting change........... 285 1,490 (2,687) 2,135 1,081 3,704 150 618 1,232
Extraordinary loss on early
extinguishment of debt...... (1,139) (23) -- -- (83) (83) -- -- --
Cumulative effect of change
in accounting for income
taxes....................... -- 1,189 -- -- -- -- -- -- --
Net income (loss)(6)......... (853) 2,655 (2,687) 2,135 998 3,621 150 618 1,232
INCOME (LOSS) PER COMMON
SHARE(3)(6):
Income (loss) from continuing
operations before
extraordinary item and
accounting change........... $ 0.03 $ 0.19 $ (0.28) $ 0.26 $ 0.12 $ 0.26 $ 0.02 $ 0.06 $ 0.08
Loss from
discontinued operations..... -- (0.01) (0.05) -- -- -- -- -- --
Extraordinary loss on early
extinguishment of debt...... (0.15) -- -- -- (0.01) (0.01) -- -- --
Cumulative effect of change
in accounting for income
taxes....................... -- 0.14 -- -- -- -- -- -- --
------- ------- ------- ------- ------- -------- ------- ------- -------
Net income (loss) per common
share....................... $ (0.12) $ 0.32 $ (0.33) $ 0.26 $ 0.11 $ 0.25 $ 0.02 $ 0.06 $ 0.08
======= ======= ======= ======= ======= ======== ======= ======= =======
Weighted average common
shares outstanding.......... 7,565 8,344 8,290 8,291 8,663 14,544 8,324 9,978 14,542
</TABLE>
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
---------------------------------------- -----------------------
1997
1992 1993 1994 1995 1996 1997 AS ADJUSTED(7)
------- ------- ------- ------- -------- -------- --------------
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Cash and cash
equivalents............ $ 1,391 $ 1,404 $ 1,048 $ 1,456 $ 6,572 $ 6,720 $ 3,220
Working capital......... 11,886 15,738 18,412 20,622 25,499 28,825 27,153
Total assets............ 48,844 57,427 61,481 61,800 134,941 138,158 144,206
Long-term debt.......... 14,970 19,153 24,330 22,925 64,298 68,815 37,242
Shareholders' equity.... 28,564 31,681 29,178 31,291 39,734 40,431 77,419
</TABLE>
See accompanying notes on following page.
14
<PAGE>
(1) The 1994 results include restructuring costs of $460,000 associated with
the closing of unprofitable patient-care centers and a loss from the
disposal of assets of $2.2 million resulting from the sale of the
Company's southern California patient-care centers. The 1996 results
include acquisition and integration costs of $2.5 million incurred in
connection with the purchase of JEH effective November 1, 1996. See Notes
F and D to the Company's Consolidated Financial Statements, respectively.
(2) Loss from discontinued operations consists of the loss from discontinued
operations and the sale of the discontinued operation of the Company's
Apothecaries, Inc. subsidiary, the assets of which were sold in 1994. See
Note E to the Company's Consolidated Financial Statements.
(3) Income (loss) per common share is calculated using the weighted average
common and common equivalent shares outstanding during the period, and has
been adjusted for preferred stock dividends.
(4) Adjusted to give effect to: (i) acquisitions which occurred during 1996
and the five months ended May 31, 1997; and (ii) the reduction in interest
expense resulting from the assumed use of the estimated net proceeds of
this Offering upon the sale by the Company of 4.5 million shares of Common
Stock offered hereby at an offering price of $9.06 per share, after
deducting the underwriting discounts and commissions and estimated
offering expenses payable by the Company, as if such transactions had
occurred as of the beginning of 1996. See "Use of Proceeds" and "Unaudited
Pro Forma Consolidated Financial Statements."
(5) Adjusted to give effect to: (i) acquisitions which occurred during the
five months ended May 31, 1997; and (ii) the reduction in interest expense
resulting from the assumed use of the estimated net proceeds of this
Offering upon the sale by the Company of 4.5 million shares of Common
Stock offered hereby at an offering price of $9.06 per share, after
deducting the underwriting discounts and commissions and estimated
offering expenses payable by the Company, as if such transactions had
occurred as of the beginning of 1997. See "Use of Proceeds" and "Unaudited
Pro Forma Consolidated Financial Statements."
(6) Pro forma as adjusted net income and net income per common share do not
include debt discounts and deferred financing fees of $2.0 million ($1.1
million net of tax benefit) for the year ended December 31, 1996 and $2.0
million ($1.1 million net of tax benefit) for the quarter ended March 31,
1997, expensed as a result of the retirement of certain indebtedness from
the assumed use of the estimated net proceeds therefrom. See "Use of
Proceeds."
(7) Adjusted to give effect to the sale by the Company of 4.5 million shares
of Common Stock in this Offering and the application of the estimated net
proceeds therefrom, assuming an offering price of $9.06 per share.
Shareholders' equity reflects debt discounts and deferred financing costs
of $2.0 million ($1.1 million net of tax benefit) expensed as a result of
the retirement of certain indebtedness from the assumed use of proceeds of
this Offering. See "Use of Proceeds."
15
<PAGE>
SELECTED UNAUDITED PRO FORMA CONSOLIDATED CONDENSED FINANCIAL INFORMATION
The following unaudited pro forma consolidated condensed statement of
operations for the quarter ended March 31, 1997 is based on the historical
financial statements of the Company, adjusted to give effect to the
acquisition of certain assets and assumption of certain liabilities of
Prosthetic Treatment Center, Inc. ("Kingsport"), the retail division of ACOR
Orthopaedic, Inc. ("ACOR"), and the financial statements of Fort Walton
Orthopedic, Inc. and Mobile Limb & Brace, Inc. ("FWM"). The following
unaudited pro forma consolidated condensed balance sheet as of March 31, 1997
is based on the historical financial statements of the Company, adjusted to
give effect to the acquisition of certain assets and assumption of certain
liabilities of ACOR and FWM. The following unaudited pro forma consolidated
condensed statement of operations for the year ended December 31, 1996 is
based on the historical financial statements of Hanger, adjusted to give
effect to the acquisition of certain assets and assumption of certain
liabilities of Kingsport, ACOR, FWM and JEH.
The unaudited pro forma consolidated condensed statement of operations for
the quarter ended March 31, 1997 has been prepared assuming the Kingsport,
ACOR and FWM acquisitions occurred as of January 1, 1997. The unaudited pro
forma consolidated condensed statement of operations for the year ended
December 31, 1996 has been prepared assuming the Kingsport, ACOR, FWM and JEH
acquisitions occurred as of January 1, 1996. The unaudited pro forma
consolidated condensed balance sheet as of March 31, 1997 has been prepared
assuming that the ACOR and FWM acquisitions occurred as of March 31, 1997. The
acquisition and related adjustments are described in the notes thereto.
The unaudited pro forma consolidated condensed financial statements of
operations do not purport to represent what the Company's results of
operations would actually have been had the transactions in fact occurred on
the aforementioned date, or to project the Company's results of operations for
any future period.
The pro forma adjustments are based upon available information and upon
certain assumptions that management believes are reasonable. These adjustments
are directly attributable to the transactions and are expected to have a
continuing impact on the financial position and results of operations of the
Company.
The unaudited pro forma consolidated condensed statements of operations
should be read in conjunction with the Company's consolidated financial
statements and the financial statements of JEH and ACOR included elsewhere in
this Prospectus. See "Capitalization" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations." The consolidated
condensed pro forma financial information does not give effect to any matters
other than those described in the notes thereto.
16
<PAGE>
UNAUDITED PRO FORMA CONSOLIDATED CONDENSED BALANCE SHEET AS OF MARCH 31, 1997
<TABLE>
<CAPTION>
HISTORICAL
------------
HANGER
ORTHOPEDIC ACQUIRED PRO FORMA OFFERING PRO FORMA
GROUP, INC. COMPANIES(1) ADJUSTMENTS PRO FORMA(8) ADJUSTMENTS(7) AS ADJUSTED
------------ ------------ ----------- ------------ -------------- ------------
<S> <C> <C> <C> <C> <C> <C>
ASSETS
Current Assets:
Cash and cash
equivalents............ $ 6,720,021 $ 572,187 $(4,072,187)(2)(3) $ 3,220,021 $ -- $ 3,220,021
Accounts receivable..... 24,528,348 1,397,001 -- 25,925,349 -- 25,925,349
Inventory............... 15,650,023 1,044,985 -- 16,695,008 -- 16,695,008
Prepaids and other
assets................. 2,756,664 18,679 -- 2,775,343 -- 2,775,343
Deferred income taxes... 3,159,280 -- -- 3,159,280 -- 3,159,280
------------ ---------- ----------- ------------ ------------ ------------
Total Current Assets..... 52,814,336 3,032,852 (4,072,187) 51,775,001 -- 51,775,001
------------ ---------- ----------- ------------ ------------ ------------
Property, plant and
equipment, net......... 17,287,656 140,304 (15,350)(2) 17,412,610 -- 17,412,610
Intangible assets, net.. 67,081,267 -- 7,002,372 74,083,639 (42,000) 74,041,639
Other assets............ 975,083 1,264 -- 976,347 -- 976,347
------------ ---------- ----------- ------------ ------------ ------------
Total Assets............. $138,158,342 $3,174,420 $ 2,914,835 $144,247,597 $ (42,000) $144,205,597
============ ========== =========== ============ ============ ============
LIABILITIES
Current Liabilities:
Current portion of long-
term debt.............. $ 6,052,939 $ 15,501 $ 1,036,461(2)(4) $ 7,104,901 $ -- $ 7,104,901
Accounts payable........ 2,834,080 337,453 -- 3,171,533 -- 3,171,533
Accrued expenses and
other.................. 15,102,741 137,121 (65,750)(2) 15,174,112 (829,000) 14,345,112
------------ ---------- ----------- ------------ ------------ ------------
Total Current
Liabilities............. 23,989,760 490,075 970,711 25,450,546 (829,000) 24,621,546
------------ ---------- ----------- ------------ ------------ ------------
Long-term debt.......... 68,815,270 40,580 4,087,889(2)(4) 72,943,739 (35,701,375) 37,242,364
Deferred income taxes... 2,377,627 -- -- 2,377,627 -- 2,377,627
Other liabilities....... 2,544,850 -- -- 2,544,850 -- 2,544,850
------------ ---------- ----------- ------------ ------------ ------------
Total Liabilities........ 97,727,507 530,655 5,058,600 103,316,762 (36,530,375) 66,786,387
------------ ---------- ----------- ------------ ------------ ------------
SHAREHOLDERS' EQUITY
Common stock............ 94,938 5,900 (5,260)(5)(6) 95,578 45,000 140,578
Additional paid-in
capital................ 41,087,021 19,296 480,064(5)(6) 41,586,381 37,589,375 79,175,756
Retained earnings
(Accumulated deficit).. (95,562) 2,618,569 (2,618,569)(5) (95,562) (1,146,000) (1,241,562)
------------ ---------- ----------- ------------ ------------ ------------
41,086,397 2,643,765 (2,143,765) 41,586,397 36,488,375 78,074,772
Treasury stock.......... (655,562) -- -- (655,562) -- (655,562)
------------ ---------- ----------- ------------ ------------ ------------
Total Shareholders'
Equity.................. 40,430,835 2,643,765 (2,143,765) 40,930,835 36,488,375 77,419,210
------------ ---------- ----------- ------------ ------------ ------------
Total Liabilities and
Shareholders' Equity.... $138,158,342 $3,174,420 $ 2,914,835 $144,247,597 $ (42,000) $144,205,597
============ ========== =========== ============ ============ ============
</TABLE>
- -------
(1) The aggregate purchase price for the acquisitions consummated subsequent to
March 31, 1997 amounts to approximately $9.2 million, comprised of $6.1
million in cash, seller notes of $2.6 million and the issuance of 64,000
shares of Common Stock with a value of approximately $500,000. Condensed
historical balance sheet information for businesses acquired subsequent to
March 31, 1997:
<TABLE>
<CAPTION>
CURRENT TOTAL CURRENT TOTAL
COMPANY ASSETS ASSETS LIABILITIES EQUITY
------- ---------- ---------- ----------- ----------
<S> <C> <C> <C> <C>
ACOR............................ $1,978,769 $2,063,355 $381,705 $1,681,650
FWM............................. 1,054,083 1,111,065 108,370 962,115
---------- ---------- -------- ----------
Total......................... $3,032,852 $3,174,420 $490,075 $2,643,765
========== ========== ======== ==========
</TABLE>
(2) Adjusts assets and liabilities to fair market value and eliminates certain
assets and liabilities not assumed by the Company.
17
<PAGE>
(3) Reflects that the $3.5 million paid in cash at settlement for the ACOR
acquisition had been funded from the Acquisition Loans on March 31, 1997
and the cash and debt amounts are included in the historical Company
balance sheet as of March 31, 1997.
(4) Reflects long-term debt and notes payable which the Company incurred to
purchase ACOR and FWM.
(5) Eliminates ownership interest in the companies acquired.
(6) Represents issuance of 64,000 shares of Company Common Stock at $7.81 per
share in conjunction with the FWM acquisition.
(7) Reflects the application of net proceeds from the sale of Common Stock in
this Offering and the recognition of the expense of $2.0 million ($1.1
million net of tax benefit) of debt discounts and deferred financing fees
as if these transactions occurred as of March 31, 1997. See "Use of
Proceeds."
(8) Excludes potential future contingent consideration to be paid to former
shareholders of acquired companies based on prescribed formulas.
Contingent consideration is to be accounted for as additional purchase
price consideration if and when it becomes probable.
18
<PAGE>
UNAUDITED PRO FORMA CONSOLIDATED CONDENSED STATEMENT OF OPERATIONS FOR THE
QUARTER ENDED MARCH 31, 1997
<TABLE>
<CAPTION>
HISTORICAL
-----------
HANGER
ORTHOPEDIC ACQUIRED PRO FORMA OFFERING PRO FORMA
GROUP, INC. COMPANIES(1) ADJUSTMENTS PRO FORMA(11) ADJUSTMENTS AS ADJUSTED
----------- ------------ ----------- ------------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C>
Net sales............... $30,949,614 $2,287,219 $ (97,780)(2) $33,139,053 $ -- $33,139,053
Cost of sales........... 16,229,929 893,000 (95,009)(2) 17,027,920 -- 17,027,920
----------- ---------- --------- ----------- -------- -----------
Gross profit............ 14,719,685 1,394,219 (2,771) 16,111,133 -- 16,111,133
Selling, general
and administrative..... 10,924,635 858,466 -- (5) 11,783,101 -- 11,783,101
Depreciation and
amortization........... 1,158,817 5,786 61,969(3)(4) 1,226,572 -- 1,226,572
----------- ---------- --------- ----------- -------- -----------
Income from operations.. 2,636,233 529,967 (64,740) 3,101,460 -- 3,101,460
Interest expense........ (1,527,269) -- (236,887)(6) (1,764,156) 824,808(8) (939,348)
Other expense........... (43,749) 5,866 (1,042)(6) (38,925) -- (38,925)
----------- ---------- --------- ----------- -------- -----------
Income from operations
before taxes........... 1,065,215 535,833 (302,669) 1,298,379 824,808 2,123,187
Provision for income
taxes.................. 447,300 -- 97,928(7) 545,228 346,420(9) 891,648
----------- ---------- --------- ----------- -------- -----------
Net income.............. $ 617,915 $ 535,833 $(400,597) $ 753,151 $478,388 $ 1,231,539
=========== ========== ========= =========== ======== ===========
Net income per common
share(10):............. $ 0.06 $ 0.07 $ 0.08
----------- ----------- -----------
Shares used to compute
net income per common
share:................. 9,977,853 10,041,853 14,541,853
----------- ----------- -----------
</TABLE>
- --------
(1) The historical statements of operations data for Kingsport, ACOR and FWM
(collectively, the "Acquired Companies") for the quarter ended March 31,
1997 represent the results of operations of such companies from January
1, 1997 to the earlier of their respective dates of acquisition or March
31, 1997. Each of the acquisitions has been accounted for as a purchase.
Accordingly, the results of operations of each of the Acquired Companies
are included in the historical results of operations of the Company from
the date of its acquisition.
Represents results of operations of the Acquired Companies prior to their
acquisition dates for the periods presented:
<TABLE>
<CAPTION>
QUARTER ENDED MARCH 31, 1997
----------------------------
COMPANY ACQUIRED AS OF NET SALES NET INCOME (LOSS)
------- -------------- ---------- -----------------
<S> <C> <C> <C>
Kingsport...................... March 5, 1997 $ 56,920 $(11,361)
ACOR........................... April 1, 1997 1,290,580 194,290
FWM............................ May 12, 1997 939,719 352,904
---------- --------
Total........................ $2,287,219 $535,833
========== ========
</TABLE>
(2) The adjustments to reduce sales ($97,780) and cost of sales ($95,009)
reflect the elimination of profit on intercompany sales during the period
presented.
(3) Reflects increases in historical amounts of the Acquired Companies for
amortization expense resulting from the revaluation in purchase
accounting of intangible assets, as follows:
<TABLE>
<CAPTION>
QUARTER ENDED
COMPANY MARCH 31, 1997
------- --------------
<S> <C>
Kingsport.................................................... $1,667
ACOR......................................................... 2,500
FWM.......................................................... 1,908
------
Total...................................................... $6,075
======
</TABLE>
19
<PAGE>
(4) Reflects additional amortization over a 40-year period, as if such
Acquired Companies were acquired as of the beginning of the period
presented, as follows:
<TABLE>
<CAPTION>
QUARTER ENDED
COMPANY MARCH 31, 1997
------- --------------
<S> <C>
JEH*......................................................... $11,146
Kingsport.................................................... 1,535
ACOR......................................................... 24,913
FWM.......................................................... 18,300
-------
Total...................................................... $55,894
=======
</TABLE>
--------
* Reflects the full-period effect of amortization incurred as a result of
the final working capital adjustment paid to the former shareholders of
JEH.
(5) Excludes reductions to historical amounts approximating $35,000 for
employee and practitioner salaries of the Acquired Companies as a result
of termination of employment of certain employees and the elimination of
employer retirement plan contributions and certain other items.
(6) The additional interest expense of $236,887 and the reduction in other
income of $1,042 reflect what would have been incurred if the
consideration (in the form of cash and promissory notes) for the Acquired
Companies had been paid at January 1, 1997. The interest rates used to
calculate pro forma interest (between 8% and 9%) on the assumed
additional debt required to fund the cash payments reflect the Company's
approximate borrowing rate.
<TABLE>
<CAPTION>
QUARTER ENDED MARCH 31, 1997
-----------------------------
COMPANY INTEREST EXPENSE OTHER INCOME
------- ---------------- ------------
<S> <C> <C>
JEH*.......................................... $ 41,264 $ --
Kingsport..................................... 3,244 (1,042)
ACOR.......................................... 117,563 --
FWM........................................... 74,816 --
-------- -------
Total....................................... $236,887 $(1,042)
======== =======
</TABLE>
--------
* Reflects the full-period effect of interest incurred as a result of the
final working capital adjustment paid to the former shareholders of JEH.
(7) Reflects income taxes as if each of the Company, JEH and the Acquired
Companies were a C Corporation for the period presented.
(8) Represents the assumed application of estimated net proceeds to be
received in this Offering as of the beginning of the period presented.
Pro forma interest expense, net income and net income per common share do
not include $2.0 million ($1.1 million net of tax benefit) in debt
discounts and deferred financing fees expensed as a result of the
retirement of certain indebtedness from such net proceeds. The following
reflects the debt to be repaid by the Company from the net proceeds in
this Offering and the debt to be outstanding as of March 31, 1997 on a
pro forma as adjusted basis.
<TABLE>
<CAPTION>
REMAINING
DESCRIPTION REPAID INDEBTEDNESS
----------- ----------- ------------
<S> <C> <C>
Senior Subordinated Notes.......................... $ 8,000,000 $ --
Acquisition Line of Credit and Revolver............ 8,565,000 --
A Term Loan Commitment............................. 10,719,507 18,280,493
B Term Loan Commitment............................. 10,349,868 17,650,132
Subordinated seller notes and other................ -- 8,416,640
----------- -----------
$37,634,375 $44,347,265
=========== ===========
</TABLE>
20
<PAGE>
(9) Represents the adjustments to income taxes which would have been provided
on a pro forma as adjusted income before income taxes basis using an
effective tax rate of 42%.
(10) Historical and pro forma net income per common share, which have been
adjusted for preferred stock dividends, are computed by dividing net
income by the number of weighted average common and common equivalent
shares outstanding for the period. The shares used in the computation of
net income per common share on a pro forma as adjusted basis also include
Common Stock issued in connection with acquisitions and Common Stock
being sold pursuant to this Offering.
(11) The unaudited pro forma amounts exclude potential future contingent
consideration to be paid to former shareholders of acquired companies
based on prescribed formulas. Contingent consideration is to be accounted
for as additional purchase price consideration if and when it becomes
probable.
21
<PAGE>
UNAUDITED PRO FORMA CONSOLIDATED CONDENSED STATEMENT OF OPERATIONSFOR THE YEAR
ENDED DECEMBER 31, 1996
<TABLE>
<CAPTION>
HISTORICAL
-----------
HANGER
ORTHOPEDIC ACQUIRED PRO FORMA OFFERING PRO FORMA
GROUP, INC. COMPANIES(1) ADJUSTMENTS PRO FORMA(13) ADJUSTMENTS AS ADJUSTED
----------- ------------ ----------- ------------- ----------- ------------
<S> <C> <C> <C> <C> <C> <C>
Net sales............... $66,805,944 $64,878,148 $ (127,555)(2) $131,556,537 $ -- $131,556,537
Cost of sales........... 32,233,373 35,113,611 (54,519)(2)(3)(4) 67,292,465 -- 67,292,465
----------- ----------- ----------- ------------ ---------- ------------
Gross profit............ 34,572,571 29,764,537 (73,036) 64,264,072 -- 64,264,072
Selling, general
and administrative..... 27,029,315 22,083,280 (496,311)(3)(6)(7) 48,616,284 -- 48,616,284
Depreciation
and amortization....... 2,848,465 1,626,639 371,266(4)(5)(6) 4,846,370 -- 4,846,370
----------- ----------- ----------- ------------ ---------- ------------
Income from operations.. 4,694,791 6,054,618 52,009 10,801,418 -- 10,801,418
Interest expense........ (2,546,561) (394,650) (4,391,721)(8) (7,332,932) 3,257,595(10) (4,075,337)
Other income
(expense), net......... (177,216) 707,134 (515,751)(3)(8) 14,167 -- 14,167
----------- ----------- ----------- ------------ ---------- ------------
Income from operations
before taxes and
extraordinary item..... 1,971,014 6,367,102 (4,855,463) 3,482,653 3,257,595 6,740,248
Provision for income
taxes.................. 889,886 76,966 603,272(9) 1,570,124 1,465,918(11) 3,036,042
Extraordinary loss on
early extinguishment of
debt, net of tax....... 83,234 -- -- 83,234 -- 83,234
----------- ----------- ----------- ------------ ---------- ------------
Net income (loss)....... $ 997,894 $ 6,290,136 $(5,458,735) $ 1,829,295 $1,791,677 $ 3,620,972
=========== =========== =========== ============ ========== ============
Net income per common
share(12):............. $ 0.11 $ 0.18 $ 0.25
----------- ------------ ------------
Shares used to compute
net income per common
share:................. 8,663,161 10,043,604 14,543,604
----------- ------------ ------------
</TABLE>
- --------
(1) The historical statements of operations data for JEH and the Acquired
Companies for the year ended December 31, 1996 represent the results of
operations of such companies from January 1, 1996 to the earlier of their
respective dates of acquisition or December 31, 1996. Each of the
acquisitions has been accounted for as a purchase. Accordingly, the
results of operations of each of the above companies are included in the
historical results of operations of the Company from the date of its
acquisition.
Represents results of operations of JEH and each of the Acquired Companies
prior to their acquisition dates for the periods presented:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1996
-----------------------------
COMPANY ACQUIRED AS OF NET SALES NET INCOME (LOSS)
------- ---------------- ----------- -----------------
<S> <C> <C> <C>
JEH......................... November 1, 1996 $56,140,445 $4,518,040
Kingsport................... March 5, 1997 382,009 (126,995)
ACOR........................ April 1, 1997 5,231,514 1,271,402
FWM......................... May 12, 1997 3,124,180 627,689
----------- ----------
Total..................... $64,878,148 $6,290,136
=========== ==========
</TABLE>
(2) The adjustments to reduce sales ($127,555) and cost of sales ($123,940)
reflect the elimination of profit on intercompany sales during the period
presented.
(3) The adjustments to reduce cost of sales ($47,279), selling, general and
administrative expenses ($56,398) and other income ($439,151) reflect the
elimination of historical income and expenses generated from JEH assets
not acquired.
22
<PAGE>
(4) Reflects increases and reductions in historical amounts of JEH and the
Acquired Companies for depreciation and amortization expenses resulting
from the revaluation in purchase accounting of fixed assets and
intangible assets, as follows:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1996
--------------------------------------------------
COMPANY COST OF SALES DEPRECIATION AMORTIZATION TOTAL
------- ------------- ------------ ------------ ---------
<S> <C> <C> <C> <C>
JEH.................... $116,700 $116,700 $(1,213,744) $(980,344)
Kingsport.............. -- -- 10,000 10,000
ACOR................... -- -- 10,000 10,000
FWM.................... -- -- 7,630 7,630
-------- -------- ----------- ---------
Total................ $116,700 $116,700 $(1,186,114) $(952,714)
======== ======== =========== =========
</TABLE>
(5) Reflects additional amortization over a 40-year period, as if JEH and the
Acquired Companies were acquired as of the beginning of the period
presented, as follows:
<TABLE>
<CAPTION>
YEAR ENDED
COMPANY DECEMBER 31, 1996
------- -----------------
<S> <C>
JEH...................................................... $809,154
Kingsport................................................ 9,048
ACOR..................................................... 98,338
FWM...................................................... 78,260
--------
Total.................................................. $994,800
========
</TABLE>
(6) Reflects adjustments to depreciation and amortization for $445,880 of
additional amortized debt issue costs and selling, general and
administrative expenses for $85,000 of loan administative expenses as if
the $90.0 million credit facility had been in place on January 1, 1996.
(7) Includes a net reduction to historical amounts of $496,000 for employee
and practitioner salaries of JEH and the Acquired Companies to reflect
the difference between such historical amounts and amounts specified in
employment contracts for comparable employment positions with the
Company. Excludes reductions to historical amounts approximating $1.3
million as a result of termination of employment of certain employees and
the elimination of employer retirement plan contributions and certain
other items.
(8) The additional interest expense of $4.4 million and the reduction in
other income of $76,600 reflect what would have been incurred if the
consideration (in the form of cash and promissory notes) for JEH and the
Acquired Companies had been paid at January 1, 1997. The interest rates
used to calculate pro forma interest (between 8% and 9%) on the assumed
additional debt required to fund the cash payments reflect the Company's
approximate borrowing rate.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, 1996
-----------------------------
COMPANY INTEREST EXPENSE OTHER INCOME
------- ---------------- ------------
<S> <C> <C>
JEH.......................................... $3,639,611 $(70,350)
Kingsport.................................... 16,691 (6,250)
ACOR......................................... 440,265 --
FWM.......................................... 295,154 --
---------- --------
Total...................................... $4,391,721 $(76,600)
========== ========
</TABLE>
(9) Reflects income taxes as if each of the Company, JEH and the Acquired
Companies were a C Corporation for the period presented.
23
<PAGE>
(10) Represents the assumed application of estimated net proceeds to be
received in this Offering as of the beginning of the period presented.
Pro forma interest expense, net income and net income per common share do
not include $2.0 million ($1.1 million net of tax benefit) in debt
discounts and deferred financing fees expensed as a result of the
retirement of certain indebtedness from such net proceeds. The following
reflects the debt to be repaid by the Company from the net proceeds in
this Offering and the debt to be outstanding as of December 31, 1996 on a
pro forma as adjusted basis:
<TABLE>
<CAPTION>
REMAINING
DESCRIPTION REPAID INDEBTEDNESS
----------- ----------- ------------
<S> <C> <C>
Senior Subordinated Notes......................... $ 8,000,000 $ --
Acquisition Line of Credit........................ 7,885,253 --
A Term Loan Commitment............................ 11,065,343 17,934,657
B Term Loan Commitment............................ 10,683,779 17,316,221
Subordinated seller notes and other............... -- 9,061,834
----------- -----------
$37,634,375 $44,312,712
=========== ===========
</TABLE>
(11) Represents the adjustments to income taxes which would have been provided
on a pro forma as adjusted income before income taxes basis using an
effective tax rate of 45%.
(12) Historical and pro forma net income per common share, which have been
adjusted for preferred stock dividends, are computed by dividing net
income by the number of weighted average common and common equivalent
shares outstanding for the period. The shares used in the computation of
net income per share on a pro forma as adjusted basis also include Common
Stock issued in connection with acquisitions and Common Stock being sold
pursuant to this Offering.
(13) Excludes potential future contingent consideration to be paid to former
shareholders of acquired companies based on prescribed formulas.
Contingent consideration is to be accounted for as additional purchase
price consideration if and when it becomes probable.
24
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ANDRESULTS OF
OPERATIONS
The following discussion is qualified in its entirety by the more detailed
information and the Consolidated Financial Statements and Notes thereto
appearing elsewhere in this Prospectus.
OVERVIEW
The significant growth in the Company's O&P professional practice management
net sales has resulted from an aggressive program of acquiring and developing
O&P patient-care centers. Similarly, growth in the Company's O&P distribution
and manufacturing net sales is attributable primarily to acquisitions. Since
1986, when the Company acquired its first O&P practice, the Company has
acquired over 40 businesses and presently operates 190 patient-care centers,
six distribution facilities, three of which contain central fabrication
operations, and two manufacturing facilities. Since 1995, the Company has
significantly expanded OPNET, its national O&P preferred provider network, in
order to facilitate contracting with managed care organizations on a national
level.
COMPANY EXPANSION
During late-1994 and 1995, the Company closed or sold nine unprofitable
patient-care centers and temporarily discontinued its acquisition program.
Following a change in executive management in mid-1995 and a refinancing in
1996, the Company's acquisition program was resumed. The significant increase
in the number of patient-care centers and certified practitioners in 1996 is
attributable primarily to the Company's acquisition of JEH. The following
table sets forth the number of patient-care centers, certified practitioners
and states (including the District of Columbia) in which the Company operated
at the end of each of the past five years and at March 31, 1996 and 1997:
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
------------------------ ---------
1992 1993 1994 1995 1996 1996 1997
---- ---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C> <C>
Number of patient-care centers.............. 63 72 85 84 178 81 178
Number of certified practitioners........... 82 104 125 119 199 90 197
Number of states (including D.C.)........... 18 22 25 24 29 26 29
</TABLE>
NON-RECURRING CHARGES
As more fully discussed below under "Results of Operations," the Company's
results of operations have been adversely affected by certain non-recurring
charges, the most significant of which were associated with: (i) the sale or
closure of unprofitable patient-care centers and related restructuring charges
recorded in 1994; and (ii) non-recurring acquisition and integration costs
incurred in 1996 in connection with the acquisition of JEH.
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
----------------------------------
1992 1993 1994 1995 1996
------ ------ ------ ------ ------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Income from continuing operations (as
reported)................................. $2,113 $4,428 $ 4 $5,843 $4,695
Nature of non-recurring charges:
Loss from disposal of assets............. -- -- 2,150 -- --
Restructuring costs...................... -- -- 460 -- --
Acquisition and integration costs........ -- -- -- -- 2,479
------ ------ ------ ------ ------
Income from continuing operations
(excluding
non-recurring charges).................... $2,113 $4,428 $2,614 $5,843 $7,174
</TABLE>
25
<PAGE>
RECENT ACQUISITIONS
On November 1, 1996, the Company acquired JEH in a transaction that was
accounted for as a purchase. The acquisition, which increased the Company's
patient-care centers from 84 in 24 states and the District of Columbia to 178
in 28 states and the District of Columbia and significantly expanded its
distribution capabilities, impacted the last two months of the Company's
reported 1996 results of operations. JEH's net sales for the ten months ended
October 31, 1996 were $57.2 million. The total purchase price for JEH
consisted of approximately $45.8 million in cash plus 1.0 million shares of
the Company's Common Stock. The Company believes that as a result of the
Company's recognition, in late- 1996, of certain non-recurring costs incurred
in connection with the JEH acquisition and integration of the companies'
operations, as well as certain post-acquisition cost savings expected to be
realized, the Company's 1997 profitability will be enhanced. This forward-
looking statement should be read in conjunction with the risk factor captioned
"Risks Associated with Acquisition Strategy" under "Risk Factors." Since
January 1, 1997, the Company has also acquired the assets of four additional
O&P practices, representing an aggregate of nine patient-care centers and 18
practitioners. The four companies acquired by the Company had net sales of
$8.8 million in the year ended December 31, 1996 and were acquired for
aggregate consideration of $9.7 million.
SAME-CENTER SALES GROWTH
In addition to acquisitions of new patient-care centers, the growth in the
Company's net sales from O&P patient-care services is attributable to a lesser
degree to increases in net sales from existing patient-care centers. In 1994,
the Company's decline in same-center net sales growth was primarily as a
result of poor operating performance at several centers that the Company
subsequently sold or closed, the loss of several practitioners and severe
weather conditions in the first quarter. The following table sets forth, for
the periods indicated, the percentage increase (decreases) in net sales
contributed by those patient-care centers that were open during the entire
period as well as the prior year's entire comparable period:
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
----------------------------- ----------------
1992 1993 1994 1995 1996 1996 1997
---- ---- ----- ---- ---- ------- -------
<S> <C> <C> <C> <C> <C> <C> <C>
Percentage increase (decrease) in
same-center sales.................. 7.3% 4.4% (3.7)% 5.2% 5.8% 8.8% 10.6%
</TABLE>
CENTER-LEVEL RESULTS BY YEAR
The Company generally experiences rapid growth in net sales in the first
full calendar year following an acquisition or a new patient-care center
opening, with rates of growth moderating in the following years. In addition
to net sales growth, the Company tracks profitability as measured by center-
level EBITDA contribution before corporate overhead allocations. The following
table represents the aggregate average net sales growth and EBITDA
contribution margin of the Company's patient-care centers that have been
acquired or opened since 1990:
<TABLE>
<CAPTION>
YEAR 1(1) YEAR 2 YEAR 3 YEAR 4 YEAR 5
--------- ------ ------ ------ ------
<S> <C> <C> <C> <C> <C>
Average net sales growth.................. 12.1% 3.7% 3.7% 6.7% 4.4%
EBITDA contribution margin(2)............. 20.6% 21.8% 26.2% 22.0% 27.6%
</TABLE>
- --------
(1) Year one represents the first full year of operation by the Company
following the center's acquisition or opening.
(2) EBITDA contribution margin defined as income (loss) before interest
expense, taxes, depreciation and amortization, discontinued operations,
non-recurring charges, extraordinary item and accounting change as a
percentage of center-level net sales.
EBITDA margins for year 4 were negatively affected due to the
underperformance in the years ended December 31, 1994 and 1995 of centers
acquired in 1990 and 1991, respectively. This underperformance is primarily
attributable to the loss of certain O&P practitioners and the underperformance
by certain of the Company's patient-care centers. As previously discussed, the
Company closed or sold nine unprofitable patient-care centers and replaced
previously vacant practitioner positions beginning in late-1994 through 1995.
26
<PAGE>
SOURCES OF REVENUE
Although the Company's net sales continue to be most significantly derived
from O&P practice management activities, including patient-care services, the
percentage of the Company's total net sales attributable to O&P distribution
activities has increased. The following table sets forth the percentage
contribution to net sales in each of the periods indicated by the principal
sources of the Company's net sales. The increase in the percentage of net
sales contributed by distribution activities in the first quarter of 1997 is
attributable to the Company's acquisition of JEH in late 1996. Manufacturing
as a percentage of net sales declined to 6.3% for the quarter ended March 31,
1997 versus 15.7% for the same period of 1996. However, there was a slight
increase in the actual dollar amount of net sales attributable to
manufacturing.
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
---------------------------- ----------------
1992 1993 1994 1995 1996 1996 1997
---- ---- ---- ---- ---- ------- -------
<S> <C> <C> <C> <C> <C> <C> <C>
Sources of revenue:
Practice management
and patient-care services..... 82.5% 76.8% 78.0% 78.5% 78.2% 78.5% 74.6%
Manufacturing.................. 10.9 18.3 17.6 16.3 12.0 15.7 6.3
Distribution................... 6.6 4.9 4.4 5.2 9.8 5.8 19.1
---- ---- ---- ---- ---- ------- -------
100% 100% 100% 100% 100% 100% 100%
</TABLE>
PAYOR MIX
The Company receives payments for O&P services rendered to patients from
private insurers, HMOs, PPOs, the patients directly and governmental payors,
including Medicare, Medicaid and the VA. The sources and amounts of the
Company's revenues derived from its patient-care centers are determined by a
number of factors, including the number and nature of O&P services rendered
and the rates of reimbursement among payor categories. Generally, private
insurance and other third-party reimbursement levels are greater than managed
care (HMO/PPO), Medicare, Medicaid and VA reimbursement levels. Changes in the
Company's payor mix can affect its profitability. The following table sets
forth the percentage contribution to net sales in each of the following
periods by the principal categories of payors:
<TABLE>
<CAPTION>
YEARS ENDED QUARTERS ENDED
DECEMBER 31, MARCH 31,
-------------- ----------------
1995 1996 1996 1997
------ ------ ------- -------
<S> <C> <C> <C> <C>
Payor Mix(1):
Private pay and other......................... 43.4% 43.2% 50.0% 43.0%
Medicare/Medicaid/VA.......................... 56.6 56.8 50.0 57.0
------ ------ ------- -------
100% 100% 100% 100%
</TABLE>
- --------
(1) Payor mix data for the years ended December 31, 1995 and 1996 and for the
quarters ended March 31, 1996 and 1997 is based on a sampling of
approximately 40%, 75%, 30% and 75% of patient-care centers, respectively.
SELLING, GENERAL AND ADMINISTRATIVE MARGIN TRENDS
The Company seeks to achieve operating leverage of its corporate
infrastructure. In recent years, the rate of growth of the Company's corporate
overhead has been lower than the rate of growth of its consolidated net sales.
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
---------------------------- ----------------
1992 1993 1994 1995 1996 1996 1997
---- ---- ---- ---- ---- ------- -------
<S> <C> <C> <C> <C> <C> <C> <C>
Selling, general and
administrative margin........ 40.3% 39.0% 42.4% 36.9% 36.7% 40.9% 35.3%
</TABLE>
EBITDA AND OPERATING MARGIN TRENDS
The Company's EBITDA and operating margins have fluctuated over the past
five years. From 1992 to 1993, margins increased as a result of the successful
integration of acquired operations. In 1994, margins decreased due to the loss
of several practitioners, poor operating performance at several centers and
severe weather in the first quarter of the year. In 1995, margins increased to
1993 levels due to the sale
27
<PAGE>
and/or closing of the unprofitable practices. In 1996, margins declined
slightly when compared to 1995 as a result of the JEH acquisition. JEH has a
larger mix of distribution revenue than the Company, and distribution
operations have lower gross profit margins than patient-care services. Also
causing the decline in margins in 1996 was a decision by the management of the
Company not to eliminate any duplicate expenses during the two months ended
December 31, 1996 following the JEH acquisition. Exclusive of the JEH
acquisition, EBITDA margins increased in 1996 as compared to 1995. In the
first quarter of 1997, margins were lower than full-year 1996 margins due to
seasonal trends in the O&P industry. See "Seasonality." The following table
tracks the trends in the Company's EBITDA and operating margins:
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
---------------------------- ----------------
1992 1993 1994 1995 1996 1996 1997
---- ---- ---- ---- ---- ------- -------
<S> <C> <C> <C> <C> <C> <C> <C>
EBITDA margin................... 12.9% 16.1% 11.1% 16.1% 14.7% 10.6% 12.1%
Operating margin................ 6.5% 10.1% 5.2% 11.1% 10.7% 5.7% 8.5%
</TABLE>
SEASONALITY
The Company's results of operations are affected by seasonal considerations.
The adverse weather conditions often experienced in certain geographical areas
of the United States during the first quarter of each year, together with a
greater degree of patients' sole responsibility for their insurance deductible
payment obligations during the beginning of each calendar year, have
contributed to lower Company net sales during that quarter.
RESULTS OF OPERATIONS
The following table sets forth for the periods indicated certain items of
the Company's statements of operations as a percentage of the Company's net
sales:
<TABLE>
<CAPTION>
YEARS ENDED QUARTERS ENDED
DECEMBER 31, MARCH 31,
------------------- ----------------
1994 1995 1996 1996 1997
----- ----- ----- ------- -------
<S> <C> <C> <C> <C> <C>
Net sales.............................. 100.0% 100.0% 100.0% 100.0% 100.0%
Cost of products and services sold..... 46.1 46.8 48.2 48.1 52.4
Gross profit........................... 53.9 53.2 51.8 51.9 47.6
Selling, general and administrative.... 42.4 36.9 36.7 40.9 35.3
Depreciation and amortization.......... 4.8 3.8 3.0 3.9 2.4
Acquisition and integration costs...... -- -- 3.7 -- --
Amortization of excess cost over net
assets acquired....................... 1.4 1.3 1.2 1.4 1.3
Restructuring costs.................... 0.9 -- -- -- --
Loss from disposal of assets........... 4.3 -- -- -- --
Income from operations................. -- 11.1 7.0 5.7 8.5
Interest expense....................... 3.5 3.9 3.8 3.2 4.9
Income (loss) from continuing
operations............................ (3.8) 7.0 3.0 2.1 3.4
Income taxes........................... 0.7 2.9 1.3 0.9 1.4
Loss from discontinued operations...... (0.8) -- -- -- --
Net income (loss)...................... (5.3) 4.1 1.5 1.2 2.0
</TABLE>
QUARTERS ENDED MARCH 31, 1997 AND 1996
Net Sales. Net sales for the quarter ended March 31, 1997 were approximately
$30.9 million, an increase of approximately $18.7 million, or 153.1%, over net
sales of approximately $12.2 million for the quarter ended March 31, 1996. The
majority of increase was attributable to Hanger's acquisition of JEH. In
addition, contributing to the increase in net sales was an 10.6% increase in
sales by those Hanger patient-care centers operating during the entire period
of both quarters. The Company believes that its net sales during the balance
of 1997 will continue to exceed 1996 net sales.
Gross Profit. Gross profit during the quarter ended March 31, 1997 was
approximately $14.7 million, an increase of approximately $8.4 million, or
132.0%, over gross profit of approximately $6.3
28
<PAGE>
million for the quarter ended March 31, 1996. Gross profit as a percentage of
net sales decreased from 51.9% in the first quarter of 1996 to 47.6% in the
first quarter of 1997. The 4.3% decrease in gross profit as a percentage of
net sales is attributable primarily to the acquisition of JEH, which operated
a large distribution division that has lower gross profit margins than
patient-care services. The Company expects that its gross profit as a
percentage of net sales for the balance of 1997 will decline below the prior
year's level as a result of the operation of this division for an entire year.
Gross profit as a percentage of net sales for patient-care services was 52.4%
in each of the quarters ended March 31, 1996 and 1997. Gross profit as a
percentage of net sales for manufacturing and distribution was 35.8% in the
quarter ended March 31, 1996 and 23.1% in the quarter ended March 31, 1997.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses in the quarter ended March 31, 1997 increased by
approximately $5.9 million, or 118.6%, compared to the quarter ended March 31,
1996. The increase in selling, general and administrative expenses was
primarily a result of the acquisition of JEH. Selling, general and
administrative expenses as a percentage of net sales decreased to 35.3% from
40.9% for the same period in 1996. The decrease in selling, general and
administrative expenses as a percentage of net sales occurred primarily as a
result of cost cutting measures completed during the first quarter of 1997.
Income from Operations. Principally as a result of the above, income from
operations in the quarter ended March 31, 1997 was approximately $2.6 million,
an increase of $1.9 million, or 275.8%, over the prior year's comparable
quarter. Income from operations as a percentage of net sales increased to 8.5%
in the first quarter of 1997 from 5.7% for the prior year's comparable period.
Interest Expense. Interest expense in the first quarter of 1997 was
approximately $1.5 million, an increase of approximately $1.1 million, or
288.4%, over approximately $393,000 incurred in the first quarter of 1996.
Interest expense as a percentage of net sales increased to 4.9% from 3.2% for
the same period a year ago. The increase in interest expense was attributable
primarily to the $44.0 million increase in bank debt resulting from the
acquisition of JEH.
Income Taxes. The Company's effective tax rate was 42.0% in the first
quarter of 1997 versus 42.9% in 1996. The provision for income taxes in the
first quarter of 1997 was approximately $447,000 compared to approximately
$113,000 in the first quarter of 1996.
Net Income. As a result of the above, the Company recorded net income of
$618,000, or $.06 per common share on approximately 10.0 million weighted
average common shares outstanding for the quarter ended March 31, 1997,
compared to net income of approximately $150,000, or $.02 per common share on
approximately 8.3 million weighted average common shares outstanding in the
quarter ended March 31, 1996.
YEARS ENDED DECEMBER 31, 1996 AND 1995
Net Sales. Net sales for the year ended December 31, 1996 were approximately
$66.8 million, an increase of approximately $14.3 million, or 27.3%, over net
sales of approximately $52.5 million for the year ended December 31, 1995. The
increase was primarily a result of: (i) an increase of $12.1 million
attributable to the acquisition of JEH; and (ii) an increase of $2.2 million,
or 5.6%, in net sales attributable to patient-care centers and facilities that
were in operation during both periods. Of the $2.2 million increase in net
sales, $1.8 million was attributable to patient-care centers and $293,000 was
attributable to manufacturing and distribution activities.
Gross Profit. Gross profit in 1996 increased approximately $6.7 million, or
23.9%, over the prior year. Gross profit as a percentage of net sales
decreased from 53.2% in 1995 to 51.8% in 1996. The 1.4% decrease in gross
profit as a percentage of net sales is primarily attributable to the
acquisition of JEH, which operated a large distribution division that had
lower gross profit margins than patient-care services. The cost of products
and services sold for the year ended December 31, 1996, was $32.2 million
compared to $24.6 million in 1995. Gross profit as a percentage of net sales
for patient-care services was 53.0% and 55.1% in the years ended December 31,
1995 and 1996, respectively. Gross profit as a percentage of net sales for
manufacturing and distribution was 47.0% and 44.9% for those years,
respectively.
29
<PAGE>
Selling, General and Administrative Expenses. Selling, general and
administrative expenses in 1996 increased approximately $5.2 million, or
26.8%, compared to 1995. The increase in selling, general and administrative
expenses was primarily a result of the acquisition of JEH. Selling, general
and administrative expenses as a percentage of net sales remained
approximately the same at 37%.
Acquisition and Integration Costs. Non-recurring acquisition and integration
costs totalling $2.5 million in 1996 consisted of: (i) $1.3 million of bonuses
and legal and consulting expenses incurred to acquire JEH; and (ii) $1.2
million of costs to integrate the operations of JEH with the Company,
including costs of severance and the conversion of its health insurance plan
and computer systems.
Income from Operations. Principally as a result of the above, income from
operations in 1996 totalled approximately $4.7 million, a decrease of $1.1
million from the prior year. Income from operations as a percentage of net
sales in 1996 decreased to 7.0% from 11.1% in 1995.
Interest Expense. Interest expense for the year ended December 31, 1996 was
approximately $2.5 million, which is an increase of $490,000, or 23.9%, over
the $2.1 million of interest expense incurred during the year ended December
31, 1995. The increase in interest expense was primarily attributable to the
increase in bank debt resulting from the acquisition of JEH. Interest expense
as a percentage of net sales was 3.8% for the year ended December 31, 1996,
compared to 3.9% for 1995.
Income Taxes. The Company's effective tax rate was 45.5% in 1996 versus
41.9% in 1995. The increase in 1996 reflects both the recognition of a state
deferred tax benefit in 1995, which did not occur in 1996, and the
disproportionate impact of permanent differences in relation to taxable
income.
Net Income. As a result of the above, the Company reported income from
operations before extraordinary item and accounting change of $1.1 million for
the year ended December 31, 1996, compared to $2.1 million for the prior year.
A pre-tax extraordinary loss of $139,000 ($83,000, net of tax) on early
extinguishment of debt was recognized in 1996 in connection with the Company's
refinancing of bank indebtedness.
As a result of the above, the Company reported net income of $998,000, or
$.11 per common share, for the year ended December 31, 1996, as compared to
net income of $2.1 million, or $.26 per common share, for the year ended
December 31, 1995.
YEARS ENDED DECEMBER 31, 1995 AND 1994
Net Sales. Net sales for the year ended December 31, 1995 were approximately
$52.5 million, an increase of approximately $2.2 million, or 4.3%, over net
sales of approximately $50.3 million for the year ended December 31, 1994. The
increase was primarily a result of an increase of $2.1 million, or 4.8%, in
net sales attributable to patient-care centers and facilities that were in
operation during both periods. Of such $2.1 million increase in net sales,
$1.7 million was attributable to patient-care centers and $355,000 was
attributable to the Company's manufacturing and distribution activities. The
balance of the increase in net sales was attributable to O&P patient-care
centers and facilities acquired by the Company in late 1994 and 1995. The
increase of $2.2 million in net sales occurred notwithstanding the sale or
closure of nine patient-care centers during late 1994 and the first quarter of
1995 in connection with the restructuring undertaken by the Company in late
1994. These nine centers accounted for net sales of $1.8 million during the
year ended December 31, 1994, compared with net sales of only $74,000 during
the year ended December 31, 1995.
Gross Profit. Gross profit increased by approximately $805,000, or 3.0%,
over the prior year. Gross profit as a percentage of net sales decreased from
53.9% in 1994 to 53.2% in 1995. The cost of products and services sold for the
year ended December 31, 1995 was $24.6 million compared to $23.2 million for
the year ended December 31, 1994. Gross profit as a percentage of net sales
for patient-care services remained the same during 1994 and 1995 at 53%. Gross
profit as a percentage of net sales for manufacturing and distribution
declined from 37% in 1994 to 36% in 1995. This decline resulted principally
from pricing pressures in the distribution and manufacturing divisions.
30
<PAGE>
Selling, General and Administrative Expenses. Selling, general and
administrative expenses in 1995 decreased by approximately $2.0 million, or
9.3%, compared to 1994. In addition to decreasing in dollar amount, selling,
general and administrative expenses as a percentage of net sales decreased to
36.9% for the year ended December 31, 1995 from 42.4% of net sales for the
year ended December 31, 1994. The decrease in selling, general and
administrative expenses was primarily a result of the sale and closure of nine
patient-care centers during late 1994 and the first quarter of 1995 in
connection with the restructuring undertaken by the Company in 1994 and
completed in March 1995. These nine centers accounted for selling, general and
administrative expenses of $1.0 million during the year ended December 31,
1994 compared with only $67,000 during the year ended December 31, 1995. The
remaining reduction in selling, general and administrative expenses was
primarily a result of additional cost cutting at the patient-care center
level.
Income from Operations. Principally as a result of the above, income from
operations in 1995 totalled approximately $5.8 million, an increase of $5.8
million over the prior year. Income from operations as a percentage of net
sales increased to 11.1% in 1995 from less than 1% in 1994.
Interest Expense. Interest expense for the year ended December 31, 1995 was
approximately $2.1 million, which is an increase of $310,000, or 17.8%, over
the $1.7 million of interest expense incurred during the year ended December
31, 1994. The increase in interest expense was primarily because average
borrowings in 1995 were $1.8 million higher than the average borrowing during
1994, and borrowing rates from the Company's lender were 1% higher in 1995
than 1994.
Income Taxes. The provision for income taxes in 1995 was approximately $1.5
million, as compared to $358,000 in 1994. The increase of $1.2 million was
primarily a result of a $5.8 million increase in income from operations and a
reduction in the non-tax deductible amortization of excess cost over net
assets acquired, offset by the reversal of the valuation allowance relating to
state net operating loss carryforwards.
Net Income. As a result of the above, the Company reported net income of
$2.1 million, or $.26 per common share, for the year ended December 31, 1995,
as compared to a net loss of $2.7 million, or $.33 per common share, for the
year ended December 31, 1994.
PRO FORMA RESULTS--YEAR ENDED DECEMBER 31, 1996 AND QUARTER ENDED MARCH
31, 1997
The Unaudited Pro Forma Consolidated Condensed Statements of Operations for
the year ended December 31, 1996 and the quarter ended March 31, 1997 are
based on the historical consolidated statements of operations of the Company,
adjusted to give effect to the acquisitions of JEH and the Acquired Companies.
The Unaudited Pro Forma Consolidated Condensed Statements of Operations have
been prepared assuming such acquisitions occurred as of January 1, 1996 and
1997. The Unaudited Pro Forma Consolidated Condensed Statements of Operations
also give effect to the reduction in interest expense resulting from the
assumed application of the estimated net proceeds to be received by the
Company in this Offering to retire certain outstanding debt as if such
retirement occurred on January 1, 1996 and 1997. See "Use of Proceeds."
The Unaudited Pro Forma Consolidated Condensed Financial Statements of
Operations do not purport to represent what the Company's results of
operations would have been had the acquisitions of JEH and the Acquired
Companies occurred as of the beginning of the period presented or to project
the Company's results of operations for any future date or period, nor do they
give effect to any matters other than those described in the notes thereto.
For a description of adjustments made to the historical financial statements,
see the "Unaudited Pro Forma Consolidated Condensed Financial Statements of
Operations" and the notes thereto.
The effect of the acquisitions of JEH and the Acquired Companies was to
increase net sales by approximately $64.8 million in the year ended December
31, 1996 and $2.2 million in the quarter ended March 31, 1997 above the
Company's historical results for such periods. JEH and the Acquired Companies
had a gross profit margin of 45.9% of net sales in the year ended December 31,
1996 and 61.0% of net sales in the quarter ended March 31, 1997. Gross profit
margins of the Company on a pro forma as adjusted basis were 48.8% of net
sales for the year ended December 31, 1996 and 48.6% of net sales for
31
<PAGE>
the quarter ended March 31, 1997. JEH and the Acquired Companies' selling,
general and administrative expenses as a percent of net sales were 34.0% in
the year ended December 31, 1996 and 37.5% in the quarter ended March 31,
1997. Selling, general and administrative expenses of the Company on a pro
forma as adjusted basis were 37.0% of net sales for the year ended December
31, 1996 and 35.6% of net sales for the quarter ended March 31, 1997 as a
result of adjustments to eliminate JEH and Acquired Companies' compensation in
connection with which salaries were contractually reduced. As a result, the
Company's income from operations on a pro forma as adjusted basis was 8.2% of
net sales for the year ended December 31, 1996 and 9.4% for the quarter ended
March 31, 1997. Interest expense on a pro forma as adjusted basis decreased by
approximately $3.3 million for the year ended December 31, 1996 and $825,000
for the quarter ended March 31, 1997 due to the application of the estimated
net proceeds to be received by the Company in this Offering to retire certain
indebtedness. See "Use of Proceeds" and "Unaudited Pro Forma Consolidated
Condensed Financial Statements."
LIQUIDITY AND CAPITAL RESOURCES
The Company's consolidated working capital at March 31, 1997 was
approximately $28.8 million, and cash and cash equivalents available were
approximately $6.7 million. The Company's cash resources were satisfactory to
meet its obligations during the year ended December 31, 1996, and the quarter
ended March 31, 1997. It is anticipated that such cash resources will
adequately meet the Company's working capital requirements during at least the
next 18 months.
On November 1, 1996, the Company repaid the outstanding balance under its
$13.0 million revolving credit agreement and its senior term loans with
NationsBank, N.A. and $5.0 million of Convertible Junior Subordinated Notes,
with a portion of the proceeds received from new term loans provided on that
date by the Bank, as agent for a syndicate of banks.
Under the terms of a new Financing and Security Agreement between the Bank
and the Company, the Bank provided up to $90.0 million principal amount of
senior financing that includes: (i) $57.0 million of Term Loans for use in
connection with the acquisition of JEH; (ii) an $8.0 million Revolver; and
(iii) up to $25.0 million principal amount of Acquisition Loans for use in
connection with future acquisitions.
The Company's total debt at March 31, 1997, including a current portion of
approximately $6.1 million, was approximately $74.9 million. Such indebtedness
included: (i) $57.0 million of Term Loans; (ii) $5.5 million of Acquisition
Loans; (iii) $500,000 borrowed under the Revolver; (iv) $6.1 million, net of
discount, borrowed on November 1, 1996 from the Bank and CVCA under the Senior
Subordinated Notes; and (v) $5.8 million of seller notes and other
indebtedness.
Of the Term Loans, approximately $29.0 million principal amount (the "A Term
Loan") is being amortized in quarterly amounts and will mature on December 31,
2001, and $28.0 million principal amount (the "B Term Loan") is being
amortized in quarterly amounts and will mature on December 31, 2003. The final
maturity of any loans under the Revolver and Acquisition Loans will mature on
November 1, 2001. The Facilities provided for an initial commitment fee of
2.625% on the $90.0 million facility. In addition, an unused commitment fee of
.5% of 1% per year on the unused portion of the Revolver and the Acquisition
Loan facilities is payable quarterly in arrears.
The Facilities are collateralized by a first priority security interest in
all of the common stock of Hanger's subsidiaries and all assets of Hanger and
its subsidiaries. At Hanger's option, the annual interest rate will be
adjusted to be either LIBOR plus 2.75% or a Base Rate (as defined below) plus
1.75% in the case of the A Term Loan, Acquisition Loans and Revolver
borrowings, and adjusted LIBOR plus 3.25% or a Base Rate plus 2.25% in the
case of the B Term Loan. The "Base Rate" is defined as the higher of the
federal funds rate plus .5%, or the prime commercial lending rate of Chase
Manhattan Bank, N.A., as announced from time to time. The Agreement relating
to the Facilities contains a minimum net worth covenant and prohibits the
payment of cash dividends on the Common Stock.
32
<PAGE>
All or any portion of outstanding loans under any of the Facilities may be
repaid at any time and commitments may be terminated in whole or in part at
the option of Hanger without premium or penalty, except that LIBOR-based loans
may only be paid at the end of the applicable interest period. Mandatory
prepayments will be required in the event of certain sales of assets, debt or
equity financings and under certain other circumstances.
Cash interest on the Senior Subordinated Notes, which mature on November 1,
2004, is payable quarterly at an annual rate of 8.0%. However, Hanger is
permitted, in lieu of cash interest, to pay interest in a combination of cash
and additional Senior Subordinated Notes ("PIK Interest Notes") at the above
interest rate. In that event, interest paid in cash will be at an annual rate
of 3.2% and interest paid in the form of PIK Interest Notes will be paid at an
annual rate of 4.8%. The Senior Subordinated Notes are subordinated to loans
under the Facilities. Hanger is, at its option, entitled to redeem the Senior
Subordinated Notes at any time at their liquidation value.
Detachable warrants issued by Hanger in conjunction with the Senior
Subordinated Notes represent 1.6 million shares of Hanger Common Stock with an
exercise price equal to $4.01 as to 929,700 shares, and $6.38 as to 670,300
shares. Up to 50% of the warrants (representing up to 800,000 shares of Hanger
Common Stock) will be terminated upon the repayment of 100% of the Senior
Subordinated Notes on or prior to May 1, 1998. An additional 5% of the
warrants (representing up to 80,000 shares of Hanger Common Stock) will be
terminated upon the repayment of 100% of the Senior Subordinated Notes on or
prior to November 1, 1997. Warrants will be terminated pro-rata across the
above two exercise prices.
Pursuant to the Merger Agreement with JEH, Hanger paid $44.0 million in cash
and issued 1.0 million shares of Hanger Common Stock in exchange for all of
JEH's outstanding common stock on November 1, 1996, and paid an additional
$1.8 million to former JEH shareholders on March 27, 1997 pursuant to
provisions in the Merger Agreement calling for a post-closing adjustment.
During the first five months of 1997, the Company acquired four O&P
companies for an aggregate consideration, excluding potential earn-out
provisions, of $9.7 million. These O&P companies, which operate nine patient-
care centers and employ 18 practitioners, had combined net sales of $8.8
million in the year ended December 31, 1996.
The Company plans to finance future acquisitions through internally
generated funds or borrowings under the Acquisition Loans or the issuance of
notes or shares of Common Stock of the Company, or through a combination
thereof.
Capital expenditures during the first quarter of 1997 approximated $500,000
and the Company expects approximately $1.5 million of additional capital
expenditures during the balance of the year. Working capital is expected to be
available to fund such capital expenditures.
OTHER
Inflation has not had a significant effect on the Company's operations, as
increased costs to the Company generally have been offset by increased prices
of products and services sold.
The Company has entered into an interest rate swap agreement to reduce the
impact of changes in interest rates on its A Term Loan commitment. At March
31, 1997, the Company had an outstanding interest rate swap agreement with a
commercial bank, having a total notional principal amount of $28.5 million.
The agreement effectively minimizes the Company's base interest rate exposure
between a floor of 5.32% and a cap of 7.0%. The interest rate swap agreement
matures on September 30, 1999. The Company is exposed to credit loss in the
event of non-performance by the other party to the interest rate swap
agreement. All other debt accrues interest at a fixed rate except the B Term
Loan commitment which accrues interest at a floating rate. A material change
in interest rates could have a significant impact on the Company's operating
results.
33
<PAGE>
The Company primarily provides services and customized devices throughout
the United States and is reimbursed, in large part, by the patients' third-
party insurers or governmentally funded health insurance programs. The ability
of the Company's debtors to meet their obligations is principally dependent
upon the financial stability of the insurers of the Company's patients and
future legislation and regulatory actions.
In February 1997, the Financial Accounting Standards Board issued SFAS 128,
"Earnings Per Share," which will replace the current rules for earnings per
share computations, presentation and disclosure. Under the new standard, basic
earnings per share excludes dilution and is computed by dividing income
available to common shareholders by the weighted average number of common
shares outstanding for the period. Diluted earnings per share reflect the
potential dilution that could occur if securities or other contracts to issue
common stock were exercised or converted into common stock. SFAS 128 requires
a dual presentation of basic and diluted earnings per share on the face of the
income statement.
The Company will be required to adopt SFAS 128 in the fourth quarter of this
year and, as required by the standard, will restate all prior period earnings
per share data. The Company's earnings per share, as calculated under SFAS
128, are not expected to be materially different from those computed under the
present accounting standard.
34
<PAGE>
BUSINESS
OVERVIEW
Hanger Orthopedic Group, Inc. is a professional practice management company
focused on the orthotic and prosthetic segment of the orthopedic
rehabilitation industry. The Company acquires and operates the practices of
orthotists and prosthetists, medical professionals that design, fabricate, fit
and supervise the use of external musculoskeletal support devices and
artificial limbs. The Company has acquired over 40 O&P businesses since 1986
and currently employs 201 certified O&P practitioners and operates 190 O&P
centers in 28 states and the District of Columbia. The Company also has
developed OPNET, a national preferred provider network of O&P service
professionals. OPNET has contractual relationships with 358 patient-care
centers (190 of which are owned and operated by the Company) with 230 managed
care contracts. In addition to its practice management and patient-care
services, the Company manufactures custom-made and prefabricated O&P devices
and is the country's largest distributor of O&P components and finished O&P
patient-care products.
INDUSTRY BACKGROUND
Orthotics is the design, fabrication, fitting and supervised use of custom-
made braces and other devices that provide external support to treat
musculoskeletal disorders. Musculoskeletal disorders are ailments of the back,
extremities or joints caused by traumatic injuries, chronic conditions,
diseases, congenital disorders or injuries resulting from sports or other
activities. Prosthetics is the design, fabrication and fitting of custom-made
artificial limbs for patients who have lost limbs as a result of traumatic
injuries, vascular diseases, diabetes, cancer or congenital disorders.
Care of O&P patients is part of a continuum of rehabilitation services from
diagnosis to treatment and prevention of future injury. This continuum
involves the integration of several medical disciplines that begins with the
attending physician's diagnosis. Once a course of treatment is determined, the
physician, generally an orthopedic surgeon, vascular surgeon or psychiatrist,
refers a patient to an O&P patient-care service provider for treatment. An O&P
practitioner then consults with both the referring physician and the patient
to formulate the prescription for, and design of, an orthotic or prosthetic
device to meet the patient's needs.
The Company estimates that the O&P patient-care services industry in the
United States represented approximately $2.0 billion in sales in 1995. Key
trends expected to increase demand for orthopedic rehabilitation services
include the following:
Growing Elderly Population. The growth rate of the over-65 age group is
nearly triple that of the under-65 age group. With broader medical insurance
coverage, increasing disposable income, longer life expectancy, greater
mobility and improved technology and devices, the elderly can be expected to
seek orthopedic rehabilitation services more often.
Cost-Effective Reduction in Hospitalization. As public and private payors
encourage reduced hospital admissions and reduced length of stay, out-patient
rehabilitation is in greater demand. O&P services and devices enable patients
to become ambulatory more quickly after receiving medical treatment in the
hospital. The Company believes that significant cost savings can be achieved
through the early use of O&P services. The provision of O&P services in many
cases reduces the need for more expensive treatments, thus representing a cost
savings to the third-party payor.
Growing Physical Health Consciousness. There is a growing emphasis on
physical fitness, leisure sports and conditioning, such as running and
aerobics, which has led to increased injuries requiring orthopedic
rehabilitative services and products. In addition, as the current middle-age
population ages, it brings a more active life-style and accompanying emphasis
on physical fitness to the over-65 age group.
35
<PAGE>
These trends are evidenced by the increasing demand for new devices that
provide support for injuries, prevent further or new injuries or enhance
physical performance.
Advancing Technology. The range and effectiveness of treatment options have
increased in connection with the technological sophistication of O&P devices.
Advances in design technology and lighter, stronger and more cosmetically
acceptable materials have enabled the industry to produce new O&P products
which provide greater comfort, protection and patient acceptability.
Therefore, treatment can be more effective and of shorter duration,
contributing to greater mobility and a more active lifestyle for the patient.
Orthotic devices are more prevalent and visible in many sports, including
skiing, running and golf.
Need for Replacement and Continuing Care. Because the useful life of most
custom-fitted and fabricated O&P devices is approximately three to five years,
such devices need retrofitting and replacement. There is also an attendant
need for continuing patient-care services, which contributes to the increasing
demand for orthopedic rehabilitation.
INDUSTRY CONSOLIDATION
The O&P services market is highly fragmented and relatively underpenetrated
by professional practice management companies. Hanger is one of the two
largest companies in the O&P industry which, combined, accounted for less than
15% of the total estimated O&P industry revenue in 1995. There are an
estimated 3,200 certified prosthetists and/or orthotists and approximately
2,670 patient-care centers in the United States, with such facilities
generally being operated as small group practices. There are also several
regional and multi-regional competitors that operate numerous patient-care
centers. The Company believes that the O&P industry will continue to
consolidate as a result of a variety of factors, including: (i) increased
pressures from growth in managed care; (ii) demonstrated benefits from
economies of scale; and (iii) desire by orthotists and prosthetists to obtain
financial liquidity and concentrate on providing patient care.
Increased Managed Care Penetration. The expanding geographical reach of the
large managed care organizations makes it increasingly important for them to
contract for their patient-care needs with counterparts who have large,
national operations. Managed care companies therefore prefer to contract with
a single professional practice management company to provide all their O&P
patient-care services. As a result, small independent O&P practices feel
pressure to consolidate in order to access managed care referrals.
Economies of Scale. A significant portion of the cost of O&P services is
attributable to the cost of materials used in orthoses and prostheses.
Achieving purchase discounts through group purchasing can increase
profitability at each patient-care center. In addition, economies of scale
provide O&P practices with access to additional capital and personnel which
can be used in growing their businesses.
Financial Liquidity for O&P Practices. The security of a large O&P network
is extremely appealing to small providers who desire to reduce the financial
and personal liabilities of their practices. Through consolidation, individual
providers are able to realize financial liquidity by turning their practices'
cash flows into cash assets. This consolidation allows smaller providers to
continue their O&P practices as employees of a national O&P professional
practice management provider.
COMPANY STRATEGY
The Company's objective is to build a major national orthopedic
rehabilitation company focused on the acquisition and operation of O&P
practices and the manufacture and distribution of O&P products. The Company's
strategy for achieving this objective is to:
. Acquire and integrate O&P practices in targeted geographic areas across
the United States;
36
<PAGE>
. Develop new patient-care centers in existing markets;
. Expand and improve O&P practice management operations at existing and
acquired patient-care centers;
. Increase the number of OPNET's O&P patient-care service members and its
contractual relationships with managed care organizations; and
. Expand the Company's O&P manufacturing and distribution operations.
Acquire and integrate O&P practices in targeted geographic areas across the
United States. The Company's expansion is focused on developing a national
network providing O&P patient-care coverage. Therefore, when identifying
patient-care centers for acquisition, the Company seeks to fill gaps in its
existing geographic coverage. By focusing on national development, the Company
is well-positioned to negotiate for national contracts as payors consolidate
and look to large providers for services.
Develop new O&P patient-care centers in existing markets. In addition to
acquiring patient-care centers, the Company intends to open new patient-care
centers in existing markets. The Company plans to pursue this strategy by
opening satellite centers in areas where a need for O&P services has been
identified. In opening satellite patient-care centers, the Company's procedure
is to staff on a part-time basis with professionals from a nearby existing
center so as to test the viability of a full-time practice.
Expand and improve O&P practice management operations at existing and
acquired patient-care centers. As the number of Hanger patient-care centers
continues to increase, the benefits of the Company's practice management
operations will be maximized. The Company will be able to spread
administrative fixed costs and capital expenditures for state-of-the-art
equipment such as CAD/CAM systems over a large number of patient-care centers.
Furthermore, sales can also be enhanced by the Company's use of marketing
programs not generally utilized by practitioners in smaller, independent
practices.
Increase the number of OPNET's O&P patient-care service members and its
contractual relationships with managed care organizations. The Company intends
to expand OPNET membership towards the goal of achieving complete nationwide
O&P patient-care coverage. A national network will enable OPNET to negotiate
for contracts with any local, regional or national third-party payor seeking a
single source O&P provider regardless of the payor's geographic scope.
Expand the Company's O&P manufacturing and distribution operations. As the
patient-care practice management division of the Company expands, it can
create captive demand for the Company's distribution business. An increase in
the number of OPNET members, to whom preferred purchasing agreements are
offered, can also increase net sales for the Company's distribution business.
The Company's manufacturing division can also benefit from increased net sales
at the distribution division by providing proprietary products to meet the
demand of an expanded captive market. The Company's manufacturing efforts will
focus on the acquisition and/or development of proprietary patented products
such as the Lenox Hill knee brace and the Charleston Bending Brace.
PRACTICE MANAGEMENT AND PATIENT-CARE SERVICES
Practice Management Services
The Company provides all senior management, accounting, accounts payable,
payroll, sales and marketing, human resources and management information
systems for its patient-care centers. By providing these services on a
centralized basis, the Company is able to provide such services to its
patient-
37
<PAGE>
care centers and practitioners more efficiently and cost-effectively than if
such services had to be generated at each center. The centralization of these
services also permits the Company's certified practitioners to allocate a
greater portion of their time to patient-care activities by reducing the
administrative responsibilities of operating their businesses. Billing and
collections are handled on a decentralized basis, which the Company believes
enhances collectibility.
The Company also develops and implements programs designed to enhance the
efficiency of its clinical practices. Such programs include: (i) sales and
marketing initiatives to attract new-patient referrals by establishing
relationships with physicians, therapists, employers, managed care
organizations, hospitals, rehabilitation centers, out-patient clinics and
insurance companies; (ii) professional management and information systems to
improve efficiencies of administrative and operational functions; (iii)
professional educational programs for practitioners emphasizing new
developments in the increasingly sophisticated field of O&P clinical therapy;
(iv) the regional centralization of fabrication and purchasing activities,
which provides overnight access to component parts and products at prices that
are typically 25% lower than traditional procurement methods; and (v) access
to expensive, state-of-the-art equipment which is financially more difficult
for smaller, independent facilities to obtain.
The Company believes that the application of sales and marketing techniques
is a key element of its O&P professional practice management strategy. Due
primarily to the fragmented nature of the industry, the success of an O&P
practice has been largely a function of its local reputation for quality of
care, responsiveness and length of service in the community. Individual
practitioners have relied almost exclusively on referrals from local
physicians or physical therapists and typically have not used marketing
techniques.
Patient-Care Services
The Company provides O&P patient-care services through 190 Company-owned and
operated O&P patient-care centers in 28 states and the District of Columbia.
Hanger currently employs 260 patient-care practitioners, of whom 201 are
certified practitioners and 59 are candidates for formal certification by the
O&P industry certifying boards. Each of the Company's patient-care centers is
closely supervised by one or more certified practitioners. The balance of the
Company's patient-care practitioners are highly trained technical personnel
who assist in the provision of services to patients and fabricate various O&P
devices.
A patient is referred to one of Hanger's patient-care centers for treatment
upon a determination by the attending physician of a course of treatment for a
patient in need of O&P patient-care services. A Hanger practitioner then
consults with both the referring physician and the patient to formulate the
prescription for, and design of, an orthotic or prosthetic device to meet the
patient's needs.
The fitting process involves several stages in order to successfully achieve
desired functional and cosmetic results. The practitioner creates a cast and
takes detailed measurements of the patient to ensure an anatomically correct
fit. All of the prosthetic devices fitted by Hanger's practitioners are custom
designed and fabricated by skilled practitioners who can balance fit, support
and comfort. Of the orthotic devices provided by Hanger, approximately 75% are
custom designed, fabricated and fitted and the balance are prefabricated but
custom fitted.
Custom devices are fabricated by the Company's skilled technicians using the
castings, measurements and designs made by the practitioner. Technicians use
advanced materials and technologies to fabricate a custom device under quality
assurance guidelines. After final adjustments to the device by the
practitioner, the patient is instructed in the use, care and maintenance of
the device. A program of scheduled follow-up and maintenance visits is used to
provide post-fitting treatment, including adjustments or replacements as the
patient's physical condition and lifestyle change.
A substantial portion of Hanger's O&P services involves treatment of a
patient in a non-hospital setting, such as a Hanger patient-care center, a
physician's office, an out-patient clinic or other facility. In
38
<PAGE>
addition, O&P services are increasingly rendered to patients in hospitals,
nursing homes, rehabilitation centers and other alternate-site healthcare
facilities. In a hospital setting, the practitioner works with a physician to
provide either orthotic devices or temporary prosthetic devices that are later
replaced by permanent prostheses.
The Company also operates the in-patient O&P patient-care centers at The
Rusk Institute of Rehabilitation Medicine at the New York University Medical
Center in New York, New York and the Harmarville Rehabilitation Center in
Pittsburgh, Pennsylvania.
OPNET
In 1995, Hanger formed OPNET, a proprietary national preferred provider O&P
referral network serving managed care organizations, including HMOs and PPOs.
Through this network, managed care organizations can contract for O&P services
with any O&P patient-care center in the OPNET network. To date, OPNET has a
network of 358 patient-care centers with 230 managed care contracts. The
Company intends to extend the network's reach nationwide through acquisitions
and marketing. OPNET also provides incentives to independent O&P service
provider members to purchase their O&P products from the Company. The Company
receives upfront annual payments from practitioners to enter the OPNET network
and OPNET does not receive payments from the managed care participants. Total
1996 net sales from these fees were approximately $250,000. The Company
believes that OPNET's membership enables it to establish significant
relationships with practitioners otherwise not affiliated with the Company.
MANUFACTURING AND DISTRIBUTION
In addition to on-site fabrication of custom O&P devices incidental to the
services rendered at its O&P patient-care centers, the Company manufactures
O&P components and finished patient-care products for both the O&P industry
and the Company's own patient-care practices. The Company manufactures
components and finished products under various name brands such as Lenox Hill,
CASH Brace, Ortho-Mold and Charleston Bending Brace. The principal products
manufactured are prefabricated and custom-made spinal orthoses as well as
custom-made and off-the-shelf derotation knee braces. The Company distributes
O&P components and finished patient-care products to the O&P industry and to
the Company's own patient-care practices. The Company inventories over 20,000
items, a majority of which are manufactured by other companies and are
distributed by Hanger.
Hanger's distribution capability allows its personnel faster access to the
products needed to fabricate devices for patients. This is accomplished at
competitive prices, as a result of either manufacturing by Hanger or direct
purchases by Hanger from other manufacturers. As a result of faster access to
products, the length of a patient's treatment in the hospital can be reduced,
thereby contributing to healthcare cost containment.
Marketing of Hanger's manufactured products and distribution services is
conducted on a national basis, primarily through approximately 72 independent
sales representatives, catalogues and exhibits at industry and medical
meetings and conventions. Hanger directs specialized catalogues to segments of
the healthcare industry, such as orthopedic surgeons and physical and
occupational therapists. In addition, the Company directs its broad-based
marketing to the O&P industry and the home healthcare industry.
To provide timely custom fabrication and service to its patients, the
Company employs technical personnel and maintains laboratories at each of its
patient-care centers. The Company uses advanced computer-aided design and
computer-aided machinery (CAD/CAM) technology to produce precise and uniform
products. Hanger has several large, fully-staffed central fabrication
facilities to service its patient-care centers. These strategically located
facilities enable Hanger to fabricate those O&P products that are more easily
produced in larger quantities and in a more cost-effective manner, as well as
serving as an auxiliary production center for products normally fabricated at
individual patient-care centers.
39
<PAGE>
ACQUISITIONS
Since 1986, the Company has acquired over 40 business in 28 states and the
District of Columbia. In November 1996, Hanger acquired JEH, a Georgia
corporation that operated 94 patient-care centers in 15 states and was the
country's largest distributor of O&P products.
On March 5, 1997, the Company purchased the assets of Prosthetic Treatment
Center, Inc., an owner-operator of one patient-care facility located in
Kingsport, Tennessee; on April 1, 1997, the Company acquired the patient-care
division of ACOR Orthopaedic, Inc., a company primarily engaged in the
operation of four O&P patient-care centers in the central Ohio area and
headquartered in Cleveland, Ohio; and on May 12, 1997, the Company acquired
Fort Walton Orthopedic, Inc. and Mobile Limb & Brace, Inc., which are
companies primarily engaged in the operation of three patient-care centers in
the Fort Walton, Florida area and one patient-care center in Mobile, Alabama.
The four companies acquired by the Company to date in 1997 had net sales of
$8.8 million in the year ended December 31, 1996 and were acquired for
aggregate consideration of $9.7 million.
The Company continues to be engaged in discussions with several O&P
companies relating to the Company's possible acquisition of their patient-care
practices. The Company's investigations of these businesses are in the
formative stages and no representations can be made as to whether, when or on
what terms such possible acquisitions may be effected. The Company's
acquisition strategy contemplates the acquisition of O&P patient-care
practices by the end of 1998 that could contribute an additional $30.0 to
$40.0 million of annual net sales. No assurance can be given as to whether, or
to what extent, the Company will be successful in achieving this goal.
The Company considers both operating and financial factors in evaluating
prospective acquisitions. Operating factors include high standards of
professionalism and patient care, the presence of certified practitioners at
each of its facilities and reputation in the O&P industry. Financial factors
include earnings and cash flow history and the projected benefits of applying
Hanger's operating model to the acquired company's practice. In evaluating
acquisitions in geographic areas where the Company has an established
presence, Hanger targets businesses that complement its existing network of
patient-care centers. In geographic areas where the Company has not yet
established a presence, the Company generally focuses on acquiring strong
regional businesses which have multiple patient-care centers and experienced
practitioners.
The Company's acquisition strategy also includes the retention and support
of the existing management of the acquired company, typically through the use
of employment contracts, non-compete agreements and incentive programs. Upon
the completion of an acquisition, the Company will integrate the business of
the acquired company by: (i) transferring all administrative and financial
management responsibilities to Hanger's corporate headquarters; (ii) providing
all new personnel with compensation and benefit packages and training by the
Company's Human Resources Department; and (iii) providing the management of
the acquired company with instruction on the Company's latest marketing and
sales techniques. Thereafter, the Company will provide the management and
staff of the newly acquired company with financial incentives to induce
greater financial performance.
NEW-CENTER DEVELOPMENT
In addition to acquired patient-care centers, the Company has developed 16
new satellite patient-care centers in existing markets with underserved demand
for O&P services. These satellite centers require less capital to develop than
complete O&P centers since the satellite centers usually consist of only a
waiting room and patient fitting rooms, but without a fabrication laboratory
for creating O&P devices. An O&P practitioner will spend one or two days each
week in a satellite center treating those patients who find it inconvenient to
visit the O&P practitioner's primary center.
40
<PAGE>
These satellite centers also tend to receive new patient referrals from
hospitals and physicians located near the newly-developed center, driving new
patient growth and center revenue. While a partial revenue shift occurs from
the O&P practitioner's main center to the satellite center because the O&P
practitioner is now seeing some of the same patients out of a new center, the
additional patient volume in the satellite center increases the O&P
practitioner's overall revenue. If demand for O&P services at a satellite
center increases beyond the ability of the O&P practitioner to service in one
or two days a week, the Company will staff the satellite office on a full-time
basis. The Company estimates that the cost of opening a new patient-care
center is approximately $100,000, which includes equipment, leasehold
improvements and working capital. The Company expects a new patient-care
center to reach profitability, as measured by EBITDA, within one year of
opening. No assurance can be given that the Company will be successful in
achieving these start-up and profitability goals with regard to new patient-
care centers.
PATIENT REIMBURSEMENT SOURCES
The principal reimbursement sources for Hanger's O&P services are: (i)
private payor/third-party insurer sources which consist of individuals,
private insurance companies, HMOs, PPOs, hospitals, vocational rehabilitation,
workers' compensation and similar sources; (ii) Medicare, which is a federally
funded health insurance program providing health insurance coverage for
persons aged 65 or older and certain disabled persons; (iii) Medicaid, which
is a health insurance program jointly funded by federal and state governments
providing health insurance coverage for certain persons in financial need,
regardless of age, and which may supplement Medicare benefits for financially
needy persons aged 65 or older; and (iv) the VA, with which Hanger has entered
into contracts to provide O&P services.
Medicare, Medicaid, the VA and certain state agencies, which accounted for
approximately 56.6%, 56.8% and 57.0% of the Company's net sales in 1995, 1996
and the first quarter of 1997, respectively, (based on a sampling of
approximately 40%, 75% and 75% of patient-care centers in 1995, 1996 and the
first quarter of 1997, respectively) have set maximum reimbursement levels for
payments for O&P services and products. The healthcare policies and programs
of these agencies have been subject to changes in payment and methodologies
during the past several years. There can be no assurance that future changes
will not reduce reimbursements for O&P services and products from these
sources.
The Company provides O&P services to eligible veterans pursuant to several
contracts with the VA. The VA establishes its reimbursement rates for itemized
products and services on a competitive bidding basis. The Company's contracts
with the VA expire in September 1997, with the option to renew for a one- or
two-year period. The contracts, awarded on a non-exclusive basis, establish
the amount of reimbursement to the eligible veteran if the veteran should
choose to use the Company's products and services. The Company has been
awarded VA contracts in the past and expects that it will obtain additional
contracts when its present agreements expire.
41
<PAGE>
PATIENT-CARE CENTERS AND FACILITIES
Hanger currently operates 190 patient-care centers, six distribution
facilities and two manufacturing facilities, as detailed in the following
table:
<TABLE>
<CAPTION>
PATIENT-
CARE DISTRIBUTION MANUFACTURING
JURISDICTION CENTERS FACILITIES FACILITIES
------------ -------- ------------ -------------
<S> <C> <C> <C>
Alabama.................................. 8 -- --
Arizona.................................. 4 -- --
California............................... 4 1 --
Colorado................................. 7 -- --
Connecticut.............................. 3 -- --
Delaware................................. 1 -- --
District of Columbia..................... 2 -- --
Florida.................................. 20 1 1
Georgia.................................. 16 1 --
Illinois................................. -- 1 1
Indiana.................................. 2 -- --
Kentucky................................. 6 -- --
Louisiana................................ 8 -- --
Maryland................................. 6 1 --
Massachusetts............................ 3 -- --
Michigan................................. 2 -- --
Mississippi.............................. 7 -- --
Montana.................................. 5 -- --
New Hampshire............................ 1 -- --
New Mexico............................... 1 -- --
New York................................. 8 -- --
North Carolina........................... 3 -- --
Ohio..................................... 18 -- --
Pennsylvania............................. 15 -- --
South Carolina........................... 11 -- --
Tennessee................................ 9 -- --
Texas.................................... 5 1 --
Virginia................................. 6 -- --
West Virginia............................ 8 -- --
Wyoming.................................. 1 -- --
--- --- ---
TOTAL.................................. 190 6 2
=== === ===
</TABLE>
COMPETITION
The competition among O&P patient-care centers is primarily for referrals
from physicians, therapists, employers, HMOs, PPOs, hospitals, rehabilitation
centers, out-patient clinics and insurance companies on both a local and
regional basis. The Company believes that distinguishing competitive factors
in the O&P industry are quality and timeliness of patient care and, to a
lesser degree, charges for services. While the Company believes it is one of
the largest suppliers of O&P services in the U.S., certain competitors may
have greater financial and personnel resources than Hanger. The Company
competes with others in the industry for trained personnel. To date, however,
Hanger has been able to achieve its staffing needs and has experienced a
relatively low turnover rate of employees. In connection with its efforts to
acquire additional O&P patient-care practices, the Company encounters
competition from several other O&P companies.
42
<PAGE>
GOVERNMENT REGULATION
Certification and Licensure
Most states do not require separate licensure for O&P practitioners.
However, several states currently require O&P practitioners to be certified by
an organization such as the ABC. The ABC conducts a certification program for
practitioners and an accreditation program for patient-care centers. The
minimum requirements for a certified practitioner are a college degree,
completion of an accredited academic program, one to four years of residency
at a patient-care center under the supervision of a certified practitioner and
successful completion of certain examinations. Minimum requirements for an
ABC-accredited patient-care center include the presence of a certified
practitioner and specific plant and equipment requirements. While the Company
endeavors to comply with all state licensure requirements, no assurance can be
given that the Company will be in compliance at all times with these
requirements.
Hanger provides services under various contracts to federal agencies. These
contracts are subject to regulations governing federal contracts, including
the ability of the government to terminate for its convenience. Revenue from
such contracts is not material to Hanger.
Medical Device Regulation
The Company manufactures and distributes products that are subject to
regulation as medical devices by the U.S. Food and Drug Administration ("FDA")
under the Federal Food, Drug, and Cosmetic Act and accompanying regulations.
The Company believes that the products it manufactures and/or distributes,
including O&P accessories and components, are exempt from FDA's regulations
for premarket clearance or approval requirements and from requirements
relating to "good manufacturing practices" (except for certain recordkeeping
and complaint handling requirements). The Company is required to adhere to
regulations regarding adverse event reporting, and is subject to inspection by
the FDA for compliance with all applicable requirements. Labeling and
promotional materials also are subject to scrutiny by the FDA and, in certain
circumstances, by the Federal Trade Commission. Although the Company has never
been challenged by FDA for noncompliance with FDA requirements, no assurance
can be given that the Company would be found to be or to have been in
compliance at all times. Noncompliance could result in a variety of civil
and/or criminal enforcement actions, which could have a material adverse
effect on the Company's business and results of operations.
Fraud and Abuse
The Company is subject to various federal and state laws pertaining to
healthcare fraud and abuse, including antikickback laws, false claims laws,
and physician self-referral laws. Violations of these laws are punishable by
criminal and/or civil sanctions, including, in some instances, imprisonment
and exclusion from participation in federal healthcare programs, including
Medicare, Medicaid, VA health programs and CHAMPUS. The Company has never been
challenged by a governmental authority under any of these laws and believes
that, based on this history, its operations are in material compliance with
such laws. However, because of the far-reaching nature of these laws, there
can be no assurance that one or more of the Company's practices would not be
challenged by governmental authorities under certain of these laws, that the
Company would not be required to alter its practices as a result, or that the
occurrence of one or more of these events would not result in a material
adverse effect on the Company's business and results of operations.
Antikickback Laws. The Company's operations are subject to federal and state
antikickback laws. The Federal Health Care Programs Antikickback Statute
(section 1128B(b) of the Social Security Act) prohibits persons or entities
from knowingly and willfully soliciting, offering, receiving, or paying any
remuneration in return for, or to induce, the referral of persons eligible for
benefits under a Federal Health Care Program (including Medicare, Medicaid,
the VA health programs and CHAMPUS), or the ordering, purchasing or leasing of
items or services that may be paid for, in whole or in part, by a Federal
Health Care Program. The statute may be violated when even one purpose (as
opposed to a primary or sole
43
<PAGE>
purpose) of a payment is to induce referrals or other business. Regulations
create a small number of "safe harbors." Practices which meet all the criteria
of an applicable safe harbor will not be deemed to violate the statute;
practices that do not satisfy all elements of a safe harbor do not necessarily
violate the statute, although such practices may be subject to scrutiny by
enforcement agencies. Several states also have antikickback laws which vary in
scope and may apply regardless of whether a Federal Health Care Program is
involved.
These laws may apply to certain of the Company's operations. The Company has
instituted various types of discount programs for individuals or entities that
purchase its products and services. The Company also maintains financial
relationships with individuals and entities who may: (i) may purchase the
Company's products and services; (ii) refer patients to Company-owned and
managed O&P patient-care centers; or (iii) receive referrals through OPNET.
These relationships include, among other things, lease arrangements with
hospitals and OPNET participation arrangements. Because some of these
arrangements may not satisfy all elements of an applicable safe harbor, they
could be subject to scrutiny and challenge under one or more such laws.
False Claims Laws. The Company is also subject to federal and state laws
prohibiting individuals or entities from knowingly and willfully presenting,
or causing to be presented, claims for payment to third-party payors
(including Medicare and Medicaid) that are false or fraudulent or are for
items or services not provided as claimed. Each Company-owned and managed O&P
patient-care center is responsible for preparation and submission of
reimbursement claims to third-party payors for items and services furnished to
patients. In addition, Company personnel may, in some instances, provide
advice on billing and reimbursement for the Company's products to purchasers.
While the Company endeavors to ensure that its billing practices comply with
applicable laws, if claims submitted to payors are deemed to be false,
fraudulent, or for items or services not provided as claimed, the Company
could face liability for presenting or causing to be presented such claims.
Physician Self-Referral Laws. The Company is also subject to federal and
state physician self-referral laws. With certain exceptions, the federal
Medicare/Medicaid physician self-referral law (the "Stark" law, section 1877
of the Social Security Act) prohibits a physician from referring Medicare and
Medicaid beneficiaries to an entity for "designated health services"--
including prosthetics, orthotics and prosthetic devices and supplies--if the
physician has either an investment interest in the entity or a compensation
arrangement with the entity. An exception is recognized for referrals made to
a publicly-traded entity in which the physician has an investment interest if,
among other things, the entity had shareholders' equity exceeding $75.0
million for its most recent fiscal year, or on average during the three
previous fiscal years. While the Company does not provide stock to referring
physicians and the Company's stock is publicly-traded, the Company is not in a
position to know or control whether some referring physicians may be
investors. Because the Company does not currently have sufficient
shareholders' equity to meet the exception that would allow physician-
investors to refer Medicare and Medicaid beneficiaries to Company-owned and
managed O&P patient-care centers, any such referrals that do occur could be
found to be in violation of the Stark law.
Antitrust
The Company is subject to federal and state antitrust laws which prohibit,
among other things, the establishment of ventures that result in certain
anticompetitive conduct. These laws have been applied to the establishment of
certain networks of otherwise competing healthcare providers. In September
1995, the Antitrust Division of the Department of Justice ("DOJ") issued a
business review letter which concluded, in part, that the description of OPNET
voluntarily furnished to the DOJ by the Company "did not pose any significant
competitive issues" and, therefore, DOJ "has no present intention of
challenging [OPNET]" under federal antitrust law. Although the Company is not
able to assure that the continued operation of OPNET will comply in all
respects with the terms specified in the business review letter, noncompliance
with these terms does not mean that the antitrust authorities or private
parties would
44
<PAGE>
challenge the conduct, and the Company believes that the current operation of
OPNET is not anticompetitive and results in significant efficiencies. However,
DOJ reserves the right to bring an investigation or proceeding if it
determines that OPNET is anticompetitive in purpose or effect. There can be no
assurance that DOJ will not bring an investigation or proceeding challenging
OPNET (or other aspects of the Company's operations) under these laws, or that
such an investigation or proceeding would not result in a material adverse
effect on the Company's business and results of operations.
PERSONNEL
As of June 20, 1997, the Company employed 1,062 persons, including 976 full-
time and 86 part-time employees. None of the Company's employees is subject to
a collective bargaining agreement. The Company believes that it has
satisfactory relationships with its employees and strives to maintain these
relationships by offering competitive benefit packages, training programs and
opportunities for advancement.
INSURANCE
The Company currently maintains insurance of the type, and in the amount,
customary in the orthopedic rehabilitation industry, including coverage for
malpractice liability, product liability, workers' compensation and property
damage. Hanger's general liability insurance coverage is at least $500,000 per
incident. Based on the Company's experience and prevailing industry practices,
Hanger believes its coverage is adequate as to risks and amount.
45
<PAGE>
MANAGEMENT
EXECUTIVE OFFICERS, DIRECTORS AND KEY EMPLOYEES
The following table sets forth certain information with respect to the
executive officers, directors and certain key employees of the Company:
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Ivan R. Sabel, CPO.................. 52 Chairman of the Board, President,
Chief Executive Officer and Director
Richard A. Stein.................... 38 Vice President--Finance, Secretary and
Treasurer
Mitchell J. Blutt, M.D.(1).......... 40 Director
Edmond E. Charrette, M.D.(2)........ 62 Director
Thomas P. Cooper, M.D.(1)........... 53 Director
Robert J. Glaser, M.D.(2)........... 78 Director
James G. Hellmuth(1)................ 74 Director
William L. McCulloch(2)............. 76 Director
Daniel A. McKeever, CP.............. 86 Director
H.E. Thranhardt, CPO................ 57 Director
John D. McNeill, CPO................ 49 President and Chief Operating Officer
of Hanger Prosthetics & Orthotics,
Inc.
Alice G. Tidwell.................... 58 President and Chief Operating Officer
of Southern Prosthetic Supply, Inc.
Juan B. Paez........................ 52 Vice President--Manufacturing of DOBI-
Symplex, Inc.
Jeffrey L. Martin................... 43 Vice President of OPNET, Inc.
</TABLE>
- --------
(1) Member of Audit Committee.
(2) Member of Compensation Committee.
Ivan R. Sabel has been Chairman of the Board of Directors and Chief
Executive Officer of Hanger since August 1995 and President of Hanger since
November 1987. Mr. Sabel also served as the Chief Operating Officer of Hanger
from November 1987 until August 1995. Prior to that time, Mr. Sabel had been
Vice President--Corporate Development from September 1986 to November 1987.
From 1968 until joining Hanger in 1986, Mr. Sabel was the founder, owner and
President of Capital Orthopedics, Inc. before that company was acquired by
Hanger. Mr. Sabel is a Certified Prosthetist and Orthotist ("CPO"), a clinical
instructor in orthopedics at the Georgetown University Medical School in
Washington, D.C., a member of the Board of Directors of the American Orthotic
and Prosthetic Association, a former Chairman of the National Commission for
Health Certifying Agencies, a former member of the Strategic Planning
Committee and a current member of the Veterans Administration Affairs
Committee of AOPA and a former President of the ABC.
Richard A. Stein has been Vice President-Finance, Secretary and Treasurer of
Hanger since April 1987. Mr. Stein was also the President of Greiner & Saur
Orthopedics, Inc., a former subsidiary of the Company, from April 1987 until
November 1989. Mr. Stein is a Certified Public Accountant and was employed by
Coopers & Lybrand L.L.P. from September 1982 until he joined Hanger in 1987.
Mitchell J. Blutt, M.D. has served as Executive Partner of Chase Capital
Partners (and its predecessor organizations), an affiliate of Chase Manhattan
Bank (and its predecessor corporations), since June 1991.
46
<PAGE>
He joined that firm in July 1987 and became a General Partner in June 1988.
Dr. Blutt also has been engaged in the practice of medicine for 15 years.
Previously, Dr. Blutt was a Robert Wood Johnson Foundation Fellow at the
University of Pennsylvania from July 1985 to June 1987. He is an adjunct
Assistant Professor at the New York Hospital/Cornell Medical Center. Dr. Blutt
is also a director of numerous privately-held companies.
Edmond E. Charrette, M.D. is the co-founder and Chairman of Health Resources
Corporation (principally engaged in occupational medicine services). He also
is a Partner of Ascendant Healthcare International (an investment group with
equity investments in the Latin American healthcare sector) and serves as
President of Latin Healthcare Investment Management Co., LLC (a group composed
of Ascendant Healthcare International and The Global Environmental Fund which
manages and directs the investment activities of the Latin Healthcare
Investment Fund). Previously, he was the Executive Vice President and Chief
Medical Officer of Advantage Health Corporation (a multi-hospital
rehabilitation and post-acute care system) from June 1994 to March 1996. From
1988 to May 1994, Dr. Charrette served as the Corporate Medical Director and
Senior Vice President of Medical Affairs of Advantage Health Corporation. Dr.
Charrette also is a director of Nu-Tech Biomed Corporation, which is
principally engaged in the development of medical diagnostic tests.
Thomas P. Cooper, M.D. is the President and Chief Executive Officer of three
private health services companies. He was the President and Chief Executive
Officer of Mobilex U.S.A., providing portable diagnostic services to long-term
care facilities, from May 1989 to July 7, 1997. Dr. Cooper has also been
employed as the President and Chief Executive Officer of Senior Psychology
Services Management, Inc., which supplies psychologists to nursing home
patients, since June 1991. Dr. Cooper was the founder of Spectrum Emergency
Care, a provider of emergency room physicians to hospitals and clinics, and
Correctional Medical Systems, a provider of health services to correctional
facilities. Dr. Cooper has served as Director of Quality Assurance for ARA
Living Centers, a company which operates long-term healthcare facilities, and
as Medical Director for General Motors Corporation Assembly Division. He
currently serves as a consultant to Chase Capital Partners and has served on
the faculty of the University of California, San Diego Medical School.
Robert J. Glaser, M.D. was the Director for Medical Science and a Trustee of
the Lucille P. Markey Charitable Trust, which provided major grants in support
of basic biomedical research, from 1984 to June 30, 1997, when the Trust
terminated in accordance with its terms. He is also a Consulting Professor of
Medicine Emeritus at Stanford University, where he served as the Dean of the
School of Medicine from 1965 to 1970. Dr. Glaser was a founding member of the
Institute of Medicine at the National Academy of Sciences and is a director of
Alza Corporation (principally engaged in pharmaceutical research) and Nellcor
Puritan Bennett Incorporated (principally engaged in the manufacture of
medical equipment). He was a director of Hewlett-Packard Company from 1971 to
1991, and has continued to serve as a consultant to that company on health
matters.
James G. Hellmuth serves as a director of BT Capital Corporation, an
affiliate of Bankers Trust New York Corporation, as well as a part-time
consultant to Chase Capital Partners. He has been a Commissioner of the Port
Authority of New York and New Jersey since 1969. In addition, Mr. Hellmuth was
a Managing Director of Bankers Trust Company from 1972 to 1988.
Brig. Gen. William L. McCulloch, USMC (Ret.) has served as the President of
Association Communication and Marketing Services, a public relations firm,
since October 1989. Previously, Gen. McCulloch was the Executive Director of
AOPA, the trade association of the orthotic and prosthetic industry, from
October 1976 to September 1989. In 1976, Gen. McCulloch retired from active
military service after serving 30 years as a U.S. Marine infantry officer.
Daniel A. McKeever, CP is the former Chairman of the Board of JEH. He served
in that capacity from September 13, 1972 to November 1, 1996, on which date
JEH was acquired by Hanger. He also served as the Treasurer of JEH from
September 31, 1937 to November 1, 1996. Mr. McKeever was President of the
47
<PAGE>
ABC in 1954 and 1955 and President of the American Orthotics and Prosthetics
Association in 1949 and 1950.
H.E. Thranhardt, CPO is the former President and Chief Executive Officer of
JEH. He served in that capacity from January 1, 1977 to November 1, 1996, on
which date JEH was acquired by Hanger. Mr. Thranhardt, who commenced his
employment with JEH in 1958, has occupied leadership positions in numerous
professional O&P associations, including Chairman of the Board of the
Orthotics and Prosthetics National Office in 1994 and 1995, President of the
American Orthotics and Prosthetics Association in 1992 and 1993, President of
the ABC in 1979 and 1980 and President of The American Academy of Orthotics
and Prosthetics in 1976 and 1977.
John D. McNeill, CPO has been the President and Chief Operating Officer of
Hanger Prosthetics & Orthotics, Inc., a wholly-owned subsidiary of the Company
that operates the Company's patient-care centers, since November 1, 1996. From
1990 to November 1, 1996, he was Senior Vice President, Chief Operating
Officer and a director of JEH. From 1986 to 1990, Mr. McNeill was a Regional
Vice President and an area manager for JEH. Mr. McNeill, who is a CPO,
conducted his own O&P practice in Marietta, Georgia from 1979 to 1986, when it
was acquired by JEH.
Alice G. Tidwell has been the President and Chief Operating Officer of
Southern Prosthetic Supply, Inc., the Company's wholly-owned distribution
subsidiary, since November 1, 1996. From 1990 to November 1, 1996, she served
as a Senior Vice President and Chief Operating Officer of Southern Prosthetic
Supply, Inc. From 1992 to 1996, Ms. Tidwell served on the Board of Directors
of JEH. Previously, she served as supervisor, office manager and Vice
President of Corporate Central Services of JEH.
Juan B. Paez has been a Vice President of DOBI-Symplex, Inc., the Company's
wholly-owned manufacturing subsidiary, since 1992. In addition to management
responsibilities relating to the Company's manufacturing, central fabrication
and distribution activities, Mr. Paez oversees new product and manufacturing
business development. From 1990 to 1992, Mr. Paez was the Director of New
Product Development of Bissell Healthcare and from 1982 to 1990 he was
employed as Manager of Engineering and Research & Development and Manager of
Industrial Engineering by Camp International.
Jeffrey L. Martin has been the Vice President of OPNET, the Company's
preferred provider network of O&P service professionals, since October 1995.
In addition to being responsible for the recruitment of OPNET members and the
planning and implementation of OPNET member services, Mr. Martin directs the
solicitation and management of OPNET managed care contracts. From 1984 until
joining Hanger in 1995, Mr. Martin was Director of Marketing for the Ohio
Willow Wood Company, a manufacturer of prosthetic componentry.
EMPLOYMENT AND NON-COMPETE AGREEMENTS
Messrs. Sabel, Stein and McNeill and Ms. Tidwell have executed employment
agreements with the Company which contain non-compete provisions.
48
<PAGE>
PRINCIPAL SHAREHOLDERS
The following table sets forth the number of shares of Common Stock
beneficially owned as of June 25, 1997 by: (i) each person known by Hanger to
be the beneficial owner of 5% or more of such class of securities; (ii) each
director and executive officer of Hanger; and (iii) all directors and
executive officers of Hanger as a group.
<TABLE>
<CAPTION>
PERCENT OF PERCENT OF
NUMBER OF COMMON STOCK COMMON STOCK
SHARES OF OUTSTANDING OUTSTANDING
DIRECTORS, EXECUTIVE COMMON BEFORE THE AFTER THE
OFFICERS AND 5% SHAREHOLDERS POSITION(S) WITH THE COMPANY STOCK(1) OFFERING(1) OFFERING(1)
- ----------------------------- ---------------------------- --------- ------------ ------------
<S> <C> <C> <C> <C>
Chase Venture Capital
Associates, L.P.(2).... -- 2,426,689 22.54% 15.89%
Ivan R. Sabel, CPO(3)... Chairman of the Board,
President and Chief
Executive Officer 238,033 2.46 1.68
Mitchell J. Blutt, Director
M.D.(4)................ -- -- --
Thomas P. Cooper, Director
M.D.(5)................ 18,000 0.19 0.13
Robert J. Glaser, Director
M.D.(6)................ 16,000 0.17 0.11
James G. Hellmuth(7).... Director 11,500 0.12 0.08
William L. Director
McCulloch(8)........... 18,750 0.20 0.13
Edmond E. Charrette, Director
M.D.(9)................ 31,250 0.33 0.22
Daniel A. McKeever, Director
CP(10)................. 572,173 6.05 4.10
H.E. Thranhardt, Director
CPO(11)................ 219,570 2.32 1.57
Richard A. Stein(12).... Vice President--
Finance, Treasurer
and Secretary 118,838 1.24 0.84
All directors and
executive officers as a
group (10 persons)(13). 1,244,114 12.87 8.78
</TABLE>
- --------
(1) Assumes in the case of each shareholder listed in the above list that all
warrants or options exercisable within 60 days that are held by such
shareholder were fully exercised by such shareholder, without the
exercise of any warrants or options held by any other shareholders.
(2) Includes 830,649 shares subject to exercisable warrants to purchase
shares from the Company and excludes 440,000 shares subject to unvested
warrants that have not yet become exercisable. Reference is made to notes
(4), (5) and (7) below for information relating to three directors of the
Company that are affiliated with CVCA. The address of CVCA and its sole
general partner, Chase Capital Partners, is 380 Madison Avenue (12th
Floor), New York, New York 10017.
(3) Includes 96,750 shares subject to exercisable options to purchase shares
from the Company and excludes 224,250 shares subject to unvested options
that have not yet become exercisable.
(4) Does not include the shares reported above as owned by CVCA. Dr. Blutt is
a General Partner of Chase Capital Partners, the sole general partner of
CVCA. He disclaims beneficial ownership of the shares beneficially owned
by CVCA.
(5) Includes 11,500 shares subject to exercisable options to purchase shares
from the Company and excludes 13,750 shares subject to unvested options
that have not yet become exercisable. Dr. Cooper currently serves as a
consultant to CVCA.
(6) Includes 15,000 shares subject to exercisable options to purchase shares
from the Company and excludes 15,000 shares subject to unvested options
that have not yet become exercisable.
49
<PAGE>
(7) Includes 11,500 shares subject to exercisable options to purchase shares
from the Company and excludes 13,750 shares subject to unvested options
that have not yet become exercisable. Mr. Hellmuth currently serves as a
part-time consultant to Chase Capital Partners.
(8) Includes 11,250 shares subject to exercisable options to purchase shares
from the Company and excludes 13,750 shares subject to unvested options
that have not yet become exercisable.
(9) Includes 1,250 shares subject to an exercisable option to purchase shares
from the Company and excludes 8,750 shares subject to unvested options
that have not yet become exercisable.
(10) Includes 105,022 shares owned indirectly by Mr. McKeever; 55,707 shares
owned indirectly by his wife through a family limited partnership; and
410,444 shares owned indirectly by other members of Mr. McKeever's family
through that family limited partnership, of which Mr. McKeever possesses
sole voting power as the Managing General Partner and with respect to
which he disclaims beneficial ownership. Does not include 5,000 shares
subject to an unvested option that has not yet become exercisable.
(11) Includes 184,027 shares owned directly by Mr. Thranhardt and 35,543
shares owned indirectly by him as trustee for members of his family; does
not include 155,000 shares subject to unvested options that have not yet
become exercisable.
(12) Includes 50,750 shares subject to exercisable options to purchase shares
from the Company and excludes 110,750 shares subject to unvested options
that have not yet become exercisable.
(13) Includes a total of 198,000 shares subject to exercisable options held by
directors and executive officers of the Company to purchase shares from
the Company and excludes a total of 560,000 shares subject to unvested
options held by such persons that have not yet become exercisable.
The preceding table does not include 300 shares of the Company's non-voting
Class C Preferred Stock, which constitutes all the outstanding shares of that
class, held by the former shareholders of Scott Orthopedics, Inc., which was
acquired by Hanger on February 13, 1990.
50
<PAGE>
DESCRIPTION OF CAPITAL STOCK
Hanger's authorized capital stock consists of 25,000,000 shares of Common
Stock, par value $.01 per share, and 10,000,000 shares of Preferred Stock, par
value $.01 per share (the "Preferred Stock"), issuable in series.
COMMON STOCK
As of June 20, 1997, there were 9,465,811 shares of Common Stock outstanding
held by approximately 910 shareholders of record. Holders of Common Stock have
one vote for each share held, are not entitled to cumulate their votes for the
election of directors and do not have preemptive rights. All shares of Common
Stock have equal rights and, subject to the rights of the holders of the
Preferred Stock, are entitled to receive such dividends, if any, as may be
declared from time to time by the Board of Directors out of funds legally
available therefor and to share pro-rata in the net assets of Hanger available
for distribution to holders of Common Stock upon liquidation. See "Dividend
Policy."
The transfer agent for the Common Stock is ChaseMellon Shareholder Services,
New York, New York.
PREFERRED STOCK
The Company has issued and outstanding one series of Preferred Stock,
designated as Class C Preferred Stock, of which 300 shares are outstanding.
Previously outstanding shares of Class A, B, D and E Preferred Stock have
either been redeemed or converted into Common Stock. The Company also has an
authorized Class F Preferred Stock, of which no shares have been, or are
planned to be, issued. The Class C Preferred Stock is non-voting and non-
convertible, accrues dividends cumulatively at 9% per annum (compounded daily)
and is required to be redeemed by Hanger on or before February 1, 2000 for its
aggregate liquidation value of $150,000, plus accrued and unpaid dividends.
Hanger's Board of Directors may, without further action by Hanger's
shareholders, direct the issuance of additional shares of Preferred Stock in
series and may, at the time of issuance, determine the rights, preferences and
limitations of each series. Satisfaction of any dividend preferences of
outstanding Preferred Stock would reduce the amount of funds available for the
payment of dividends on the Common Stock. Also, the holders of Preferred Stock
would normally be entitled to receive a preference payment in the event of any
liquidation, dissolution or winding-up of Hanger before any payment is made to
the holders of the Common Stock.
While issuance of Preferred Stock could provide needed flexibility in
connection with possible acquisitions and other corporate purposes, such
issuance could also make it more difficult for a third party to acquire a
majority of the outstanding voting stock of the Company or discourage an
attempt to gain control of the Company. Such potential anti-takeover
provisions could adversely affect the market price of the Common Stock. In
addition, the Board of Directors, without shareholder approval, can issue
shares of Preferred Stock with voting and conversion rights which could
adversely affect the voting power and other rights of holders of Common Stock.
51
<PAGE>
UNDERWRITING
Subject to the terms and conditions of the Underwriting Agreement, the
Underwriters named below (the "Underwriters"), through their Representatives,
Alex. Brown & Sons Incorporated, Montgomery Securities and Legg Mason Wood
Walker, Incorporated, have severally agreed to purchase from the Company the
following respective numbers of shares of Common Stock at the public offering
price less the underwriting discounts and commissions set forth on the cover
page of the Prospectus:
<TABLE>
<CAPTION>
NUMBER OF
UNDERWRITER SHARES
----------- ---------
<S> <C>
Alex. Brown & Sons Incorporated.......................................
Montgomery Securities.................................................
Legg Mason Wood Walker, Incorporated..................................
---------
Total............................................................... 4,500,000
=========
</TABLE>
The Underwriting Agreement provides that the obligations of the Underwriters
are subject to certain conditions precedent and that the Underwriters will
purchase all shares of Common Stock offered hereby if any such shares are
purchased.
The Company has been advised by the Representatives of the Underwriters that
the Underwriters propose to offer the shares of Common Stock to the public at
the public offering price set forth on the cover page of this Prospectus and
to certain dealers at such price less a concession not in excess of $ per
share. The Underwriters may allow, and such dealers may reallow, a concession
not in excess of $ per share to certain other dealers. After the public
offering contemplated hereby, the offering price and other selling terms may
be changed by the Representatives of the Underwriters.
The Company has granted the Underwriters an option, exercisable not later
than 30 days after the date of this Prospectus, to purchase up to 675,000
additional shares of Common Stock at the public offering price less the
underwriting discounts and commissions set forth on the cover page of this
Prospectus. To the extent that the Underwriters exercise such option, each of
the Underwriters will have a firm commitment to purchase approximately the
same percentage thereof that the number of shares of Common Stock to be
purchased by it shown in the above table bears to 4,500,000, and the Company
will be obligated, pursuant to such option, to sell such shares to the
Underwriters. The Underwriters may exercise such option only to cover over-
allotments made in connection with the sale of the Common Stock offered
hereby. If purchased, the Underwriters will offer such additional shares on
the same terms as those on which the 4,500,000 shares are being offered.
The Company has agreed to indemnify the Underwriters against certain
liabilities, including liabilities under the Securities Act.
The Company and the beneficial owners of approximately 4,030,803 shares of
Common Stock have agreed not to offer, sell or otherwise dispose of any shares
of Common Stock for a period 90 days after the date of this Prospectus without
the prior written consent of Alex. Brown & Sons Incorporated on behalf of the
Representatives of the Underwriters. Alex. Brown & Sons Incorporated may, in
its sole discretion and at any time without notice, release all or any portion
of the Common Stock subject to these lock-up agreements.
52
<PAGE>
In connection with the Offering of the Common Stock, the Underwriters may
engage in transactions that stabilize, maintain or otherwise affect the market
price of the Common Stock. Specifically, the Underwriters may over-allot
shares of the Common Stock in connection with the Offering, thereby creating a
short position in the Underwriters' account. Additionally, to cover such short
position or to stabilize the market price of the Common Stock, the
Underwriters may bid for, and purchase, shares of the Common Stock at a level
above that which might otherwise prevail in the open market. The Underwriters
are not required to engage in these activities, and, if commenced, any such
activities may be discontinued at any time. These activities may be effected
on the American Stock Exchange, in the over-the-counter market or otherwise.
The Underwriters also may impose a penalty bid whereby they may reclaim
selling concessions allowed to an Underwriter or dealer, if the Underwriters
repurchase, in stabilizing or covering transactions, shares distributed by
that Underwriter or dealer.
Under Rule 2720 ("Rule 2720") of the Conduct Rules of the National
Association of Securities Dealers, Inc. (the "NASD"), when more than 10% of
the outstanding voting securities of an issuer are beneficially owned by a
member or persons associated with a member of the NASD participating in the
distribution of a public offering of equity securities of the issuer, the
issuer is presumed to be an "affiliate" of the member, and the offering must
be conducted pursuant to the requirements of Rule 2720. Chase Securities Inc.,
which is expected to be an underwriter in the Offering, is related to Chase
Venture Capital Associates, L.P., which beneficially owns more than 10% of the
outstanding voting securities of the Company. Accordingly, the Offering is
being conducted pursuant to the requirements of Rule 2720.
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby is being passed
upon for the Company by Freedman, Levy, Kroll & Simonds, Washington, D.C.
Certain legal matters relating to the sale of the Common Stock offered hereby
will be passed upon for the Underwriters by Hogan & Hartson L.L.P., Baltimore,
Maryland.
EXPERTS
The consolidated balance sheets of the Company as of December 31, 1995 and
1996, and the consolidated statements of operations, changes in shareholders'
equity and cash flows of the Company for each of the years in the three-year
period ended December 31, 1996, the balance sheets of ACOR Orthopaedic, Inc.--
Retail Division as of December 31, 1995 and 1996 and the statements of income,
changes in divisional equity and cash flows of that entity for each of the
years then ended, and the combined balance sheets of Ft. Walton Orthopedic
Inc. and Mobile Limb and Brace Inc. as of December 31, 1995 and 1996 and the
related combined statements of income, changes in stockholders' equity and
cash flows for the years then ended, have been included herein and in the
Registration Statement in reliance upon the report of Coopers & Lybrand
L.L.P., independent accountants, given on the authority of that firm as
experts in accounting and auditing.
The consolidated statements of income, retained earnings and cash flow of
JEH for each of the years in the two-year period ended December 31, 1995, have
been included herein and in the Registration Statement in reliance upon the
report of Windham Brannon, P.C., independent accountants, given on the
authority of that firm as experts in accounting and auditing.
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith, files reports and other information with the
53
<PAGE>
Securities and Exchange Commission (the "Commission"). Reports, proxy and
information statements filed by the Company with the Commission pursuant to
the informational requirements of the Exchange Act may be inspected and copied
at the public reference facilities maintained by the Commission at 450 Fifth
Street, N.W., Washington, D.C. 20549, and at the Regional Offices of the
Commission: Northeast Regional Office, 7 World Trade Center, Suite 1300, New
York, New York 10048; and Midwest Regional Office, Northwestern Atrium Center,
500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of such
material may be obtained from the Public Reference Section of the Commission
at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates and
such materials may be inspected and copied at the Commission's Web Site
(http://www.sec.gov). In addition, reports, proxy statements and other
information concerning the Company can be inspected at the offices of the
American Stock Exchange, 86 Trinity Place, New York, New York 10006, on which
the Common Stock of the Company is listed.
The Company has filed with the Commission a Registration Statement on Form
S-2 (herein, together with all amendments and exhibits, referred to as the
"Registration Statement") under the Securities Act of 1933, as amended (the
"Securities Act"). This Prospectus does not contain all of the information set
forth in the Registration Statement, certain parts of which are omitted in
accordance with the rules and regulations of the Commission. For further
information, reference is hereby made to the Registration Statement.
DOCUMENTS INCORPORATED BY REFERENCE
The following documents filed by the Company with the Commission (File No.
1-10670) pursuant to Section 13 of the Exchange Act are hereby incorporated by
reference in this Prospectus:
1. Annual Report on Form 10-K for the fiscal year ended December 31,
1996.
2. Quarterly Report on Form 10-Q for the quarter ended March 31, 1997.
3. Current Reports on Form 8-K filed on April 15, 1997 (and amended on
June 13, 1997) and June 5, 1997 (and amended on July 16, 1997).
Any statement contained herein or in any document incorporated by reference
herein will be deemed to be modified or superseded for purposes of this
Prospectus to the extent that any statement contained in this Prospectus
modifies or supersedes such a statement. Any such statements so modified or
superseded will not be deemed, except as so modified or superseded, to
constitute a part of this Prospectus.
The Company will provide without charge to each person to whom a copy of
this Prospectus is delivered, upon the written or oral request of any such
person, a copy of the documents described above (other than exhibits).
Requests for such copy should be directed to Hanger Orthopedic Group, Inc.,
7700 Old Georgetown Road, Bethesda, Maryland 20814, Attention: Mr. Richard A.
Stein, Secretary, telephone number (301) 986-0701.
54
<PAGE>
INDEX TO FINANCIAL STATEMENTS
<TABLE>
<S> <C>
HANGER ORTHOPEDIC GROUP, INC.
Report of Independent Accountants......................................... F-1
Consolidated balance sheets as of December 31, 1995 and 1996 and
March 31, 1997 (unaudited)............................................... F-2
Consolidated statements of operations for the years ended December 31,
1994, 1995 and 1996 and the quarters ended March 31, 1996 and 1997
(unaudited).............................................................. F-4
Consolidated statements of changes in shareholders' equity for the years
ended December 31, 1994, 1995 and 1996 and the quarter ended March 31,
1997 (unaudited)......................................................... F-5
Consolidated statements of cash flows for the years ended December 31,
1994, 1995 and 1996 and the quarters ended March 31, 1996 and 1997
(unaudited).............................................................. F-6
Notes to Consolidated Financial Statements................................ F-7
J.E. HANGER, INC. OF GEORGIA
Report of Independent Accountants......................................... F-21
Balance sheets as of December 3, 1995, 1994 and 1993...................... F-22
Statements of income for the years ended December 31, 1995, 1994 and
1993..................................................................... F-23
Statements of retained earnings for the years ended December 31, 1995,
1994 and 1993............................................................ F-24
Statements of cash flows for the years ended December 31, 1995, 1994 and
1993..................................................................... F-25
Notes to Consolidated Financial Statements................................ F-28
Balance sheet at June 30, 1996 (unaudited)................................ F-34
Statement of income for the six months ended June 30, 1996 (unaudited).... F-35
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
Report of Independent Accountants......................................... F-36
Balance sheets as of December 31, 1995 and 1996........................... F-37
Statements of income for the years ended December 31, 1995 and 1996....... F-38
Statements of changes in divisional equity for the years ended December
31, 1995 and 1996........................................................ F-39
Statements of cash flows for the years ended December 31, 1995 and 1996... F-40
FT. WALTON ORTHOPEDIC INC. AND MOBILE LIMB AND BRACE INC.
Report of Independent Accountants........................................ F-44
Combined balance sheets as of December 31, 1995 and 1996................. F-45
Combined statements of income for the years ended December 31, 1995 and
1996.................................................................... F-46
Combined statements of changes in stockholders' equity................... F-47
Combined statements of cash flows........................................ F-48
Notes to combined financial statements................................... F-49
</TABLE>
55
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders of
Hanger Orthopedic Group, Inc.
We have audited the accompanying consolidated balance sheets of Hanger
Orthopedic Group, Inc. and Subsidiaries as of December 31, 1995 and 1996 and
the related consolidated statements of operations, changes in shareholders'
equity and cash flows for each of the three years in the period ended December
31, 1996. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Hanger
Orthopedic Group, Inc., and Subsidiaries as of December 31, 1995 and 1996, and
the consolidated results of their operations and their cash flows for each of
the three years in the period ended December 31, 1996, in conformity with
generally accepted accounting principles.
Coopers & Lybrand L.L.P.
2400 Eleven Penn Center
Philadelphia, Pennsylvania
March 21, 1997, except as to
the information presented in
the third paragraph of
Note D, for which the date
is March 27, 1997
F-1
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
------------------------ ------------
1995 1996 1997
----------- ------------ ------------
(UNAUDITED)
<S> <C> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents.............. $ 1,456,305 $ 6,572,402 $ 6,720,021
Accounts receivable, less allowances
for doubtful accounts of $1,144,000,
$2,478,800 and 3,052,000 in 1995,
1996, and 1997, respectively.......... 13,324,991 24,321,872 24,528,348
Inventories............................ 10,312,289 15,916,638 15,650,023
Prepaid and other assets............... 1,040,914 1,595,169 2,756,664
Deferred income taxes.................. 804,499 3,159,280 3,159,280
----------- ------------ ------------
Total current assets................. 26,938,998 51,565,361 52,814,336
----------- ------------ ------------
PROPERTY, PLANT AND EQUIPMENT
Land................................... 2,991,245 4,269,045 4,269,045
Buildings.............................. 2,592,214 8,017,547 8,168,006
Machinery and equipment................ 3,654,780 6,275,307 6,466,540
Furniture and fixtures................. 1,575,493 2,095,900 2,124,041
Leasehold improvements................. 1,184,782 2,139,207 2,287,630
----------- ------------ ------------
11,998,514 22,797,006 23,315,262
Less accumulated depreciation and
amortization.......................... 4,232,858 5,497,809 6,027,606
----------- ------------ ------------
7,765,656 17,299,197 17,287,656
----------- ------------ ------------
INTANGIBLE ASSETS
Excess cost over net assets acquired... 27,133,528 63,935,447 66,405,465
Non-compete agreements................. 4,786,371 1,981,329 2,031,329
Other intangible assets................ 3,825,240 6,152,607 6,192,616
----------- ------------ ------------
35,745,139 72,069,383 74,629,410
Less accumulated amortization.......... 9,035,394 6,917,960 7,548,143
----------- ------------ ------------
26,709,745 65,151,423 67,081,267
----------- ------------ ------------
OTHER ASSETS
Other.................................. 385,662 925,446 975,083
----------- ------------ ------------
TOTAL ASSETS............................. $61,800,061 $134,941,427 $138,158,342
=========== ============ ============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-2
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31,
------------------------- MARCH 31,
1995 1996 1997
----------- ------------ ------------
(UNAUDITED)
<S> <C> <C> <C>
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Current portion of long-term debt... $ 1,828,953 $ 4,902,572 $ 6,052,939
Accounts payable.................... 1,612,401 4,141,993 2,834,080
Accrued expenses.................... 710,510 7,815,028 9,222,640
Customer deposits................... 489,758 578,219 706,173
Accrued compensation related cost... 1,495,013 8,321,395 4,887,416
Deferred revenue.................... 180,587 306,998 286,512
----------- ------------ ------------
Total current liabilities......... 6,317,222 26,066,205 23,989,760
----------- ------------ ------------
Long-term debt........................ 22,925,124 64,297,801 68,815,270
Deferred income taxes................. 706,965 2,377,627 2,377,627
Other liabilities..................... 305,499 2,188,278 2,260,854
Mandatorily redeemable preferred stock
class C, 300 shares authorized,
liquidation preference of $500 per
share (See Note N)................... 253,886 277,701 283,996
Mandatorily redeemable preferred stock
class F, 100,000 shares authorized,
liquidation preference of $1,000 per
share (See Note N)................... -- -- --
Commitments and contingent
liabilities..........................
SHAREHOLDERS' EQUITY
Common Stock, $.01 par value;
25,000,000 shares authorized,
8,424,039; 9,449,129 and 9,493,766
shares issued and 8,290,544;
9,315,634 and 9,360,270 shares
outstanding in 1995, 1996 and 1997,
respectively....................... 84,241 94,492 94,938
Additional paid-in capital.......... 33,574,058 41,008,363 41,087,022
Accumulated deficit................. (1,711,372) (713,478) (95,563)
----------- ------------ ------------
31,946,927 40,389,377 41,086,397
Treasury stock, cost--(133,495
shares)............................ (655,562) (655,562) (655,562)
----------- ------------ ------------
31,291,365 39,733,815 40,430,835
----------- ------------ ------------
TOTAL LIABILITIES & SHAREHOLDERS'
EQUITY............................... $61,800,061 $134,941,427 $138,158,342
=========== ============ ============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-3
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
------------------------------------- ------------------------
1994 1995 1996 1996 1997
----------- ----------- ----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Net sales............... $50,300,297 $52,467,899 $66,805,944 $12,229,029 $30,949,614
Cost of products and
services sold.......... 23,208,944 24,572,089 32,233,373 5,884,724 16,229,929
----------- ----------- ----------- ----------- -----------
Gross profit............ 27,091,353 27,895,810 34,572,571 6,344,305 14,719,685
Selling, general and
administrative......... 21,340,148 19,361,701 24,549,802 4,997,078 10,924,635
Depreciation and
amortization........... 2,435,727 2,005,113 2,016,390 476,155 749,305
Amortization of excess
cost over net assets
acquired............... 701,018 686,275 832,075 169,615 409,512
Restructuring cost...... 459,804 -- -- -- --
Loss from disposal of
assets................. 2,150,310 -- -- -- --
Acquisition costs....... -- -- 1,297,819 -- --
Integration costs....... -- -- 1,181,694 -- --
----------- ----------- ----------- ----------- -----------
Income from continuing
operations............. 4,346 5,842,721 4,694,791 701,457 2,636,233
Interest expense........ (1,745,781) (2,056,140) (2,546,561) (393,236) (1,527,269)
Other expense, net...... (180,940) (106,644) (177,216) (45,512) (43,749)
----------- ----------- ----------- ----------- -----------
Income (loss) from
continuing operations
before taxes and
extraordinary item..... (1,922,375) 3,679,937 1,971,014 262,709 1,065,215
Provision for income
taxes.................. 358,029 1,544,498 889,886 112,700 447,300
----------- ----------- ----------- ----------- -----------
Income (loss) from
continuing operations
before extraordinary
item................... (2,280,404) 2,135,439 1,081,128 150,009 617,915
----------- ----------- ----------- ----------- -----------
Loss from discontinued
operations............. (247,655) -- -- -- --
Loss from sale of
discontinued
operations............. (159,379) -- -- -- --
----------- ----------- ----------- ----------- -----------
Income (loss) before
extraordinary item..... (2,687,438) 2,135,439 1,081,128 150,009 617,915
----------- ----------- ----------- ----------- -----------
Extraordinary loss on
early extinguishment of
debt, net of tax....... -- -- (83,234) -- --
----------- ----------- ----------- ----------- -----------
Net income (loss)....... $(2,687,438) $ 2,135,439 $ 997,894 $ 150,009 $ 617,915
=========== =========== =========== =========== ===========
Income (loss) from
continuing operations
before extraordinary
item applicable to
common stock........... $(2,300,286) $ 2,113,640 $ 1,057,313 $ 144,254 $ 611,620
=========== =========== =========== =========== ===========
Income (loss) per common
share:
Income (loss) from
continuing operations
before extraordinary
item................... $ (0.28) $ 0.26 $ 0.12 $ 0.02 $ 0.06
Loss from discontinued
operations............. (0.03) -- -- -- --
Loss from sale of
discontinued
operations............. (0.02) -- -- -- --
Extraordinary loss on
early extinguishment of
debt................... -- -- (0.01) -- --
----------- ----------- ----------- ----------- -----------
Net income (loss) per
common share........... $ (0.33) $ 0.26 $ 0.11 $ 0.02 $ 0.06
=========== =========== =========== =========== ===========
Weighted average number
of common shares
outstanding used in
computing net income
(loss) per common
share.................. 8,290,276 8,290,544 8,663,161 8,324,263 9,977,853
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-4
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 1994, 1995 AND 1996 AND THE
QUARTER ENDED MARCH 31, 1997 (UNAUDITED)
<TABLE>
<CAPTION>
ADDITIONAL
COMMON COMMON PAID-IN ACCUMULATED TREASURY DEFERRED
SHARES STOCK CAPITAL DEFICIT STOCK COMPENSATION TOTAL
--------- ------- ----------- ----------- --------- ------------ -----------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, December 31,
1993................... 8,257,891 $83,914 $33,416,066 $(1,159,373) $(655,562) $(4,197) $31,680,848
Issuance of Common Stock
for purchase of
Columbia Brace......... 32,653 327 199,673 -- -- -- 200,000
Amortization of deferred
compensation........... -- -- -- -- -- 4,197 4,197
Preferred dividends
declared............... -- -- (19,882) -- -- -- (19,882)
Net Loss................ -- -- -- (2,687,438) -- -- (2,687,438)
--------- ------- ----------- ----------- --------- ------- -----------
Balance, December 31,
1994................... 8,290,544 84,241 33,595,857 (3,846,811) (655,562) -- 29,177,725
Preferred dividends
declared............... -- -- (21,799) -- -- -- (21,799)
Net Income.............. -- -- -- 2,135,439 -- -- 2,135,439
--------- ------- ----------- ----------- --------- ------- -----------
Balance, December 31,
1995................... 8,290,544 84,241 33,574,058 (1,711,372) (655,562) -- 31,291,365
--------- ------- ----------- ----------- --------- ------- -----------
Preferred dividends
declared............... -- -- (23,815) -- -- -- (23,815)
Issuance of Common Stock
in connection with the
exercise of stock
options................ 13,758 138 46,733 -- -- -- 46,871
Issuance of Common Stock
in connection with the
exercise of stock
warrants............... 11,332 113 (113) -- -- -- --
Issuance of Common Stock
in connection with the
purchase of JEH........ 1,000,000 10,000 5,240,000 -- -- -- 5,250,000
Issuance of warrants in
connection with the
purchase of JEH........ -- -- 133,000 -- -- -- 133,000
Issuance of warrants in
connection with the
Senior Subordinated
Note Agreement......... -- -- 2,038,500 -- -- -- 2,038,500
Net Income.............. -- -- -- 997,894 -- -- 997,894
--------- ------- ----------- ----------- --------- ------- -----------
Balance, December 31,
1996................... 9,315,634 94,492 41,008,363 (713,478) (655,562) -- 39,733,815
--------- ------- ----------- ----------- --------- ------- -----------
Preferred dividends
declared............... -- -- (6,295) -- -- -- (6,295)
Net Income.............. -- -- -- 617,915 -- -- 617,915
Issuance of Common Stock
in connection with the
exercise of stock
options................ 9,636 96 (96) -- -- -- --
Issuance of Common Stock
in connection with the
exercise of stock
warrants............... 35,000 350 85,050 -- -- -- 85,400
--------- ------- ----------- ----------- --------- ------- -----------
Balance, March 31,
1997................... 9,360,270 $94,938 $41,087,022 $ (95,563) $(655,562) -- $40,430,835
========= ======= =========== =========== ========= ======= ===========
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-5
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOW
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31, QUARTERS ENDED MARCH 31,
-------------------------------------- --------------------------
1994 1995 1996 1996 1997
----------- ----------- ------------ ------------ ------------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Cash flow from operating
activities:
Net income (loss)...... $(2,687,438) $ 2,135,439 $ 997,894 $ 150,008 $ 617,915
Adjustments to reconcile
net income (loss) to
net cash provided by
(used in) continuing
operations:
Discontinued
operations............ 426,991 -- -- -- --
Loss from sale of
discontinued
operations............ 274,791 -- -- -- --
Loss from sale of
disposal of assets.... 2,150,310 -- -- -- --
Provision for bad
debt.................. 973,678 1,008,731 1,629,065 236,503 999,208
Amortization of
deferred
compensation.......... 4,197 -- -- -- --
Depreciation and
amortization.......... 2,435,727 2,005,113 2,016,390 476,155 749,305
Amortization of excess
cost over net assets
acquired.............. 701,018 686,275 832,075 169,615 409,512
Amortization of debt
discount.............. -- -- 42,469 -- 318,515
Deferred taxes......... (629,674) 631,899 (684,119) -- --
Extraordinary loss on
early extinguishment
of debt............... -- -- 138,724 -- --
Changes in assets and
liabilities, net of
effects from acquired
companies:
Accounts receivable.... (3,639,274) (1,922,572) (2,772,619) 789,170 (1,145,684)
Inventories............ (1,169,232) (800,933) 737,104 (122,556) 274,166
Prepaid and other
assets................ 131,714 108,112 (199,638) (413,599) (1,161,495)
Other assets........... 3,782 151,367 27,342 8,341 (49,638)
Accounts payable....... (54,555) 48,462 361,441 194,358 (1,314,988)
Accrued expenses....... 776,860 (618,105) 709,638 131,530 1,407,612
Accrued wages & payroll
taxes................. (116,852) 72,272 1,942,581 (177,539) (3,433,979)
Customer deposits...... 143,070 97,036 88,461 (183,771) 127,954
Deferred revenue....... (22,691) 82,897 126,411 3,833 (20,486)
Other liabilities...... 156,884 35,628 (66,459) (85,955) 72,577
----------- ----------- ------------ ------------ ------------
Net cash provided by
(used in) continuing
operations............. (140,694) 3,721,621 5,926,760 1,176,093 (2,149,506)
Net cash used in
discontinued
operations............. (172,146) -- -- -- --
----------- ----------- ------------ ------------ ------------
Net cash provided by
(used in) operating
activities............. (312,840) 3,721,621 5,926,760 1,176,093 (2,149,506)
----------- ----------- ------------ ------------ ------------
Cash flow from investing
activities:
Purchase of fixed
assets................ (1,114,551) (934,798) (1,239,364) (158,891) (495,970)
Acquisitions, net of
cash.................. (2,599,133) (273,939) (37,671,754) -- (2,301,618)
Purchase of patent..... (59,382) (70,552) (31,840) (10,513) (40,009)
Proceeds from sale of
certain assets........ 180,806 -- -- -- --
Purchase of non-compete
agreements............ (480,500) (35,000) (200,000) -- (50,000)
Decrease in other
intangibles........... (265,624) (24,321) (7,596) (1,045) --
----------- ----------- ------------ ------------ ------------
Net cash used in
investing activities... (4,338,384) (1,338,610) (39,150,554) (170,449) (2,887,597)
----------- ----------- ------------ ------------ ------------
Cash flow from financing
activities:
Net borrowings
(repayments) under
revolving credit
agreement............. 2,635,449 (100,000) (12,700,000) (900,000) 500,000
Proceeds from the sale
of Common Stock....... -- -- 46,871 -- 85,400
Proceeds from long-term
debt.................. 5,000,000 -- 65,000,000 -- 5,500,000
Repayment of debt...... (3,276,608) (1,882,706) (11,040,029) (415,639) (900,678)
(Increase) decrease in
financing costs....... (63,393) 7,619 (2,966,951) -- --
----------- ----------- ------------ ------------ ------------
Net cash provided by
(used in) financing
activities............. 4,295,448 (1,975,087) 38,339,891 (1,315,639) 5,184,722
----------- ----------- ------------ ------------ ------------
Increase (decrease) in
cash and cash
equivalents............ (355,776) 407,924 5,116,097 (309,995) 147,619
Cash and cash
equivalents at
beginning of
year/period............ 1,404,157 1,048,381 1,456,305 1,456,305 6,572,402
----------- ----------- ------------ ------------ ------------
Cash and cash
equivalents at end of
year/period............ $ 1,048,381 $ 1,456,305 $ 6,572,402 $ 1,146,310 $ 6,720,021
=========== =========== ============ ============ ============
</TABLE>
The accompanying notes are an integral part of the consolidated financial
statements.
F-6
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE A--THE COMPANY
Hanger Orthopedic Group, Inc. is one of the nation's largest professional
practice management companies in the O&P rehabilitation industry. In addition
to providing O&P patient-care services through its operating subsidiaries, the
Company also manufactures and distributes components and finished patient-care
products to the O&P industry primarily in the United States. Hanger's largest
subsidiary, Hanger Prosthetics & Orthotics, Inc. formerly known as J.E.
Hanger, Inc., was founded in 1861 by a Civil War amputee and is the oldest
company in the O&P industry in the United States. Orthotics is the design,
fabrication, fitting and supervised use of custom-made braces and other
devices that provide external support to treat musculoskeletal disorders.
Prosthetics is the design, fabrication and fitting of custom-made artificial
limbs.
NOTE B--SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation: The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiaries. All significant
intercompany transactions and balances have been eliminated.
Use of Estimates: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents: Cash includes currency on hand and demand
deposits with high quality financial institutions. Management considers all
highly liquid investments with original maturities of three months or less at
the date of purchase to be cash equivalents. At various times throughout the
year, the Company maintains cash balances in excess of FDIC limits.
Fair Value of Financial Instruments: At December 31, 1995 and 1996, the
carrying value of financial instruments such as cash and cash equivalents,
trade receivables, trade payables, and debt approximates fair value.
Inventories: Inventories, which consist principally of purchased parts, are
stated at the lower of cost or market using the first-in, first-out (FIFO)
method.
Long-Lived Asset Impairment: Effective January 1, 1996, the Company adopted
Statement of Financial Accounting Standards ("SFAS") 121, "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of."
The provisions of SFAS 121 require the Company to review its long-lived assets
for impairment on an exception basis whenever events or changes in
circumstances indicate that the carrying amount of the assets may not be
recoverable through future cash flows. If it is determined that an impairment
loss has occurred based on expected cash flows, then the loss is recognized in
the income statement. The adoption of SFAS 121 did not have an effect on the
Company's consolidated financial statements.
Property, Plant and Equipment: Property, plant and equipment are recorded at
cost. The cost and related accumulated depreciation of assets sold, retired or
otherwise disposed of are removed from the respective accounts, and any
resulting gains or losses are included in the statement of operations.
Depreciation is computed for financial reporting purposes using the straight-
line method over the estimated useful lives of the related assets.
Depreciation expense was approximately $1,090,000, $1,136,000 and $1,288,000
for the years ended December 31, 1994, 1995 and 1996, respectively and
$288,000 and $530,000 for the quarters ended March 31, 1996 and 1997,
respectively.
F-7
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
Intangible Assets: Intangible assets, including non-compete agreements, are
recorded based on agreements entered into by the Company and are being
amortized over their estimated useful lives ranging from 5 to 7 years using
the straight-line method. Other intangible assets are recorded at cost and are
being amortized over their estimated useful lives of up to 16 years using the
straight-line method. Excess cost over net assets acquired represents the
excess of purchase price over the value assigned to net identifiable assets of
purchased businesses and is being amortized using the straight-line method
over 40 years. It is the Company's policy to periodically review and evaluate
whether there has been a permanent impairment in the value of excess cost over
net assets acquired and other intangible assets. Factors considered in the
evaluation include current operating results, trends, prospects and
anticipated undiscounted future cash flows. Fully amortized intangible assets
amounting to approximately $3,225,000 were removed from the financial
statements at December 31, 1996.
Pre-opening Costs: The Company capitalizes certain costs relating to the
pre-opening of new patient-care centers. These costs are amortized over a
twelve-month period using the straight-line method commencing on the date in
which the patient-care center opens.
Revenue Recognition: Revenue on the sale of orthotic and prosthetic devices
is recorded when the device is accepted by the patient. Revenues from referral
service contracts is recognized over the term of the contract. Deferred
revenue represents billings made prior to the final fitting and acceptance by
the patient and unearned service contract revenue. Revenue is recorded at its
net realizable value taking into consideration all governmental and
contractual discounts.
Credit Risk: The Company primarily provides services and customized devices
throughout the United States and is reimbursed by the patients' third-party
insurers or governmentally funded health insurance programs. The Company
performs ongoing credit evaluations of its distribution customers. The
accounts receivable are not collateralized. The ability of the Company's
debtors to meet their obligations is dependent upon the financial stability of
the insurers of the Company's customers and future legislation and regulatory
actions. Additionally, the Company maintains reserves for potential losses
from these receivables that historically have been within management's
expectations.
Income Taxes: Income taxes are determined in accordance with SFAS 109, which
requires recognition of deferred income tax liabilities and assets for the
expected future tax consequences of events that have been included in the
financial statements or tax returns. Under this method, deferred income tax
liabilities and assets are determined based on the difference between
financial statement and tax bases of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to reverse.
SFAS 109 also provides for the recognition of deferred tax assets if it is
more likely than not that the assets will be realized in future years.
Net Income (Loss) Per Common Share: Net income per common share is
calculated using the weighted average of common and common equivalent shares
outstanding during the year. Common equivalent shares are attributable to
unexercised stock options and warrants. In the years ended 1994, 1995 and 1996
and the quarters ended March 31, 1996 and 1997, common equivalents which would
be considered in a fully diluted calculation are not included in the per share
calculation as the effect is not material. Income (loss) from continuing
operations before extraordinary item applicable to Common Stock has been
adjusted for the dividends declared applicable to certain classes of
cumulative preferred stock.
Stock-Based Compensation: Compensation costs attributable to stock option
and similar plans are recognized based on any difference between the quoted
market price of the stock on the date of the grant over the amount the
employee is required to pay to acquire the stock (the intrinsic value method
under
F-8
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
Accounting Principles Board Opinion 25). Such amount, if any, is accrued over
the related vesting period, as appropriate. SFAS 123, "Accounting for Stock-
Based Compensation," requires companies electing to continue to use the
intrinsic value method to make pro forma disclosures of net income and
earnings per share as if the fair value based method of accounting had been
applied. The Company has adopted the disclosure only provisions of SFAS 123.
New Accounting Standard: In February 1997, the Financial Accounting
Standards Board issued SFAS 128, "Earnings per Share," which will replace the
current rules for earnings per share computations, presentation and
disclosure. Under the new standard, basic earnings per share excludes dilution
and is computed by dividing income available to common shareholders by the
weighted average number of common shares outstanding for the period. Diluted
earnings per share reflects the potential dilution that could occur if
securities or other contracts to issue Common Stock were exercised or
converted into Common Stock. SFAS 128 requires a dual presentation of basic
and diluted earnings per share on the face of the income statement.
The Company will be required to adopt SFAS 128 in the fourth quarter of 1997
and, as required by the standard, will restate all prior period earnings per
share data. The Company's new earnings per share amounts as calculated under
SFAS 128 are not expected to be materially different from those computed under
the present accounting standard.
Interim Financial Information: The accompanying unaudited consolidated
interim financial statements have been prepared in accordance with generally
accepted accounting principles for interim financial information and with the
instructions for Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they
do not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included.
Operating results for the quarter ended March 31, 1997 are not necessarily
indicative of the results that may be expected for the year ending December
31, 1997.
Reclassifications: Certain previously reported amounts have been
reclassified to conform with the current presentation.
F-9
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE C--SUPPLEMENTAL CASH FLOW FINANCIAL INFORMATION
The following are the supplemental disclosure requirements for the
statements of cash flows:
<TABLE>
<CAPTION>
QUARTERS ENDED
YEARS ENDED DECEMBER 31, MARCH 31,
-------------------------------- -----------------
1994 1995 1996 1996 1997
---------- ---------- ---------- -------- --------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Cash paid during the period
for:
Interest................. $1,690,742 $2,166,877 $2,273,629 $542,255 $641,926
Income taxes............. 212,000 712,800 1,893,990 207,780 --
Non-cash financing and
investing activities:
Preferred dividends
declared.................. 19,882 21,799 23,815 5,755 6,295
Issuance of notes in
connection with
acquisition............... 1,925,000 175,000 -- -- 250,000
Issuance of Common Stock in
connection with
acquisition............... 200,000 -- 5,250,000 -- --
Issuance of warrants in
connection with
acquisition............... -- -- 133,000 -- --
Issuance of warrants in
connection with Senior
Subordinated Notes........ -- -- 2,038,500 -- --
Issuance of Common Stock in
connection with exercise
of warrants/options....... -- -- 113 -- 96
</TABLE>
NOTE D--ACQUISITIONS AND SALE OF ASSETS
During 1994, the Company acquired the net assets of several orthotic and
prosthetic companies and one manufacturer of orthotic devices. The purchase
price for these companies was $2,780,000 in cash, plus $1,925,000 in notes and
32,653 shares of Common Stock valued at $200,000. The notes are payable over
one to five years with interest from 6% to 7%.
During 1995, the Company acquired two orthotic and prosthetic companies. The
aggregate purchase price was $385,000 comprised of $210,000 in cash and
$175,000 in promissory notes. The cash portion of the purchase prices for
these acquisitions was borrowed under the Company's revolving credit facility.
During 1996, the Company acquired one orthotic and prosthetic company, J.E.
Hanger, Inc. of Georgia, pursuant to the terms of a Merger Agreement. As of
the acquisition date, JEH, headquartered in Alpharetta, Georgia, operated 94
patient-care centers and five warehouses located primarily in the Mid-Atlantic
and Southeastern United States. Under the terms of the agreement, which became
effective on November 1, 1996, the Company paid JEH shareholders $44.0 million
in cash and issued 1.0 million shares of Company Common Stock and paid an
additional $1,783,000 to former JEH shareholders on March 27, 1997 pursuant to
provisions in the Merger Agreement calling for a post-closing adjustment. In
addition, the Company issued 35,000 warrants to one JEH noteholder in order to
facilitate assumption of this debt under the same terms and conditions that
had existed prior to the acquisition. Included in accrued expenses at December
31, 1996, is approximately $3,119,000 and $1,554,000 of severence and
relocation costs incurred in connection with the acquisition of JEH.
All of the above acquisitions have been accounted for as business
combinations in accordance with the purchase method. The results of operations
for these acquisitions are included in the Company's results of operations
from their date of acquisition. Excess cost over net assets acquired in these
F-10
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
acquisitions amounting to approximately $376,000 and $36,699,000 in 1995 and
1996, respectively, are amortized using the straight-line method over 40
years.
The following table summarizes the unaudited consolidated pro forma
information, assuming the acquisitions had occurred at the beginning of each
of the following periods:
<TABLE>
<CAPTION>
1995 1996
------------ ------------
<S> <C> <C>
Net sales...................................... $112,292,000 $122,946,000
Income from operations......................... 10,938,243 8,728,783
Net income..................................... 2,535,567 1,225,925
Net income per common share.................... .27 .12
</TABLE>
The pro forma results do not necessarily represent results which would have
occurred if the acquisitions had taken place at the beginning of each period,
nor are they indicative of the results of future combined operations.
During 1994 the Company commenced discussions and on March 23, 1995, the
Company entered into an agreement to sell certain assets related to its
operations in southern California for $288,000 under a 10-year promissory note
bearing interest at 8%. As a result, the Company recorded a loss in 1994 of
$2,150,000, which primarily consisted of the write-off of the related
goodwill.
During the first quarter of 1997, the Company acquired one orthotic and
prosthetic company. The aggregate purchase price was $500,000, comprised of
$250,000 in cash and $250,000 in promissory notes. The cash portion of this
acquisition was borrowed under the Company's acquisition loan facility.
NOTE E--DISCONTINUED OPERATIONS
In the fourth quarter of 1993, the Company declared its intent to seek a
buyer for the assets of its subsidiary, Apothecaries, Inc. On September 30,
1994, the Company sold those assets for $181,000 in cash and reported a loss
on the sale of $159,379 (net of a tax benefit of $115,412). Apothecaries has
been classified in the Consolidated Statements of Operations as a discontinued
operation, with all revenue, expenses and other income having been excluded
from continuing operations.
The operating results of Apothecaries for the nine months ended September
30, 1994, were as follows:
<TABLE>
<CAPTION>
1994
----------
<S> <C>
Sales........................................................ $1,294,341
Loss before taxes............................................ (426,991)
Tax benefit.................................................. (179,336)
----------
Loss from discontinued operations............................ $ (247,655)
==========
</TABLE>
NOTE F--RESTRUCTURING COSTS
Results of operations for 1994 include a charge of $460,000 which was
recorded in the fourth quarter for costs associated with the closing of
several patient-care centers in conjunction with management's plan to
consolidate the Company's operations. The restructuring charges include future
rental payments on buildings that the Company has abandoned, for which the
leases cannot be cancelled and subleasing attempts have been unsuccessful.
F-11
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE G--INVENTORY
Inventories at December 31, 1995 and 1996 and March 31, 1997 consist of the
following:
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
----------------------- -----------
1995 1996 1997
----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C>
Raw materials......................... $ 6,603,619 $ 7,504,442 $ 7,592,991
Work in-process....................... 1,107,289 831,632 916,755
Finished goods........................ 2,601,381 7,580,564 7,140,277
----------- ----------- -----------
$10,312,289 $15,916,638 $15,650,023
=========== =========== ===========
</TABLE>
NOTE H--LONG-TERM DEBT
Long-term debt consists of the following at December 31, 1995 and 1996:
<TABLE>
<CAPTION>
1995 1996
----------- -----------
<S> <C> <C>
A Term Loan Commitment payable in quarterly
installments through December 2001 with interest
payable monthly at the Company's option of either the
Bank's prime rate plus 1.75%, or the one, three or
six month LIBOR plus 2.75%. (8.31% at December 31,
1996). The base interest rate is subject to a floor
of 5.32% and a cap of 7.0% by an agreement that
became effective on December 31, 1996 and terminates
on September 30, 1999................................ $ -- $29,000,000
B Term Loan Commitment payable in quarterly
installments through December 2003 with interest
payable monthly at the Company's option of either the
Bank's prime rate plus 2.25%, or the one, three or
six month LIBOR plus 3.25% (8.81% at December 31,
1996)................................................ -- 28,000,000
8% Senior Subordinated Notes with detachable warrants
due November 2004, net of unamortized discount of
$1,996,031, 11.19% effective interest rate........... -- 6,003,969
Revolving credit facility expiring in June, 1997 with
interest payable monthly at the Company's option of
either the Bank's prime rate plus .25% or the three
month LIBOR plus 2.50% (8.175% and 8.75% at December
31, 1995)............................................ 12,700,000 --
Senior term loans, with principal and interest payable
monthly and with one loan at the Bank's prime rate
plus .75%, with the remaining loans at the Company's
option of either the Bank's prime rate plus .50% or
the three-month LIBOR plus 2.75% (9.25% and 8.44% at
December 31, 1995) with balloon payments due in No-
vember and December 1998............................. 4,596,663 --
8.5% Convertible Junior Subordinated Note............. 4,000,000 --
8.25% Convertible Junior Subordinated Note............ 1,000,000 --
Subordinated seller notes, non-collateralized net of
unamortized discount of $612,696, with principle and
interest payable in either monthly or quarterly
installments at effective interest rates ranging from
6% to 11%, maturing through January 2009 ............ 2,375,609 5,574,793
Other miscellaneous obligations with principle and in-
terest payable in either monthly or annual install-
ments at interest rates ranging from 6% to 10% matur-
ing through December 2007............................ 81,805 621,611
----------- -----------
24,754,077 69,200,373
Less current portion.................................. 1,828,953 4,902,572
----------- -----------
$22,925,124 $64,297,801
=========== ===========
</TABLE>
F-12
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
In November 1996, the Company entered into a new $90,000,000 Credit
Agreement with a syndication of banks which provides for a: (i) "A Term Loan"
in the principal amount of $29,000,000 with scheduled incrementally varying
quarterly repayments commencing March 1997 through December 2001; (ii) "B Term
Loan" in the principal amount of $28,000,000 with scheduled varying quarterly
repayments commencing March 1997 through December 2003; (iii) $25,000,000
Acquisition Loan Commitment and; (iv) $8,000,000 Revolving Loan Commitment.
The Acquisition Loan Commitment and Revolving Loan Commitment bear interest
at the Company's option of either the Prime Lending Rate plus 1.75%, or the
one, three or six month LIBOR plus 2.75%. The Credit Agreement is
collateralized by substantially all the assets of the Company and contains
certain affirmative and negative covenants customary in an agreement of this
nature.
The Credit Agreement provides for an initial commitment fee of 2.625% on the
total $90,000,000 facility and an annual fee of .5% per year on the aggregate
unused portion of the Credit Agreement. As of December 31, 1996, the Company
had no outstanding balances on both the Acquisition and Revolving Loan
Commitments.
The Company has entered into an interest rate swap agreement to reduce the
impact of changes in interest rates on its A Term Loan Commitment. At December
31, 1996, the Company had an outstanding interest rate swap agreement with a
commercial bank, having a total notional principle amount of $28,500,000. The
agreement effectively minimizes the Company's base interest rate exposure
between a floor of 5.32% and a cap of 7.0%. The interest rate swap agreement
matures on September 30, 1999. The Company is exposed to credit loss in the
event of non-performance by the other party to the interest rate swap
agreement. However, the Company does not anticipate non-performance by the
counterparties.
In November 1996, the Company also entered into a Senior Subordinated Note
Purchase Agreement in the principal amount of $8,000,000 which is due in its
entirety November 2004 bearing interest at 8.0%. Upon entering into this
Agreement, the Company issued 1,600,000 warrants to noteholders. This
transaction resulted in the Company recording a debt discount of $2,038,500
which is being amortized ratably over the life of the notes. The Note Purchase
Agreement is subordinate to the Credit Agreement and contains covenants
restricting the payment of dividends, the incurrence of indebtedness and the
making of acquisitions and other transactions. It should be noted that a
shareholder owns 50% of the Senior Subordinated Notes.
The Company used the proceeds of the A Term Loan, B Term Loan and Senior
Subordinated Notes to finance the acquisition of JEH and to repay all amounts
then outstanding under the Revolving credit facility, Senior Financing
Facility, the 8.5% Convertible Junior Subordinated Note and the 8.25%
Convertible Junior Subordinate Note. In connection with this transaction, the
Company recorded an extraordinary charge of $138,724 pre-tax, $83,234 after
tax, or $.01 per share for the write-off of unamortized discounts and
financing costs, in 1996.
Maturities of long-term debt, at December 31, 1996, are as follows:
<TABLE>
<S> <C>
1997.......................................................... $ 4,902,572
1998.......................................................... 7,141,513
1999.......................................................... 7,774,296
2000.......................................................... 8,628,500
2001.......................................................... 9,388,507
Thereafter.................................................... 31,364,985
-----------
$69,200,373
===========
</TABLE>
F-13
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE I--INCOME TAXES
The provisions for income taxes for the years ended December 31, 1994, 1995
and 1996 consisted of the following:
<TABLE>
<CAPTION>
1994 1995 1996
--------- ---------- ----------
<S> <C> <C> <C>
Current:
Federal.................................... $ 454,955 $ 541,626 $1,146,564
State...................................... 238,000 370,973 427,441
--------- ---------- ----------
Total........................................ 692,955 912,599 1,574,005
Deferred:
Federal and State.......................... (334,926) 631,899 (684,119)
--------- ---------- ----------
Provision for income taxes on income before
discontinued operations and extraordinary
item........................................ 358,029 1,544,498 889,886
Tax benefit from discontinued operations..... (179,336) -- --
Tax benefit from sale of discontinued
operations.................................. (115,412) -- --
Tax benefit from extraordinary item.......... -- -- (55,489)
--------- ---------- ----------
Provision for income taxes................... $ 63,281 $1,544,498 $ 834,397
========= ========== ==========
</TABLE>
A reconciliation of the federal statutory tax rate to the effective tax rate
for the years ended December 31, 1994, 1995 and 1996 is as follows:
<TABLE>
<CAPTION>
1994 1995 1996
--------- ---------- --------
<S> <C> <C> <C>
Federal statutory tax rate................... $(653,608) $1,251,349 $670,145
Increase (reduction) in taxes resulting from:
State income taxes (net of federal effect)... 151,080 249,047 98,573
Amortization of the excess cost over net
assets acquired............................. 178,160 92,777 92,777
Disposal of assets........................... 459,340 -- --
Valuation allowance.......................... 70,000 (70,000) --
Other, net................................... 153,057 21,325 28,391
--------- ---------- --------
Provision for income taxes on income before
extraordinary item.......................... 358,029 1,544,498 889,886
Tax benefit from discontinued operations..... (179,336) -- --
Tax benefit from sale of discontinued
operations.................................. (115,412) -- --
Tax benefit from extraordinary item.......... -- -- (55,489)
--------- ---------- --------
Provision for income taxes................... $ 63,281 $1,544,498 $834,397
========= ========== ========
</TABLE>
F-14
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
Temporary differences and carry forwards which give rise to deferred tax
assets and liabilities as of December 31, 1995 and 1996 are as follows:
<TABLE>
<CAPTION>
1995 1996
---------- ----------
<S> <C> <C>
Deferred Tax Liabilities:
Book basis in excess of tax.............................. $ 775,838 $ 775,838
Depreciation and amortization............................ 666,920 2,498,527
---------- ----------
1,442,758 3,274,365
---------- ----------
Deferred Tax Assets:
Net operating loss, Federal.............................. 369,624 319,039
Net operating loss, States............................... 211,165 281,051
Accrued expenses......................................... 334,790 1,554,907
Reserve for bad debts.................................... 393,322 965,116
Inventory capitalization................................. 218,086 664,371
Restructuring............................................ 13,305 --
Acquisition costs........................................ -- 271,534
---------- ----------
Gross deferred tax assets................................ 1,540,292 4,056,018
---------- ----------
Net deferred tax assets.................................. $ 97,534 $ 781,653
========== ==========
</TABLE>
For Federal and State tax purposes at December 31, 1996, the Company has
available approximately $938,000 of net operating loss carryforwards expiring
from 1998 through 2007 and are subject to a limitation in their utilization of
approximately $149,000 per year as a result of several changes in shareholder
control.
At December 31, 1995, the Company evaluated the realizability of the state
net operating losses and, based upon projections of taxable income by state,
concluded that a valuation allowance was not necessary. The remaining balance
of the deferred tax assets should be realized through future taxable income
and the reversal of taxable temporary differences.
NOTE J--DEFERRED COMPENSATION
In conjunction with the JEH acquisition, the Company assumed the unfunded
deferred compensation plan that had been established for certain key JEH
officers. The plan accrues benefits ratably over the period of active
employment from the time the contract is entered into to the time the
participant retires. Participation had been determined by JEH's Board of
Directors. The Company has purchased individual life insurance contracts with
respect to each employee covered by this plan. The Company is the owner and
beneficiary of the insurance contracts. The accrual related to the deferred
compensation arrangements amounted to approximately $1,985,000 at December 31,
1996.
NOTE K--COMMITMENTS AND CONTINGENT LIABILITIES
The Company is engaged in legal proceedings in the normal course of
business. The Company believes that any unfavorable outcome from these suits
not covered by insurance would not have a material adverse effect on the
financial statements of the Company.
F-15
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE L--OPERATING LEASES
The Company leases office space under noncancellable operating leases.
Certain of these leases contain escalation clauses based on the consumer price
index. Future minimum rental payments, by year and in the aggregate, under
operating leases with terms of one year or more consist of the following at
December 31, 1996:
<TABLE>
<S> <C>
1997.......................................................... $ 3,925,000
1998.......................................................... 3,064,000
1999.......................................................... 2,401,000
2000.......................................................... 1,932,000
2001.......................................................... 1,432,000
Thereafter.................................................... 1,974,000
-----------
$14,728,000
===========
</TABLE>
Rent expense was approximately $2,499,000, $2,144,000 and $2,554,000 for the
years ended December 31, 1994, 1995 and 1996, respectively.
NOTE M--PENSION AND PROFIT SHARING PLANS
Previously, the Company had a 401(k) Saving and Retirement Plan (the "Plan")
available to all employees of J.E. Hanger, Inc. ("J. E. Hanger"), a wholly-
owned subsidiary of the Company. The Company matched the participant's
contributions and made discretionary matching contributions. On January 1,
1993, the Company froze the Plan such that no new employees of J. E. Hanger
were able to participate. On December 31, 1995, the Company terminated the
Plan. There was no employer contribution made to the Plan in 1995. Benefit
expense was $130,000 for the year ended December 31, 1994.
The Company maintains a separate defined contribution profit sharing and
401(k) plan ("JEH Plan") covering all the employees of JEH, a recently
acquired wholly-owned subsidiary of the Company. On November 1, 1996, the
Company froze the JEH Plan such that no new employees of JEH were able to
participate. The Company did not make any contributions to the JEH Plan during
1996.
The Company maintains a 401(k) Savings and Retirement plan to cover all of
the employees of the Company. The Company may make discretionary
contributions. Under this 401(k) plan, employees may defer such amounts of
their compensation up to the levels permitted by the Internal Revenue Service.
The Company has not made any contributions to this plan.
NOTE N--REDEEMABLE PREFERRED STOCKS
The Company has 10,000,000 authorized shares of preferred stock, par value
$.01 per share, which may be issued in various classes with different
characteristics.
The 300 issued and outstanding shares of non-voting, non-convertible Class C
preferred stock have an aggregate liquidation value equal to $150,000 plus
accrued dividends at 9% and are required to be redeemed on February 1, 2000.
Accrued dividends at December 31, 1995 and 1996, were $21,799 and $23,815,
respectively.
The 100,000 authorized shares of Class F preferred stock, accrues dividends
cumulatively at 16.5% and is required to be redeemed prior to any other class
of preferred stock, before September 1998, for the aggregate liquidation value
of $1,000 per share, plus accrued dividends. As of December 31, 1995 and 1996,
none of the Class F preferred stock was issued or outstanding.
F-16
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE O--WARRANTS AND OPTIONS
WARRANTS
In November 1990, the Company entered into a $2,450,000 Note which required
the Company, based on certain repayment provisions, to issue to an affiliate
in 1991 warrants to purchase 297,883 and 322,699 shares of Common Stock at
$4.16 and $7.65 per share, respectively. These warrants are exercisable
through December 31, 2001. In May 1996, 71,969 warrants were exercised at
$4.16 per share which resulted in the issuance of 11,332 shares.
In November 1996, the Company issued warrants for 1.6 million shares of
Common Stock to the holders of the Senior Subordinated Notes. The warrants
provide that the noteholders may purchase 929,700 shares and 670,300 shares
for $4.01 and $6.375, respectively. If the Company repays 100% of the Senior
Subordinated Notes within 18 or 12 months, 50% or 55%, respectively, of the
warrants will terminate. Warrants will terminate pro-rata across the exercise
prices.
In November 1996, the Company issued warrants for 35,000 shares of common
stock as an incentive to one JEH noteholder to allow the notes to be assumed
by the Company under the same terms and conditions that had existed prior to
the acquisition. The warrants provide that the noteholder may purchase Common
Stock at an exercise price of $2.44 per share. The warrants are exercisable at
any time during the eight year term. In January 1997, the noteholder exercised
the warrants and purchased 35,000 shares of Common Stock for $2.44 per share.
OPTIONS
Under the Company's 1991 Stock Option Plan ("SOP"), 1,500,000 shares of
Common Stock are authorized for issuance under options that may be granted to
employees. The number of shares that remain available for grant at December
31, 1995 and 1996, were 892,790 and 113,501, respectively. Under the SOP,
options may be granted at an exercise price not less than the fair market
value of the Common Stock on the date of grant. Vesting and expiration periods
are established by the Compensation Committee of the Board of Directors and
generally vest three years following grant and generally expire eight to ten
years after grant.
In addition to the SOP, non-qualified options may be granted with exercise
prices that are less than the current market value. Accordingly, compensation
expense for the difference between current market value and exercise price
would be recorded at the date of grant.
F-17
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
The following is a summary of option transactions and exercise prices:
<TABLE>
<CAPTION>
STOCK NON-QUALIFIED
OPTION PLAN STOCK OPTIONS
-------------------------- ------------------------
PRICE WEIGHTED PRICE WEIGHTED
SHARES PER SHARE AVERAGE SHARES PER SHARE AVERAGE
--------- --------------- -------- ------- --------------- --------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at December
31, 1993............... 473,434 $4.76 to $14.08 $ 6.17 47,693 $6.00 to $14.08 $ 9.42
========= =======
Granted................. 82,000 $6.00 6.00 30,000 $4.38 4.38
Terminated.............. (17,833) $6.00 to $12.25 6.72 --
Expired................. (3,559) $14.08 14.08 (5,191) $14.08 14.08
--------- -------
Outstanding at December
31, 1994............... 534,042 $6.00 to $12.25 6.57 72,502 $4.38 to $6.00 7.78
========= =======
Granted................. 171,918 $2.75 to $3.25 2.83 37,500 $3.00 3.00
Terminated.............. (57,291) $6.00 to $12.25 7.20 --
--------- -------
Outstanding at December
31 1995................ 648,669 $2.75 to $12.25 5.49 110,002 $3.00 to $6.00 6.81
========= =======
Granted................. 802,250 $3.50 to $6.125 5.54 30,000 $5.875 5.875
Terminated.............. (22,961) $2.81 to $12.25 4.93 --
Exercised............... (7,508) $2.81 2.81 (6,250) $3.00 to $6.00 4.75
--------- -------
Outstanding at December
31, 1996............... 1,420,450 $2.75 to $12.25 5.54 133,752 $3.00 to $6.00 6.74
========= =======
Vested at December 31,
1996................... 467,782 57,500
========= =======
</TABLE>
The Company applies APB Opinion 25 and related Interpretations in accounting
for its plans. Historically, the Company granted stock options at exercise
prices equal to the fair market value of the stock on the date of grant for
fixed stock options. Accordingly, no compensation cost has been recognized for
its fixed stock option plans. Had compensation cost for the Company's stock-
based compensation plans been determined based on the fair value at the grant
dates for awards under those plans consistent with the method of SFAS 123, the
Company's net income and earnings per share would have been reduced to the
unaudited pro forma amounts indicated below:
<TABLE>
<CAPTION>
1995 1996
---------- --------
<C> <S> <C> <C>
Net Income: As reported ....................... $2,135,439 $997,894
Pro forma ......................... 2,017,179 745,714
Income Per Share: As reported ....................... .26 .11
Pro forma ......................... .24 .08
</TABLE>
The weighted average fair value of stock options granted during 1995 was
$2.51 and $5.03 during 1996.
F-18
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
The following is a summary of stock options exercisable at December 31,
1994, 1995 and 1996, and their respective weighted-average share prices:
<TABLE>
<CAPTION>
WEIGHTED
AVERAGE
NUMBER OF EXERCISE
SHARES PRICE
--------- --------
<S> <C> <C>
Options exercisable December 31, 1994.................. 262,484 $7.31
Options exercisable December 31, 1995.................. 396,043 6.83
Options exercisable December 31, 1996.................. 525,282 6.45
</TABLE>
The pro forma information regarding net income and earnings per share is
required by SFAS 123, and has been determined as if the Company had accounted
for its employee stock options under the fair value method of SFAS 123. The
fair value for these options was estimated at the date of grant using a Black-
Scholes option pricing model with the following weighted average assumptions
for 1995 and 1996: a risk-free interest rate ranging from 5.83% to 7.6%, 0%
dividend yield, volatility factor of the expected market price of the
Company's Common Stock of 120% and a weighted average life of the option of 7
years.
The Black-Scholes option valuation model was developed for use in estimating
the fair value of traded options which have no vesting restrictions and are
fully transferable. In addition, option valuation models require the input of
highly subjective assumptions including the expected stock price volatility.
Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in
the subjective input assumptions can materially affect the fair value
estimate, in management's opinion, the existing models do not necessarily
provide a reliable single measure of the fair value of its employee stock
options.
The following table summarizes information concerning outstanding and
exercisable options as of December 31, 1996:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
-------------------------------- -------------------------
WEIGHTED AVERAGE
NUMBER OF --------------------- NUMBER OF WEIGHTED
RANGE OF OPTIONS REMAINING EXERCISE OPTIONS AVERAGE
EXERCISE PRICES AND AWARDS LIFE (YEARS) PRICE AND AWARDS EXERCISE PRICE
- --------------- ---------- ------------ -------- ---------- --------------
<S> <C> <C> <C> <C> <C>
$2.750 to $3.000........... 175,199 8.30 $2.82 77,699 $2.82
$3.250 to $4.125........... 229,878 8.67 3.77 25,375 3.75
$4.375 to $5.875........... 63,750 7.78 5.12 18,750 4.50
$6.000 to $6.000........... 168,750 6.69 6.00 138,083 6.00
$6.125 to $6.125........... 600,000 9.84 6.13 -- --
$6.250 to $6.250........... 205,000 6.70 6.25 153,750 6.25
$6.520 to $8.000........... 10,000 0.98 7.27 10,000 7.27
$8.125 to $8.125........... 25,000 5.75 8.13 25,000 8.13
$12.000 to $12.000......... 50,000 5.52 12.00 50,000 12.00
$12.250 to $12.250......... 26,625 5.17 12.25 26,625 12.25
--------- ---- ----- ------- -----
$ 2.750 to $12.250......... 1,554,202 8.31 $5.69 525,282 $6.45
</TABLE>
In a series of transactions beginning August 1990, a principal shareholder
(the "Grantor") granted options to members of management (the "Managers") of
the Company to purchase 577,912 shares of Company Common Stock owned by the
Grantor at exercise prices that ranged from $3.875 to $8.00 per share. In five
related transactions during August 1996 and January 1997, the Managers
exchanged their entire rights to the total number of shares for 229,672 shares
of Common Stock owned by the Grantor.
F-19
<PAGE>
HANGER ORTHOPEDIC GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
These events satisfied the Grantor's obligations under the agreement. As a
result of those transactions, none of such options remain outstanding.
Under the Company's 1993 Non-Employee Director Stock Option Plan, 250,000
shares of Common Stock are authorized for issuance to directors of the Company
who are not employed by the Company or any affiliate of the Company. Under
this plan, an option to purchase 5,000 shares of Common Stock is granted
automatically on an annual basis to each eligible director on the third
business day following the date of each Annual Meeting of Stockholders of the
Company at which the eligible director is elected. The exercise price of each
option is equal to 100% of the fair market value of the Common Stock on the
date of grant. Each option vests at the rate of 25% each year for the first
four years after the date of grant of the option and each such option expires
ten years from the date of grant; provided, however, that in the event of
termination of a director's service other than by reason of total and
permanent disability or death, then the outstanding options of such holder
expires three months after such termination. Outstanding options remain
exercisable for one year after termination of service by reason of total and
permanent disability or death. The number of shares that remain available for
grant at December 31, 1995 and 1996 were 160,000 and 130,000, respectively.
NOTE P--OTHER EVENTS
On April 1, 1997 and May 12, 1997, the Company purchased the net assets of
two orthotic and prosthetic companies. The total consideration to acquire
these companies, excluding potential earn-out provisions, is expected to total
approximately $9,200,000.
F-20
<PAGE>
W I N D H A M B R A N N O N, P. C.
C E R T I F I E D P U B L I C A C C O U N T A N T S
INDEPENDENT AUDITOR'S REPORT
To The Stockholders and Directors
J. E. Hanger, Inc. of Georgia
We have audited the accompanying balance sheets of J.E. Hanger, Inc. of
Georgia as of December 31, 1995, 1994 and 1993, and the related statements of
income, retained earnings and cash flows for the years then ended. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of J.E. Hanger, Inc. of
Georgia as of December 31, 1995, 1994 and 1993 and the results of its
operations and its cash flows for the years then ended in conformity with
generally accepted accounting principles.
As discussed in Note 2 to the financial statements, the Company changed its
method of accounting for certain investments in debt and equity securities
during 1994 to adopt the provisions of Statement of Financial Accounting
Standards No. 115, "Accounting for Certain Investments in Debt and Equity
Securities".
Windham Brannon, P.C.
Certified Public Accountants
February 23, 1996, except for
Note 14, as to which the date is
September 17, 1996.
F-21
<PAGE>
J.E. HANGER, INC. OF GEORGIA
BALANCE SHEETS
DECEMBER 31, 1995, 1994 AND 1993
ASSETS
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents (Notes 2 and
4)...................................... $ 6,805,953 $ 7,094,940 $ 3,943,276
Marketable securities, at fair value
(Notes 2 and 6) ........................ 4,196,946 3,531,902 --
Accounts receivable, trade (Note 2)...... 10,634,928 8,728,216 8,681,256
Notes receivable......................... 56,704 77,045 189,136
Inventories (Notes 2 and 3).............. 4,102,218 3,540,840 3,284,394
Other receivables and prepaid expenses... 346,207 294,124 338,666
----------- ----------- -----------
Total Current Assets................. 26,142,956 23,267,067 16,436,728
----------- ----------- -----------
PROPERTY, PLANT AND EQUIPMENT--at remaining
cost (Notes 2, 3, 5, 9 and 10)............ 7,019,776 7,150,841 7,241,169
----------- ----------- -----------
OTHER ASSETS:
Notes receivable, long term.............. 141,785 156,258 --
Investments (Notes 2 and 6):
Marketable securities at lower of cost
or market ............................ -- -- 3,209,089
CRP, Inc. Dba Springlite............... 250,000 250,000 250,000
Cash value of life insurance............. 322,576 295,485 510,756
Other intangible assets, at unamortized
cost (Notes 2 and 7) 5,023,911 4,656,529 5,316,483
----------- ----------- -----------
Total Other Assets................... 5,738,272 5,358,272 9,286,328
----------- ----------- -----------
Total Assets......................... $38,901,004 $35,776,180 $32,964,225
=========== =========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable......................... $ 1,942,347 $ 1,638,311 $ 1,252,447
Accrued salaries and wages............... 3,362,850 3,104,323 2,557,586
Accrued compensated absences............. 753,488 601,108 534,645
Accrued interest......................... 67,989 87,819 23,747
Accrued deferred comensation (Note 8).... -- -- 53,330
Current portion of Industrial Revenue
Bonds (Notes 9 and 10).................. 66,660 66,660 66,660
Mortgage and other notes (Note 10)....... 1,913,415 1,720,228 1,209,044
Accrued contribution to profit sharing
plan (Note 12) 484,683 420,000 354,896
Other accrued liabilities................ 387,003 319,244 --
----------- ----------- -----------
Total Current Liabilities............ 8,978,435 7,957,693 6,052,355
LIABITIES DUE AFTER ONE YEAR:
Acccrued compensated absences............ 277,111 279,219 252,361
Accrued deferred compensation (note 8)... 2,0007,385 1,725,002 1,698,942
Long term portion of Industrial Revenue
Bonds (Notes 9 and 10).................. 288,960 355,620 422,280
Mortgages and other notes (Note 10)...... 4,422,114 4,683,608 6,073,096
----------- ----------- -----------
Total Liabilities.................... 15,974,005 15,001,142 14,499,034
STOCKHOLDERS' EQUITY
Common Stock, $1 par value, 250,000
shares authorized, 21,900 shares
outstanding (Note 11)................... 21,900 21,900 21,900
Retained Earnings........................ 22,905,099 20,753,138 18,443,291
----------- ----------- -----------
Total Stockholders' Equity........... 22,926,999 20,775,038 18,465,191
----------- ----------- -----------
Total Liabilities and Stockholders'
Equity.............................. $38,901,004 $35,776,180 $32,964,225
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these statements.
F-22
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENTS OF INCOME
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993*
----------- ----------- -----------
<S> <C> <C> <C>
SALES...................................... $59,780,443 $52,463,383 $48,026,084
COST OF SALES.............................. 32,812,637 28,177,501 25,871,325
----------- ----------- -----------
GROSS PROFIT............................... 26,967,806 24,285,882 22,154,759
SELLING AND ADMINISTRATIVE EXPENSES........ 22,086,561 20,049,872 18,829,013
----------- ----------- -----------
OPERATING PROFIT........................... 4,881,245 4,236,010 3,325,746
OTHER INCOME............................... 1,130,869 244,257 244,062
----------- ----------- -----------
INCOME BEFORE PROVISION FOR INCOME TAXES... 6,012,114 4,480,267 3,569,808
PROVISION FOR STATE INCOME TAXES (Notes 1
and 2).................................... 65,832 21,832 45,901
----------- ----------- -----------
NET INCOME BEFORE CUMULATIVE EFFECT OF
CHANGE IN ACCOUNTING FOR INVESTMENTS...... 5,946,282 4,458,435 3,523,907
CUMULATIVE EFFECT THROUGH DECEMBER 31, 1993
OF CHANGE IN ACCOUNTING FOR INVESTMENTS
(Notes 2 and 6)........................... -- 371,157 --
----------- ----------- -----------
NET INCOME................................. $ 5,946,282 $ 4,829,592 $ 3,523,907
=========== =========== ===========
</TABLE>
- --------
* Certain reclassifications have been made to conform to the 1994 presentation.
The accompanying notes are an integral part of these statements.
F-23
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENTS OF RETAINED EARNINGS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
BALANCE, BEGINNING OF YEAR.............. $20,753,138 $18,443,291 $17,497,269
NET INCOME.............................. 5,946,282 4,829,592 3,523,907
LESS--DIVIDEND DISTRIBUTIONS ($173.26
per share in 1995, $115.06 per share in
1994 and $117.71 per share in 1993)
(Notes 1 and 11)....................... (3,794,321) (2,519,745) (2,577,885)
----------- ----------- -----------
BALANCE, END OF YEAR.................... $22,905,099 $20,753,138 $18,443,291
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these statements.
F-24
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
------------ ------------ ------------
<S> <C> <C> <C>
INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS:
Cash Flows From Operating Activities:
Cash received from customers....... $ 58,320,751 $ 52,514,317 $ 47,699,276
Cash paid to suppliers and
employees......................... (50,904,474) (43,933,958) (40,378,081)
Interest received.................. 383,160 236,273 141,751
Dividends received................. 65,051 44,967 43,966
Interest paid...................... (520,207) (453,329) (700,143)
Net purchase of trading
investments....................... (212,809) (106,661) --
Profit sharing contribution paid... (420,000) (354,896) (420,000)
Deferred compensation paid......... -- (17,828) (53,330)
Income taxes paid.................. (65,832) (21,832) (59,020)
------------ ------------ ------------
Net Cash Provided By Operating
Activities...................... 6,645,640 7,907,053 6,274,419
------------ ------------ ------------
Cash Flows From Investing Activities:
Proceeds from sale of investments.. -- -- 1,142,568
Purchase of investments............ -- -- (1,241,426)
Proceeds from sale of property and
equipment......................... 165,670 98,995 13,760
Purchase of property and
equipment......................... (571,708) (1,021,393) (1,159,457)
Collection of notes receivable..... 32,814 157,351 123,968
Payments of premiums resulting in
an increase in cash surrender
value life insurance.............. (27,091) (31,336) (55,158)
Proceeds from surrender of life
insurance policies................ -- 246,607 170,125
Payments for purchase of
professional services companies,
net of cash acquired (Note 3)..... (1,138,000) (232,365) (210,000)
------------ ------------ ------------
Net Cash Used In Investing
Activities...................... (1,538,315) (782,141) (1,215,620)
------------ ------------ ------------
Cash Flows from Financing Activities:
Payments on mortgages and other
notes............................. (1,535,331) (1,386,843) (1,404,012)
Payments on Industrial Revenue
Bonds............................. (66,660) (66,660) (66,660)
Distributions to stockholders...... (3,794,321) (2,519,745) (2,577,885)
------------ ------------ ------------
Net Cash Used In Financing
Activities...................... (5,396,312) (3,973,248) (4,048,557)
------------ ------------ ------------
Net Increase (Decrease) in Cash
and Cash Equivalents............ (288,987) 3,151,664 1,010,242
Cash and Cash Equivalents at
Beginning of Year................... 7,094,940 3,943,276 2,933,034
------------ ------------ ------------
Cash and Cash Equivalents at End of
Year................................ $ 6,805,953 $ 7,094,940 $ 3,943,276
============ ============ ============
</TABLE>
F-25
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENTS OF CASH FLOWS--(CONTINUED)
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
<TABLE>
<CAPTION>
1995 1994 1993
---------- ---------- ----------
<S> <C> <C> <C>
RECONCILIATION OF NET INCOME TO NET CASH
PROVIDED BY OPERATING ACTIVITIES:
Net Income................................. $5,946,282 $4,829,592 $3,523,907
---------- ---------- ----------
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation............................. 899,677 890,643 816,610
Amortization of intangibles.............. 1,421,641 1,193,493 1,211,142
Net gain (loss) on sale and abandonment
of equipment............................ (23,476) (40,052) 2,259
Realized and unrealized (gain) loss on
trading investments..................... (452,235) 155,005 (2,759)
Cumulative effect through December 31,
1995 of change in accounting for
investments (Notes 2 and 6)............. -- (371,157) --
Change in assets and liabilities, net of
effects from purchase of various
companies:
Increase in accounts receivable.......... (1,862,642) (81,545) (124,534)
Write off of accounts and note
receivables............................. 248,086 172,067 62,371
Decrease (increase) in inventories....... (374,631) (225,946) 639,039
Net purchase of trading investments...... (212,809) (106,661) --
Decrease (increase) in other receivables
and prepaid expenses.................... (52,083) 44,542 (254,158)
Increase in accounts payable............. 304,036 385,864 67,414
Increase in accrued interest............. (19,830) 64,072 (80,420)
Increase in accrued salaries, compensated
absences and deferred compensation...... 691,182 612,788 569,492
Increase (decrease) in accrued profit
sharing contribution.................... 64,683 65,104 (65,104)
Decrease in accrued income taxes......... -- -- (13,119)
Increase (decrease) in other accrued
liabilities............................. 67,759 319,244 (77,721)
---------- ---------- ----------
Total Adjustments...................... 699,358 3,077,461 2,828,233
---------- ---------- ----------
Net Cash Provided By Operating Activities.. $6,645,640 $7,907,053 $6,274,419
========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these statements.
F-26
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENTS OF CASH FLOWS--(CONTINUED)
FOR THE YEARS ENDED DECEMBER 31, 1995, 1994 AND 1993
NONCASH INVESTING AND FINANCING ACTIVITIES:
During 1995, the Company issued notes totaling $1,467,024 ($1,423,879 for
intangible assets and $43,143 for accounts receivable, equipment and
inventory) in connection with the acquisition of three professional service
companies (See Note 3).
During 1994, the Company issued a note totaling $508,539 for a non-compete
agreement in connection with the acquisition of one professional service
company. The Company also sold the assets of one professional service company
for notes receivable totaling $189,000 ($124,000 for building, $35,000 for
intangible assets and $30,000 for accounts receivable, inventory and
equipment) (See Note 3).
During 1993, the Company issued notes totaling $309,874 ($254,874 for
intangible assets and $55,000 for equipment and inventory) in connection with
the acquisition of two professional service companies (See Note 3).
Approximately $20,000 during 1994 and $228,000 during 1993 of accounts
receivable were transferred to notes receivable.
The Company retired fully depreciated property and equipment of $32,310
during 1995 and $126,024 during 1994.
The Company retired fully amortized intangibles of $81,000 during 1995,
$829,862 during 1994 and $156,000 during 1993.
During 1994, $3,209,089 of investment securities were transferred to trading
securities (See Note 2).
The accompanying notes are an integral part of these statements.
F-27
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1995, 1994 AND 1993
1. COMPANY ORGANIZATION AND INDUSTRY
The Company's principal business is the manufacture, sale and distribution
of prosthetic and orthotic appliances, durable medical equipment, components
and supplies. The Company also distributes prosthetic and orthotic materials
to other manufacturers. The Company grants credit to prosthetic and orthotic
manufacturers and to medical patients with insurance, Medicare or Medicaid,
primarily in the south, midwest and eastern United States.
The Company and its stockholders have elected, under the provisions of
Subchapter S of the Internal Revenue Code, to have the corporate earnings
taxed directly to the stockholders. Accordingly, the accompanying financial
statements do not reflect corporate income taxes that otherwise would have
applied had the Company not elected S Corporation status.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Inventories, consisting of materials, components and supplies, are valued at
last-in, first-out cost (LIFO), not in excess of market. If the first-in,
first-out method of inventory valuation had been used by the Company,
inventories would have been stated $1,282,311 more at December 31, 1995,
$1,154,880 more at December 31, 1994 and $1,196,034 more at December 31, 1993
than they are reported. In addition, certain costs under Internal Revenue Code
Section 263(a) have been included in inventory cost. These amounts do not have
a material effect on the financial statements.
The provision for bad debts is determined by the reserve accounting method.
The reserve was $140,000 at December 31, 1995 and $66,000 at December 31,
1994. Uncollectible accounts are charged off at the time they are determined
to be worthless. The reserve method was not used in 1993 because uncollectible
accounts were immaterial and management was of the opinion that all accounts
were collectible.
Property, plant and equipment are recorded at cost. Buildings, land
improvements and factory equipment are depreciated by accelerated methods over
useful lives ranging from five to thirty-one years; leasehold improvements are
amortized over periods up to thirty-one years; automobiles and office
equipment are depreciated by the straight-line method and accelerated methods
over lives ranging from five to seven years.
The compensation and noncompete agreements are amortized by the straight-
line method over their terms ranging from four to ten years. Other intangible
assets are amortized by the straight-line method over two to five years.
In May 1993, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards (SFAS) No. 115, "Accounting for Certain
Investments in Debt and Equity Securities." SFAS No. 115 requires investments
to be classified in three categories: securities held to maturity reported at
amortized cost, trading securities reported at fair value, and securities
available for sale reported at fair value. Unrealized gains or losses on
trading securities are included in earnings. Unrealized gains or losses
F-28
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
on securities available for sale are excluded from earnings and reported as a
separate component of stockholders' equity.
Effective January 1, 1994, the Company adopted SFAS No. 115 and transferred
investment securities totaling $3,209,089, which were previously accounted for
at lower of cost or market value, to trading securities. The Company has
reported the cumulative effect, equal to the net unrealized holding gains on
the securities at January 1, 1994, of the change in accounting as a separate
component of net income.
Trading security investments are reported at fair value, as determined by
market quotations. Realized gains and losses of trading security investments
are recognized on the trade date. In computing realized gains and losses, the
specific identification method was used in determining the investment costs.
The current accrual and provision for income taxes relates to the states
that do not recognize the S Corporation status.
For purposes of the statement of cash flows, the Company considers all cash
on deposit and short-term liquid investments with original maturities of three
months or less to be cash equivalents.
3. ACQUISITIONS
During 1995, the Company acquired the inventory, accounts receivable,
equipment, goodwill and other intangible assets of four professional service
companies. The Company paid cash of $1,138,000 issued notes totaling
$1,467,024 in connection with these acquisitions. Part of the total cost
includes noncompete agreements with the former owners. One of these purchase
agreements provides for contingent consideration of up to $360,000 to be
determined based on net sales between June 1, 1995 through June 1, 1999.
During 1994, the Company acquired the inventory, accounts receivable,
equipment, goodwill and other intangible assets of two professional service
companies. The Company paid cash of $232,365 and issued notes totaling
approximately $508,000 in connection with these acquisitions. Part of the
total cost includes noncompete agreements with the former owners. One of these
agreements provides for contingent consideration of up to $245,100 to be
determined based on net sales between July 1, 1994 through June 30, 1997.
During 1994, the Company sold the inventory, accounts receivable, equipment,
goodwill and other intangible assets of one of its professional service
branches. The Company received cash of $10,000 and a note receivable for
$65,000 in connection with this sale. The Company also received a note
receivable for $124,000 for the building sold.
During 1993, the Company acquired the inventory, accounts receivable,
equipment, goodwill and other intangible assets of three professional service
companies. The Company paid cash of $210,000 and issued notes totaling
approximately $310,000 in connection with these acquisitions. Part of the
total cost includes noncompete agreements with the former owners.
4. CASH AND CASH EQUIVALENTS
The Company maintains the majority of its cash accounts in two Georgia
commercial banks and one investment brokerage firm. The bank balances are
guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $100,000
per bank. During 1995, 1994 and 1993, the Company had an overnight investment
arrangement with one of its banking institutions under which funds are
invested in a government money market fund.
F-29
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
5. PROPERTY, PLANT AND EQUIPMENT
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Land.................................. $ 1,520,001 $ 1,520,001 $ 1,593,965
Land improvements..................... 47,813 45,683 33,963
Buildings............................. 6,449,380 6,565,059 6,670,141
Leasehold improvements................ 794,716 513,048 393,267
Factory and office equipment.......... 4,784,060 4,405,615 3,904,191
Automobile equipment.................. 619,325 636,005 624,196
----------- ----------- -----------
Total Cost.......................... 14,215,295 13,685,411 13,219,723
Accumulated depreciation.............. (7,195,519) (6,534,570) (5,978,554)
----------- ----------- -----------
Remaining Cost...................... $ 7,019,776 $ 7,150,841 $ 7,241,169
=========== =========== ===========
</TABLE>
6. INVESTMENTS
Marketable securities are summarized below:
<TABLE>
<CAPTION>
COST FAIR VALUE
---------- ----------
<S> <C> <C>
At December 31, 1995:
Investment cash account............................ $ 18,416 $ 18,416
Municipal government and educational institution
bonds............................................. 1,060,416 1,140,722
Tax exempt mutual funds............................ 331,487 331,487
Marketable equity securities....................... 2,144,016 2,706,321
---------- ----------
Total............................................ $3,554,335 $4,196,946
========== ==========
<CAPTION>
COST FAIR VALUE
---------- ----------
<S> <C> <C>
At December 31, 1994:
Investment cash account............................ $ 124,172 $ 124,172
Municipal government and educational institution
bonds............................................. 1,017,203 1,079,221
Tax exempt mutual funds............................ 242,714 242,714
Marketable equity securities....................... 1,999,801 2,085,795
---------- ----------
Total............................................ $3,383,890 $3,531,902
========== ==========
<CAPTION>
COST FAIR VALUE
---------- ----------
<S> <C> <C>
At December 31, 1993:
Investment cash account............................ $ 369,446 $ 369,446
Municipal government and educational institution
bonds............................................. 987,011 1,088,321
Tax exempt mutual funds............................ 19,457 19,457
Marketable equity securities....................... 1,833,175 2,103,022
---------- ----------
Total............................................ $3,209,089 $3,580,246
========== ==========
</TABLE>
Included in 1995 other income are $78,982 net realized gains on sale of
trading security investments and a $373,253 increase in the net unrealized
holding gains.
Included in 1994 other income are $92,560 net realized gains on sale of
trading security investments and a $247,565 decrease in the net unrealized
holding gains.
F-30
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
The issuers of the above municipal government and educational institution
bonds are entities located predominately in the State of Georgia.
During 1990, the Company purchased 20% of the voting stock and 100% of the
non-voting stock of CRP, Inc. dba Springlite, a Utah based company. The
investment of $250,000 is accounted for under the cost method.
7. OTHER INTANGIBLE ASSETS
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Noncompete agreements with the former
owners of acquired companies, being
amortized on a straight-line basis
over four to ten years through 2009... $ 8,535,787 $ 7,088,524 $ 7,407,347
Customer lists, trade names and
goodwill from various professional
service companies, being amortized
over two to five years on a straight-
line basis with various maturities.... 704,604 443,846 421,346
----------- ----------- -----------
Total Other Intangible Assets.......... 9,240,391 7,532,370 7,828,693
Less accumulated amortization.......... (4,216,480) (2,875,841) (2,512,210)
----------- ----------- -----------
Unamortized Cost of Other Intangible
Assets................................ $ 5,023,911 $ 4,656,529 $ 5,316,483
=========== =========== ===========
</TABLE>
8. DEFERRED COMPENSATION CONTRACTS
During 1975, the Company entered into a deferred compensation contract with
a principal officer. The Company agreed to pay compensation for life upon his
retirement, or to his beneficiaries upon his death for a ten year period from
retirement. The present value of the obligation is accrued over the employment
tenure.
The Company has an unfunded deferred compensation plan for certain other
officers. The plan accrues benefits ratably over the period of active
employment from the time the contract is entered into to the time the
participant retires. Participation is determined by the Company's Board of
Directors.
The Company assumed a deferred compensation agreement in 1995 in connection
with the acquisition of a professional service company. Under the agreement,
the Company is to pay the employee $2,000 per month beginning in July 1995
through December 1998.
The financial reporting expense for retirement and deferred compensation was
$282,383 in 1995, $2,489 in 1994 and $347,603 in 1993, including interest on
the discounted amounts. During 1994, a retired officer died and another
officer resigned. The obligations related to these deferred compensation
contracts resulted in a reduction of $290,084 in the accrued liability, which
was used to offset the increase in the accrued benefits required by the other
contracts. The Company is deducting the compensation for income tax purposes
in the year of payment.
9. INDUSTRIAL DEVELOPMENT REVENUE BONDS
During December 1985, the Company entered into an agreement with The
Development Authority of Forsyth County and The First National Bank of Atlanta
(Wachovia Bank of Georgia, N.A.) for the issuance of an Industrial Development
Revenue Bond loan in the amount of $1,000,000 to construct a new
F-31
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
facility for its home office and wholesale distribution division. The bonds
are due in monthly installments of $5,555, plus interest at 70% of prime,
through April 1, 2000. The balance owing on these bonds as of December 31,
1995 was $355,620. The land and the facilities constructed are pledged as
collateral. The agreement includes a covenant related to the Company's net
worth.
10. MORTGAGES AND OTHER NOTES PAYABLE
<TABLE>
<CAPTION>
1995 1994 1993
----------- ----------- -----------
<S> <C> <C> <C>
Notes payable to former owners of
acquired companies, due in varying
payments through 2009, interest at
rates ranging to 11%.................. $ 6,960,852 $ 6,786,549 $ 7,743,917
Discount on noninterest-bearing notes.. (921,795) (698,020) (853,358)
Bank note due in monthly installments
of $1,021 through December, 2006 plus
interest fluctuating at prime plus 1%,
secured by certain property and
equipment and inventory............... 132,111 144,359 156,609
U.S. Small Business Administration note
due in monthly installments of $1,997
including interest at 10.35% through
December, 2007, secured by certain
land, property and equipment.......... 164,361 170,948 176,890
Note secured by cash surrender value of
life insurance policies, interest at
5%.................................... -- -- 58,082
----------- ----------- -----------
Total.................................. 6,171,168 6,232,888 7,047,168
Less current maturities................ (1,913,415) (1,720,228) (1,209,044)
----------- ----------- -----------
Amount Due After One Year.............. $ 4,422,114 $ 4,683,608 $ 6,073,096
=========== =========== ===========
</TABLE>
Maturities of long term debt as of December 31, 1995, including the
Industrial Revenue Bonds (See Note 9), during the next five years and
thereafter are:
<TABLE>
<S> <C>
1996........................................................... $1,980,075
1997........................................................... 1,645,179
1998........................................................... 1,158,044
1999........................................................... 912,397
2000........................................................... 236,546
Thereafter..................................................... 758,908
----------
Total........................................................ $6,691,149
==========
</TABLE>
Based on the borrowing rates currently available to the Company for bank
loans with similar terms and average maturities, the fair value of long term
debt is approximately $6,021,000.
11. COMMON STOCK
The Company has an option to purchase its capital stock if a stockholder
proposes to transfer the stock to any person other than another stockholder,
the Company, or the stockholder's spouse. The purpose of the option is to
permit the Company to protect its election to be taxed as an S Corporation.
The purchase price and terms are, at the option of the Company, either the
price and terms set forth in the proposed transfer or the formula price and
terms described in a stockholder agreement.
F-32
<PAGE>
J.E. HANGER, INC. OF GEORGIA
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
12. PROFIT SHARING PLAN
The Company has a defined contribution profit sharing plan covering
substantially all employees. Contributions are determined annually at the
discretion of the Board of Directors. The contributions were $484,817 for
1995, $420,000 for 1994 and $354,896 for 1993.
The Hanger of Ohio 401(k) Retirement Plan was merged with the Company's
profit sharing plan effective January 1, 1994. Also effective January 1, 1994,
the profit sharing plan was amended to include a 401(k) provision.
13. OPERATING LEASES
The Company leases office space and vehicles in several states. Generally,
leases are renewable each year subject to escalations based on CPI or amounts
stated in the lease agreement. The following is a schedule of future minimum
lease payments required under operating leases as of December 31, 1995:
<TABLE>
<CAPTION>
YEAR ENDING DECEMBER 31:
------------------------
<S> <C>
1996........................................................ $1,413,779
1997........................................................ 1,112,778
1998........................................................ 849,077
1999........................................................ 572,927
2000........................................................ 368,866
Thereafter.................................................. 796,194
----------
$5,113,622
==========
</TABLE>
14. SUBSEQUENT EVENT
On July 29, 1996, the Company entered into an Agreement and Plan of Merger
under which all of the common stock of the Company would be sold to Hanger
Orthopedic Group, Inc. in exchange for approximately $44,000,000 and 1,000,000
shares of the Common Stock of Hanger Orthopedic Group, Inc.
F-33
<PAGE>
J.E. HANGER, INC. OF GEORGIA
BALANCE SHEETS
(UNAUDITED)
<TABLE>
<CAPTION>
JUNE 30, 1996
-------------
<S> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents....................................... $ 4,478,457
Marketable securities, at fair value............................ 4,390,249
Accounts receivable, trade...................................... 10,757,313
Notes receivable................................................ 87,853
Inventories..................................................... 4,215,942
Other receivables and prepaid expenses.......................... 428,360
-----------
Total Current Assets.......................................... 24,358,174
-----------
PROPERTY, PLANT AND EQUIPMENT--at remaining cost.................. 7,439,738
-----------
OTHER ASSETS:
Note receivable, long term...................................... 146,263
Investment in CRP, Inc.......................................... 250,000
Cash value of life insurance.................................... 336,799
Other intangible assets, at unamortized cost.................... 4,355,902
-----------
Total Other Assets............................................ 5,088,964
-----------
Total Assets.................................................. $36,886,876
===========
LIABILITIES AND STOCKHOLDER'S EQUITY
CURRENT LIABILITIES:
Accounts payable................................................ $ 2,204,856
Accrued salaries and wages...................................... 2,165,758
Accrued compensated absences.................................... 543,762
Accrued interest................................................ 796
Current portion of Industrial Revenue Bonds..................... 66,660
Mortgage and other notes........................................ 1,625,287
Accrued contribution to profit sharing plan..................... 264,738
Other accrued liabilities....................................... 571,797
-----------
Total Current Liabilities..................................... 7,443,654
-----------
LIABILITIES DUE AFTER ONE YEAR:
Accrued compensated absences.................................... 201,118
Accrued deferred compensation................................... 2,206,056
Long term portion of Industrial Revenue Bonds................... 255,630
Mortgages and other notes....................................... 3,590,047
-----------
Total Liabilities............................................. 13,696,505
-----------
STOCKHOLDERS' EQUITY:
Common stock.................................................... 21,900
Retained Earnings............................................... 23,168,471
-----------
Total Stockholders' Equity.................................... 23,190,371
-----------
Total Liabilities and Stockholders' Equity.................... $36,886,876
===========
</TABLE>
F-34
<PAGE>
J.E. HANGER, INC. OF GEORGIA
STATEMENT OF INCOME
(UNAUDITED)
<TABLE>
<CAPTION>
SIX MONTHS
ENDED
JUNE 30, 1996
-------------
<S> <C>
SALES............................................................. $32,696,693
COST OF SALES:
Materials....................................................... 12,143,993
Salaries and wages.............................................. 2,913,898
Payroll taxes................................................... 300,132
Profit sharing plan contribution................................ 76,042
Group insurance................................................. 374,201
Other taxes..................................................... 154,717
Factory expense and professional training....................... 862,523
Depreciation.................................................... 236,489
Rent............................................................ 838,548
Hazard insurance................................................ 299,759
-----------
Total Cost of Sales........................................... 18,200,302
-----------
GROSS PROFIT...................................................... 14,496,391
-----------
SELLING AND ADMINISTRATIVE EXPENSES:
Salaries........................................................ 7,215,983
Deferred compensation........................................... 198,671
Payroll taxes................................................... 462,510
Profit sharing plan contribution................................ 186,695
Group insurance................................................. 359,527
Sales expense................................................... 875,693
Depreciation.................................................... 230,069
Office expense and telephone.................................... 897,573
Legal and accounting............................................ 156,291
Interest........................................................ 256,627
Amortization.................................................... 736,230
Bad debt expense................................................ 200,717
Miscellaneous................................................... 225,835
-----------
Total Selling and Administrative Expenses..................... 12,002,421
-----------
OPERATING PROFIT.................................................. 2,493,970
OTHER INCOME...................................................... 442,766
-----------
INCOME BEFORE PROVISION FOR INCOME TAXES.......................... 2,936,736
PROVISION FOR INCOME TAXES........................................ 63,467
-----------
NET INCOME........................................................ $ 2,873,269
===========
</TABLE>
F-35
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Shareholders of
ACOR Orthopaedic, Inc.--Retail Division:
We have audited the accompanying balance sheets of ACOR Orthopaedic, Inc.--
Retail Division as of December 31, 1995 and 1996 and the related statements of
income, changes in divisional equity, and cash flows for the years then ended.
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements
based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of ACOR Orthopaedic, Inc.--
Retail Division as of December 31, 1995 and 1996 and the results of its
operations and its cash flows for the years then ended, in conformity with
generally accepted accounting principles.
Coopers & Lybrand L.L.P.
2400 Eleven Penn Center
Philadelphia, Pennsylvania
April 18, 1997
F-36
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
BALANCE SHEETS
DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
---------- ----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents.............................. $ 586,219 $ 153,393
Accounts receivable, net of allowance for doubtful
accounts of $32,000 and $28,000, respectively......... 737,857 852,716
Inventories............................................ 588,067 641,139
Prepaid expenses....................................... 9,972 13,500
---------- ----------
Total current assets................................. 1,922,115 1,660,748
---------- ----------
Property, plant and equipment:
Machinery and equipment................................ 73,334 74,004
Leasehold improvements................................. 52,197 56,783
Furniture and fixtures................................. 40,267 42,909
---------- ----------
165,798 173,696
Less: accumulated depreciation........................... 84,328 96,594
---------- ----------
Net property, plant and equipment.................... 81,470 77,102
Deposits................................................. 924 1,500
---------- ----------
Total assets......................................... $2,004,509 $1,739,350
========== ==========
LIABILITIES AND DIVISIONAL EQUITY
Current liabilities:
Accounts payable....................................... 160,630 160,265
Accrued payroll and other.............................. 38,664 54,715
Related party payable.................................. 83,000 37,000
---------- ----------
Total current liabilities............................ 282,294 251,980
Commitments and contingent liabilities
Divisional equity........................................ 1,722,215 1,487,370
---------- ----------
Total liabilities and divisional equity.............. $2,004,509 $1,739,350
========== ==========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-37
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
STATEMENTS OF INCOME
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
---------- ----------
<S> <C> <C>
Net sales................................................ $4,754,460 $5,231,514
Cost of goods sold....................................... 1,624,301 1,758,246
---------- ----------
Gross profit......................................... 3,130,159 3,473,268
---------- ----------
Operating expenses:
Salaries and related expenses.......................... 1,611,946 1,637,517
Selling, general and administrative.................... 539,109 564,349
---------- ----------
Total operating expenses............................. 2,151,055 2,201,866
---------- ----------
Net income........................................... $ 979,104 $1,271,402
========== ==========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-38
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
STATEMENTS OF CHANGES IN DIVISIONAL EQUITY
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<S> <C>
Balance at December 31, 1994........................................ $1,347,303
Net income........................................................ 979,104
Cash distributions to owners...................................... (604,192)
----------
Balance at December 31, 1995........................................ 1,722,215
Net income........................................................ 1,271,402
Cash distributions to owners...................................... (1,506,247)
----------
Balance at December 31, 1996........................................ $1,487,370
==========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-39
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
--------- ----------
<S> <C> <C>
Cash flows from operating activities:
Net income............................................ $ 979,104 $1,271,402
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation........................................ 15,347 12,266
Provision (recovery) for bad debt................... 10,000 (4,000)
Changes in assets and liabilities:
Accounts receivable............................... (25,207) (110,859)
Inventories....................................... (35,167) (53,072)
Other assets...................................... (2,396) (4,104)
Accounts payable and accrued expenses............. 90,062 15,686
Related party payable............................. 23,000 (46,000)
--------- ----------
Net cash provided by operating activities....... 1,054,743 1,081,319
--------- ----------
Cash flows from investing activities:
Capital expenditures.................................. (1,817) (7,898)
--------- ----------
Net cash used in investing activities........... (1,817) (7,898)
--------- ----------
Cash flows from financing activities:
Cash distributions to owners.......................... (604,192) (1,506,247)
--------- ----------
Net cash used in financing activities........... (604,192) (1,506,247)
--------- ----------
Net change in cash and cash equivalents................. 448,734 (432,826)
Cash and cash equivalents, beginning of year............ 137,485 586,219
--------- ----------
Cash and cash equivalents, end of year.................. $ 586,219 $ 153,393
========= ==========
</TABLE>
The accompanying notes are an integral part of these financial statements.
F-40
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
NOTES TO FINANCIAL STATEMENTS
1. BACKGROUND
ACOR Orthopaedic, Inc.--Retail Division (the "Company") is one of the
leading retailers of orthopedic and prosthetic products in Cleveland, Ohio.
Each of the three retail locations provide various products including
orthopedic braces, orthotics, prosthetics, custom footwear and durable medical
equipment. The Company is an operating division of ACOR Orthopaedic, Inc. (the
"Corporation") and is not a separate legal entity.
The financial statements for the Company as of December 31, 1995 and 1996
and for the years then ended have been prepared from books and records
maintained by the Corporation. These financial statements reflect the
financial position and results of operations of the Company at their
historical bases, including allocations of certain costs by the Corporation.
The Company's cash balance was determined using cash flow contributions less
distributions. Certain income statement amounts were determined using
estimates based on factors such as square footage utilized by the Company as
compared to total square footage and divisional sales. These allocated costs,
while reasonable under the circumstances, may not represent the cost of
similar activities on a separate entity basis. The accounts and transactions
between the divisions have been disclosed as related party transactions.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
CASH AND CASH EQUIVALENTS:
The Company considers all highly liquid investments purchased with original
maturities of three months or less to be cash and cash equivalents. Cash
includes currency on hand and demand deposits with high quality institutions.
At various times throughout the year, the Company maintains cash balances in
excess of FDIC limits.
FAIR VALUE OF FINANCIAL INSTRUMENTS:
At December 31, 1995 and 1996, the carrying value of financial instruments
such as cash and cash equivalents, trade receivables and trade payables
approximates fair value.
INVENTORIES:
Inventories are stated at the lower of cost or market and consists
predominantly of finished goods available for sale. Cost is determined on the
average cost method.
PROPERTY, PLANT AND EQUIPMENT:
Property, plant and equipment are recorded at cost and are depreciated by
either the straight-line or double-declining balance method over their
estimated useful lives. Costs of major additions and betterments are
capitalized; maintenance and repairs which do not improve or extend the life
of respective assets are charged to operations as incurred. When an asset is
sold or otherwise disposed of, the cost of the property and the related
accumulated depreciation are removed from the respective accounts, and any
resulting gains or losses are reflected in income.
F-41
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
LONG-LIVED ASSET IMPAIRMENT:
Effective January 1, 1996, the Corporation adopted Statement of Financial
Accounting Standards ("SFAS") No. 121, "Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to be Disposed of." The provisions of
SFAS 121 require the Company to review its long-lived assets for impairment on
an exception basis whenever events or changes in circumstances indicate that
the carrying amount of the assets may not be recoverable through future cash
flows. If it is determined that an impairment loss has occurred based on
expected cash flows, then the loss is recognized in the income statement. The
adoption of SFAS 121 did not have an effect on the Company's financial
statements.
REVENUE RECOGNITION:
Revenue on the sale of orthotic and prosthetic devices is recorded when the
device is accepted by the patient.
CREDIT RISK:
The Company primarily provides customized devices or services throughout the
north-central region of Ohio and is reimbursed by the patients' third-party
insurers or governmentally funded health insurance programs such as Medicaid,
Medicare, and U.S. Veteran Administration. The accounts receivable are not
collateralized. The ability of the Company's debtors to meet their obligations
is dependent upon the financial stability of the insurers of the Company's
customers and future legislation and regulatory actions. Additionally, the
Company maintains reserves for potential losses.
INCOME TAXES:
The Corporation elected to be taxed pursuant to Subchapter "S" of the
Internal Revenue Code. Accordingly, federal and state income taxes or credits
accrue directly to the shareholders.
USE OF ESTIMATES:
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting periods. Actual results could differ from those estimates.
3. RELATED PARTY TRANSACTIONS:
In the ordinary course of business, the Company purchases certain products
from the Corporation's wholesale division. These purchases amounted to
approximately $273,960 and $332,047 in 1995 and 1996, respectively. The
Company's payable to the wholesale division at December 31, 1995 and 1996 was
$83,000 and $37,000, respectively. Management believes these transactions were
under terms no less favorable to the Company than those arranged with other
parties.
Two of the Company's locations are leased from a shareholder of the
Corporation for a total of $9,300 per month.
F-42
<PAGE>
ACOR ORTHOPAEDIC, INC.--RETAIL DIVISION
NOTES TO FINANCIAL STATEMENTS--(CONTINUED)
4. COMMITMENTS AND CONTINGENCIES:
The Company leases buildings at three retail locations and a corporate
location as well as leases one automobile. The future minimum payments under
lease commitments as of December 31, 1996 are as follows:
<TABLE>
<S> <C>
1997............................................................. $128,426
1998............................................................. 131,247
1999............................................................. 108,000
2000............................................................. 108,000
2001............................................................. 54,000
--------
$529,673
========
</TABLE>
The Company's total rental expense was approximately $138,000 in 1995 and
$163,000 in 1996.
5. RETIREMENT PLAN:
The Corporation has a 401(k) plan (the "Plan") which is offered to all
employees with over one year of service. The Plan provides, at the discretion
of management, an amount not to exceed 25% of the first 6% contributed by the
eligible employees each year. The Company's matching contributions to the plan
were approximately $16,000 and $12,000 for the years ended December 31, 1995
and 1996, respectively.
6. SUBSEQUENT EVENT:
On April 1, 1997, the Corporation sold certain assets and liabilities of the
Company for $5.2 million to Hanger Orthopedic Group, Inc.
F-43
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Shareholders of
Ft. Walton Orthopedic Inc.
and Mobile Limb and Brace Inc.:
We have audited the accompanying combined balance sheets of Ft. Walton
Orthopedic Inc. and Mobile Limb and Brace Inc. as of December 31, 1995 and
1996 and the related combined statements of income, changes in stockholders'
equity, and cash flows for the years then ended. These combined financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these combined financial statements
based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the combined financial statements referred to above present
fairly, in all material respects, the combined financial position of Ft.
Walton Orthopedic Inc. and Mobile Limb and Brace, Inc. as of December 31, 1995
and 1996 and the combined results of their operations and their cash flows for
the years then ended, in conformity with generally accepted accounting
principles.
Coopers & Lybrand L.L.P.
2400 Eleven Penn Center
Philadelphia, Pennsylvania
June 12, 1997
F-44
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
COMBINED BALANCE SHEETS
DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
ASSETS -------- --------
<S> <C> <C>
Current assets:
Cash and cash equivalents................................... $ 75,109 $104,182
Accounts receivable, net of allowance for doubtful accounts
of $64,300 and $13,100, respectively....................... 256,399 381,544
Inventories................................................. 355,067 357,656
Prepaid expenses and other current assets................... 6,390 4,450
-------- --------
Total current assets....................................... 692,965 847,832
-------- --------
Property, plant and equipment:
Buildings................................................... 208,010 --
Machinery and equipment..................................... 121,202 135,142
Furniture and fixtures...................................... 10,375 10,375
Leasehold improvements...................................... 31,895 44,449
-------- --------
371,482 189,966
Less accumulated depreciation................................ 152,195 120,512
-------- --------
Net property, plant and equipment............................ 219,287 69,454
-------- --------
Total assets............................................. $912,252 $917,286
======== ========
<CAPTION>
LIABILITIES AND STOCKHOLDERS' EQUITY
<S> <C> <C>
Current liabilities:
Accounts payable............................................ 93,573 119,296
Accrued expenses............................................ 1,597 17,103
Current portion of long-term debt........................... 145,411 21,424
-------- --------
Total current liabilities................................ 240,581 157,823
Long-term debt............................................... 45,525 39,345
Commitments and contingent liabilities.......................
Common stock, $1.00 par value; 11,000 authorized;
5,900 issued and outstanding................................ 5,900 5,900
Additional paid-in capital................................... 19,296 19,296
Retained earnings............................................ 600,950 694,922
-------- --------
Total stockholders' and equity........................... 626,146 720,118
-------- --------
Total liabilities and stockholders' equity............... $912,252 $917,286
======== ========
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-45
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
COMBINED STATEMENTS OF INCOME
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
---------- ----------
<S> <C> <C>
Net sales............................................... $2,575,609 $3,069,921
Cost of goods sold...................................... 1,386,908 1,537,107
---------- ----------
Gross profit........................................ 1,188,701 1,532,814
---------- ----------
Operating expenses:
Selling, general and administrative.................... 832,181 833,118
Depreciation........................................... 34,935 33,697
---------- ----------
Total operating expenses............................ 867,116 866,815
---------- ----------
Other income (expense).................................. (363) (38,310)
---------- ----------
Net income.......................................... $ 321,222 $ 627,689
========== ==========
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-46
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
COMBINED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
ADDITIONAL
COMMON PAID-IN RETAINED
STOCK CAPITAL EARNINGS TOTAL
------ ---------- -------- --------
<S> <C> <C> <C> <C>
Balance at December 31, 1994.............. 5,900 $19,296 $564,014 $589,210
Net income.............................. 321,222 321,222
Cash distributions to owners............ (284,286) (284,286)
----- ------- -------- --------
Balance at December 31, 1995.............. 5,900 19,296 600,950 626,146
Net income.............................. 627,689 627,689
Cash distributions to owners............ (533,717) (533,717)
----- ------- -------- --------
Balance at December 31, 1996............ 5,900 $19,296 $694,922 $720,118
===== ======= ======== ========
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-47
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
COMBINED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 1995 AND 1996
<TABLE>
<CAPTION>
1995 1996
--------- --------
<S> <C> <C>
Cash flows from operating activities:
Net income............................................... $ 321,222 $627,689
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation............................................ 34,935 33,697
Provision for bad debt.................................. 13,100 64,300
Changes in assets and liabilities:
Accounts receivable.................................... (1,675) (189,445)
Inventories............................................ (12,628) (2,589)
Prepaid expenses....................................... (6,085) 1,940
Accounts payable and accrued expenses.................. (30,665) 41,229
--------- --------
Net cash provided by operating activities............. 318,204 576,821
--------- --------
Cash flows from investing activities:
Capital expenditures.................................... (86,182) (10,414)
--------- --------
Net cash used in investing activities................. (86,182) (10,414)
--------- --------
Cash flows from financing activities:
Cash distributions to owners............................. (284,286) (533,717)
Payments on long-term debt............................... (18,860) (21,428)
Proceeds from long-term debt............................. 42,201 17,811
--------- --------
Net cash used in financing activities................. (260,945) (537,334)
--------- --------
Net change in cash and cash equivalents.................. (28,923) 29,073
Cash and cash equivalents, beginning of year............. 104,032 75,109
--------- --------
Cash and cash equivalents, end of year................... $ 75,109 $104,182
========= ========
Supplemental disclosures of cash flow information:
Interest paid during the year on long-term debt.......... $ 14,486 $ 5,623
Noncash investing activity:
Distribution of building and mortgage to Deckert Proper-
ties.................................................... -- $126,550
</TABLE>
The accompanying notes are an integral part of these combined financial
statements.
F-48
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
NOTES TO COMBINED FINANCIAL STATEMENTS
1. BACKGROUND:
Ft. Walton Orthopedic Inc. and Mobile Limb and Brace Inc. (the "Company")
are producers and retailers of orthopedic and prosthetic products along the
Emerald Coast of Florida and the Mobile, Alabama area. Each of the retail
locations provide various products including orthopedic braces, orthotics,
prosthetics, custom footwear and durable medical equipment. Since these
companies are under common ownership and management, combined financial
statements have been presented. All intercompany transactions and balances
have been eliminated.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
CASH AND CASH EQUIVALENTS
The Company considers all highly liquid investments purchased with original
maturities of three months or less to be cash and cash equivalents. Cash
includes currency on hand and demand deposits with high quality institutions.
At various times throughout the year, the Company maintains cash balances in
excess of FDIC limits.
FAIR VALUE OF FINANCIAL INSTRUMENTS:
At December 31, 1995 and 1996, the carrying value of financial instruments
such as cash and cash equivalents, trade receivables, trade payables and long-
term debt approximates fair value.
INVENTORIES:
Inventories are stated at the lower of cost or market and consists
predominantly of finished goods available for sale. Cost is determined on the
average cost method.
PROPERTY, PLANT AND EQUIPMENT:
Property, plant and equipment are recorded at cost and are depreciated by
either the straight-line or double-declining balance method over their
estimated useful lives. Costs of major additions and betterments are
capitalized; maintenance and repairs which do not improve or extend the life
of respective assets are charged to operations as incurred. When an asset is
sold or otherwise disposed of, the cost of the property and the related
accumulated depreciation are removed from the respective accounts, and any
resulting gains or losses are reflected in income.
LONG-LIVED ASSET IMPAIRMENT:
Effective January 1, 1996, the Company adopted Statement of Financial
Accounting Standards ("SFAS") No. 121, "Accounting for the Impairment of Long-
Lived Assets and for Long-Lived Assets to be Disposed of." The provisions of
SFAS 121 require the Company to review its long-lived assets for impairment on
an exception basis whenever events or changes in circumstances indicate that
the carrying amount of the assets may not be recoverable through future cash
flows. If it is determined that an impairment loss has occurred based on
expected cash flows, then the loss is recognized in the income statement. The
adoption of SFAS 121 did not have an effect on the Company's financial
statements.
REVENUE RECOGNITION:
Revenue on the sale of orthotic and prosthetic devices is recorded when the
device is accepted by the patient.
F-49
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
NOTES TO COMBINED FINANCIAL STATEMENTS, CONTINUED
2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED:
CREDIT RISK:
The Company primarily provides customized devices or services throughout the
Emerald Coast region of Florida and the Mobile, Alabama area, and is
reimbursed by the patients' third-party insurers or governmentally funded
health insurance programs such as Medicaid, Medicare, and U.S. Veteran
Administration. The accounts receivable are not collateralized. The ability of
the Company's debtors to meet their obligations is dependent upon the
financial stability of the insurers of the Company's customers and future
legislation and regulatory actions. Additionally, the Company maintains
reserves for potential losses.
INCOME TAXES:
The Company elected to be taxed pursuant to Subchapter "S" of the Internal
Revenue Code. Accordingly, federal and state income taxes or credits accrue
directly to the stockholders.
USE OF ESTIMATES:
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting periods. Actual results could differ from those estimates.
3. LONG-TERM DEBT:
Long-term debt consists of the following:
<TABLE>
<CAPTION>
1995 1996
-------- -------
<S> <C> <C>
Bank loans to various financial institutions
maturing in varying monthly installments
through May 2000, interest ranging from
8.0% to 10.6%................................................ $190,936 $60,769
-------- -------
190,936 60,769
Less current maturities....................................... 145,411 21,424
-------- -------
$ 45,525 $39,345
======== =======
</TABLE>
The aggregate estimated payments of long-term obligations outstanding at
December 31, 1996 are:
<TABLE>
<S> <C>
1997........................................... $21,424
1998........................................... 22,458
1999........................................... 13,586
2000........................................... 3,301
</TABLE>
4. RELATED PARTY TRANSACTIONS:
In April 1996, the Company transferred the title to the Ft. Walton, Florida
office building to Deckert Properties, a real estate company that is also
owned by owners of the Company. Deckert Properties also assumed the balance of
the mortgage on the building. The amount of debt transferred to Deckert
Properties was approximately $126,550 which approximated the net book value of
the building at that date. After the transfer, Deckert Properties leased the
building to the Company at a monthly rent of $2,140 under an agreement which
expires on April 30, 1998. The Company paid $17,120 in rent payments to
Deckert Properties during 1996.
F-50
<PAGE>
FT. WALTON ORTHOPEDIC INC.
AND MOBILE LIMB AND BRACE INC.
NOTES TO COMBINED FINANCIAL STATEMENTS, CONTINUED
5. COMMITMENTS AND CONTINGENCIES:
The Company leases office space at several locations. The future minimum
payments under lease commitments as of December 31, 1996 are as follows:
<TABLE>
<S> <C>
1997.......................................... $ 62,000
1998.......................................... 25,000
1999.......................................... 20,000
2000.......................................... 12,000
--------
$119,000
========
</TABLE>
The Company's total rental expense was approximately $59,000 and $78,000 in
1995 and 1996, respectively.
6. RETIREMENT PLAN:
The Company has a 401(k) plan (the "Plan") which is offered to all
employees. The Plan provides, at the discretion of management the Company's
contribution to the Plan, an amount not to exceed 15% of the eligible
employees salary each year. The Company's matching contributions to the plan
were approximately $57,000 and $53,000 for the years ended December 31, 1995
and 1996, respectively.
7. SUBSEQUENT EVENT:
On May 12, 1997, the Company sold certain assets and liabilities to Hanger
Orthopedic Group, Inc.
F-51
<PAGE>
[PHOTOGRAPH OF FOOTBALL PLAYER WITH [PHOTOGRAPH OF YOUNG CHILD WITH
LENOX HILL KNEE BRACE] CHARLESTON BENDING BRACE]
[PHOTOGRAPH OF PRACTITIONER WITH [PHOTOGRAPH OF TECHNICIAN
PROSTHETIC CAD-CAM SYSTEM] BUILDING A PROSTHESIS]
<PAGE>
================================================================================
NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THE OFFERING MADE HEREBY TO
GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED IN THIS PRO-
SPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE
RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY UNDERWRITER. THIS
PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF ANY OFFER
TO BUY ANY OF THE SECURITIES OFFERED HEREBY TO ANY PERSON OR BY ANYONE IN ANY
JURISDICTION IN WHICH IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEI-
THER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER
ANY CIRCUMSTANCES, CREATE ANY IMPLICATIONS THAT THE INFORMATION CONTAINED
HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO THE DATE HEREOF.
------------
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Prospectus Summary....................................................... 3
Risk Factors............................................................. 7
Use of Proceeds.......................................................... 10
Dividend Policy.......................................................... 10
Price Range of Common Stock.............................................. 11
Capitalization........................................................... 12
Selected Historical and Pro Forma Consolidated Financial Information..... 13
Management's Discussion and Analysis of Financial Condition and Results
of Operations........................................................... 25
Business................................................................. 35
Management............................................................... 46
Principal Shareholders................................................... 49
Description of Capital Stock............................................. 51
Underwriting............................................................. 52
Legal Matters............................................................ 53
Experts.................................................................. 53
Available Information.................................................... 53
Documents Incorporated by Reference...................................... 54
Index to Financial Statements............................................ 55
</TABLE>
================================================================================
================================================================================
4,500,000 Shares
[LOGOOF HANGER ORTHOPEDIC GROUP INC. APPEARS HERE]
Common Stock
-------------
PROSPECTUS
-------------
Alex. Brown & Sons
INCORPORATED
Montgomery Securities
Legg Mason Wood Walker
Incorporated
, 1997
================================================================================
<PAGE>
PART II. INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 16. EXHIBITS
The following documents are filed herewith or incorporated herein by
reference:
<TABLE>
<CAPTION>
EXHIBITS
<C> <S>
1 Form of Underwriting Agreement. (Filed with the original Form S-2
Registration Statement.)
5 Legal opinion, dated June 27, 1997 of Freedman, Levy, Kroll &
Simonds. (Filed with the original Form S-2 Registration Statement.)
10(a) Registration Agreement, dated May 15, 1989, between Sequel
Corporation, First Pennsylvania Bank, N.A., Gerald E. Bisbee, Jr.,
Ivan R. Sabel, Richard A. Stein, Ronald J. Manganiello, Joseph M.
Cestaro and Chemical Venture Capital Associates. (Incorporated herein
by reference to Exhibit 10(l) to the Registrant's Current Report on
Form 8-K dated May 15, 1989.)
10(b) First Amendment dated as of February 12, 1990, to the Registration
Agreement, dated as of May 15, 1989, by and among Hanger Orthopedic
Group, Inc., First Pennsylvania Bank, N.A., Ivan R. Sabel, Richard A.
Stein, Ronald J. Manganiello, Joseph M.Cestaro and Chemical Venture
Capital Associates. (Incorporated herein by reference to Exhibit
10(m) to the Registrant's Current Report on Form 8-K dated February
13, 1990.)
</TABLE>
- --------
* Management contract or compensatory plan
II-1
<PAGE>
<TABLE>
<CAPTION>
EXHIBITS
<C> <S>
10(c) Fifth Amendment, dated as of November 8, 1990, to the Stock and Note
Purchase Agreement, dated as of February 28, 1989 and as amended on
May 9, 1989, May 15, 1989, February 12, 1990, and June 19, 1990 by
and among J. E. Hanger, Inc., as successor to Hanger Acquisition
Corporation, Ronald J. Manganiello, Joseph M. Cestaro, Chemical
Venture Capital Associates and Chemical Equity Associates.
(Incorporated herein by reference to Exhibit 10(f) to the
Registrant's Current Report on Form 8-K filed on November 21, 1990.)
10(d) Form of Stock Option Agreements, dated as of August 13, 1990, between
Hanger Orthopedic Group, Inc. and Thomas P. Cooper, James G.
Hellmuth, Walter F. Abendschein, Jr., Norman Berger, Bruce B.
Grynbaum and Joseph S. Torg. (Incorporated herein by reference to
Exhibit 10(rrr) to the Registrant's Registration Statement on Form S-
2, File No. 33-37594.) *
10(e) Employment and Non-Compete Agreement, dated as of May 16, 1994,
between Hanger Orthopedic Group, Inc. and Ivan R. Sabel.
(Incorporated herein by reference to Exhibit 10(xx) of the
Registrant's Annual Report on Form 10-K for the year ended December
31, 1994.) *
10(f) Employment and Non-Compete Agreement, dated as of May 16, 1994,
between Hanger Orthopedic Group, Inc. and Richard A. Stein.
(Incorporated herein by reference to Exhibit 10(yy) of the
Registrant's Annual Report on Form 10-K for the year ended December
31, 1994.) *
10(g) Agreement and Plan of Merger, dated as of July 29, 1996, among Hanger
Orthopedic Group, Inc., SEH Acquisition Corporation and J.E. Hanger,
Inc. of Georgia. (Incorporated herein by reference to Exhibit 2 to
the Registrant's Current Report on Form 8-K filed on November 12,
1996.)
10(h) Credit Agreement, dated November 1, 1996, among Hanger Orthopedic
Group, Inc., various banks and Banque Paribas, as agent.
(Incorporated herein by reference to Exhibit 10(a) to the
Registrant's Current Report on Form 8-K filed on November 12, 1996.)
10(i) Senior Subordinated Note Purchase Agreement, dated as of November 1,
1996, among Hanger Orthopedic Group, Inc. and the purchasers listed
therein. (Incorporated hereby by reference to Exhibit 10(b) to the
Registrant's Current Report on Form 8-K filed on November 12, 1996.)
10(j) Warrants to purchase Common Stock of Hanger Orthopedic Group, Inc.
issued November 1, 1996. (Incorporated herein by reference to Exhibit
10(c) to the Registrant's Current Report on Form 8-K filed on
November 12, 1996.)
</TABLE>
- --------
* Management contract or compensatory plan
II-2
<PAGE>
<TABLE>
<CAPTION>
EXHIBITS
<C> <S>
10(l) 1991 Stock Option Plan of the Registrant. (Incorporated herein by
reference to Exhibit 4(b) to the Registrant's Registration Statement
on Form S-8 (File No. 33-48265).)*
10(m) 1993 Non-Employee Directors Stock Option Plan of the Registrant.
(Incorporated herein by reference to Exhibit 4(b) to the Registrant's
Registration Statement on Form S-8 (File
No. 33-63191).)*
10(n) Employment and Non-Compete Agreement, dated as of November 1, 1996,
and Amendment No. 1 thereto, dated January 1, 1997, between the
Registrant and H.E. Thranhardt. (Incorporated herein by reference to
Exhibit 10(p) to the Registrant's Annual Report on Form 10-K for the
year ended December 31, 1996. )*
10(o) Employment and Non-Compete Agreement, dated as of November 1, 1996,
between the Registrant and John McNeill. (Incorporated herein by
reference to Exhibit 10(q) to the Registrant's Annual Report on Form
10-K for the year ended December 31, 1996.)*
10(p) Employment and Non-Compete Agreement, dated as of November 1, 1996,
between the Registrant and Alice Tidwell. (Incorporated herein by
reference to Exhibit 10(r) to the Registrant's Annual Report on Form
10-K for the year ended December 31, 1996.)*
10(q) Asset Purchase Agreement, dated as of March 26, 1997, by and between
Hanger Prosthetics and Orthotics, Inc, Acor Orthopaedic, Inc., and
Jeff Alaimo, Greg Alaimo and Mead Alaimo. (Incorporated herein by
reference to Exhibit 2 to the Current Report on Form 8-K filed by the
Registrant on April 15, 1997.)
10(r) Second Amendment, dated June 25, 1997, to Credit Agreement, dated
November 1, 1996, among Hanger Orthopedic Group, Inc., various banks
and Banque Paribas, as agent. (Filed with the original Form S-2
Registration Statement.)
23(a) Consent of Freedman, Levy, Kroll & Simonds. (Included in Exhibit No.
5 hereto.)
23(b) Consent of Coopers & Lybrand, L.L.P.
23(c) Consent of Windham Brannon, P.C.
24 Power of Attorney. (Included on page II-4 of the original Form S-2
Registration Statement.)
27 Financial Data Schedule. (Filed with the original Form S-2
Registration Statement.)
</TABLE>
- --------
* Management contract or compensatory plan
II-3
<PAGE>
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THE REGISTRANT
CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE THAT IT MEETS ALL OF THE
REQUIREMENTS FOR FILING ON FORM S-2 AND HAS DULY CAUSED THIS REGISTRATION
STATEMENT OR AMENDMENT THERETO TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED,
THEREUNTO DULY AUTHORIZED, IN THE CITY OF BETHESDA, STATE OF MARYLAND, ON THIS
25TH DAY OF JULY, 1997.
Hanger Orthopedic Group, Inc.
(Registrant)
Ivan R. Sabel
By: __________________________________
Ivan R. Sabel
Chairman of the Board, President
and Chief Executive Officer
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS REGISTRATION
STATEMENT OR AMENDMENT THERETO HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS
IN THE CAPACITIES AND ON THE DATES INDICATED:
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
<S> <C> <C>
Ivan R. Sabel Chairman of the July 25, 1997
- ------------------------------------ Board, Chief
IVAN R. SABEL Executive Officer
and Director
(Principal
Executive Officer)
* Vice President-- July 25, 1997
- ------------------------------------ Finance, Treasurer
RICHARD A. STEIN and Secretary
(Principal
Financial and
Accounting
Officer)
* Director July 25, 1997
- ------------------------------------
MITCHELL J. BLUTT, M.D.
* Director July 25, 1997
- ------------------------------------
EDMOND E. CHARRETTE, M.D.
Director
- ------------------------------------
THOMAS P. COOPER, M.D.
*
- ------------------------------------
RICHARD J. GLASER, M.D. Director July 25, 1997
</TABLE>
II-4
<PAGE>
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
<S> <C> <C>
* Director July 25, 1997
- -------------------------------------
JAMES G. HELLMUTH
* Director July 25, 1997
- -------------------------------------
WILLIAM L. MCCULLOCH
* Director July 25, 1997
- -------------------------------------
DANIEL A. MCKEEVER
Director
- -------------------------------------
H.E. THRANHARDT
*By: Ivan R. Sabel July 25, 1997
Ivan R. Sabel
Attorney--in fact
</TABLE>
(The power of attorney, dated June 25, 1997, was included on the signature
page (page II-4) contained in the original Registration Statement as filed on
June 27, 1997.)
II-5
<PAGE>
EXHIBIT 23(B)
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the inclusion in this Registration Statement on Form S-2 of
(i) our report, dated March 21, 1997, except as to the information presented
in the third paragraph of Note D, for which the date is March 27, 1997, on our
audits of the consolidated financial statements of Hanger Orthopedic Group,
Inc. and subsidiaries as of December 31, 1995 and 1996, and for the years
ended December 31, 1994, 1995 and 1996; (ii) our report, dated April 18, 1997,
on our audits of the financial statements of ACOR Orthopedic, Inc.--Retail
Division as of December 31, 1995 and 1996, and for the years then ended; and
(iii) our report, dated June 12, 1997, on our audits of the combined financial
statements of Ft. Walton Orthopedic Inc. and Mobile Limb and Brace Inc. as of
December 31, 1995 and 1996, and for the years then ended. We also consent to
the reference to our firm under the caption "Experts."
Coopers & Lybrand L.L.P.
Philadelphia, Pennsylvania
July 25, 1997
<PAGE>
EXHIBIT 23(C)
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the inclusion in this Registration Statement on Form S-2 of
our report, dated February 23, 1996, on our audits of the consolidated
financial statements of J.E. Hanger, Inc. of Georgia, as of December 31, 1994
and 1995, and for the years ended December 31, 1993, 1994 and 1995. We also
consent to the reference to our firm under the caption "Experts."
Windham Brannon, P.C.
Atlanta, Georgia July 25, 1997